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ABSTRACT 
CHRONIC STRESS AND REPRODUCTIVE FUNCTION IN FEMALE 
CHILDHOOD CANCER SURVIVORS 
 
 
Theresa M. Hardy, BA, BSN 
 
Marquette University, 2018 
 
Reproductive dysfunction is reported as a major concern for childhood 
cancer survivors (CCS) and is highly correlated with quality of life in this 
population. Few predictors of post-treatment reproductive function in CCS have 
been identified. CCS report high levels of psychological stress. Psychological 
stress activates the hypothalamic-pituitary-adrenal axis, which can disrupt 
reproductive function.  
The purpose of this exploratory study was to explore the relationship 
between perceived stress, biomarkers of hypothalamic-pituitary-adrenal activity, 
gonadotropin levels, and anti-Müllerian hormone levels in female CCS. 
This exploratory cross-sectional study included female cancer survivors 
(ages 16-35) treated for pediatric cancer at the Royal Hospital for Sick Children 
in Edinburgh, Scotland. Perceived stress was measured using the Perceived 
Stress Scale (PSS-10). Hypothalamic-pituitary-adrenal activity (HPA) was 
measured using salivary and hair cortisol levels. Ovarian function was measured 
using serum gonadotropin levels and serum anti-Müllerian hormone levels. 
Latent growth curve modeling was used to determine diurnal cortisol slope and 
intercept. Bayesian structural equation modeling was used to explore the 
relationship between perceived stress, biomarkers of HPA activity and ovarian 
function.  
Twenty-four female (mean age 21.79 ± 5.68) CCS were included in the 
study. We found an inverse association between perceived stress and ovarian 
function and a positive association between biomarkers of HPA activity and 
ovarian function.  
The findings from this study suggest that perceived stress is negatively 
associated with ovarian function and that threshold cortisol levels are required for 
healthy ovarian function in female childhood cancer survivors.  
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Chapter 1. Introduction 
 
 
Significance 
 
 
An estimated one in 1000 adults under the age of 35 is a survivor of 
childhood cancer (Blumenfeld, 2012). Due to significant advances in the 
treatment of pediatric cancer, the five year survival rate now exceeds 80% in the 
United States (Barton et al., 2013) with similar statistics worldwide (Reinmuth et 
al., 2013). With an increasing number of survivors, there has been growing 
recognition of the potential late effects of cancer treatment (Kremer et al., 2013). 
Reproductive dysfunction is one such major concern for cancer survivors, and is 
highly correlated with quality of life in this population (Cherven, Mertens, 
Wasilewski-Masker, Williamson, & Meacham, 2015; Knopman, Papadopoulos, 
Grifo, Fino, & Noyes, 2010; Letourneau, Chan, & Rosen, 2013). Among female 
childhood cancer survivors (CCS), 6.3% suffer from acute ovarian failure and 
another 22.6% suffer from a significant reduction in ovarian function (Salih et al., 
2015). Premenopausal female CCS are at risk for persistent chemotherapy-
related amenorrhea and early menopause; however, not all experience these 
effects (Abusief, Missmer, Ginsburg, Weeks, & Partridge, 2012).  
The American Society for Clinical Oncology has recommended that 
options for fertility preservation be discussed with cancer patients at the earliest 
opportunity; however, it remains challenging for healthcare providers to predict 
individual risk of post-treatment reproductive dysfunction because of the limited 
knowledge of factors associated with this late effect (Knight et al., 2015; 
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Letourneau et al., 2013). While the etiology of reproductive dysfunction in cancer 
survivors has been examined (El-Shalakany, Ali, Abdelmaksoud, Abd El-Ghany, 
& Hasan, 2013; Letourneau et al., 2013), few predictors of this effect of treatment 
have been identified (Dewailly, et al., 2014, Anderson et al., 2015). Further 
research is warranted to provide reliable biomarkers to help clinicians accurately 
identify cancer survivors at increased risk for reproductive dysfunction (Abusief et 
al., 2012).  
In clinical practice, a woman’s level of ovarian function is currently 
determined with measures of FSH, LH, and the presence or absence of menses. 
However, neither FSH nor menstrual cyclicity post-cancer treatment are reliable 
predictors of future fertility (Knight et al., 2015). A more reliable measure of the 
risk for premature ovarian failure and subsequent infertility is the size of the 
ovarian follicle pool (ovarian reserve). A biomarker which more closely reflects 
the number of remaining follicles in the ovary would have significant clinical 
potential.  
A biomarker is defined as ‘‘a characteristic that is objectively measured 
and evaluated as an indicator of normal biological processes, pathogenic 
processes, or pharmacologic responses to a therapeutic intervention’’ (National 
Institute of Health Biomarker Definition Working Group, 2001, p. 91). A recently 
identified biomarker of ovarian reserve is anti-Müllerian hormone (AMH). Plasma 
levels of AMH reflect the continuous non-cyclic growth of small follicles, and 
therefore mirror the size of the remaining follicle pool (Jeppesen, Anderson, 
Kelsey, Christiansen, Kristensen, Jayaprakasan, Campbell, et al., 2013). Kelsey 
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et al. developed and validated the first model of AMH, mapping out the 
chronological trajectory of the hormone from conception to menopause (Kelsey, 
Wright, Nelson, Anderson, & Wallace, 2011). La Marca et al. went on to establish 
normative age-ranges to aid in the clinical interpretation of AMH values (La 
Marca et al., 2012).  
Ovarian reserve declines naturally with age; however, recent research 
demonstrates that chronological age alone is not an accurate indicator of 
reproductive age and that other factors affect the depletion of the ovarian 
follicular pool over time (Dolleman et al., 2013). Identifying factors that contribute 
to the decline of the ovarian reserve may aid in the prevention and early 
detection of follicle depletion, premature ovarian insufficiency and impaired 
fertility. AMH is prematurely reduced in CCS (Anderson & Wallace, 2013; 
Charpentier et al., 2014; Miyoshi et al., 2013), and may be an early marker of 
significant gonadotoxicity post treatment (Brougham et al., 2012; Lie Fong et al., 
2009). Several studies have demonstrated the utility of pre-treatment AMH 
concentrations to predict risk of post treatment ovarian dysfunction in cancer 
survivors (Anderson & Wallace, 2013; Lunsford, Whelan, McCormick, & McLaren, 
2014). However, the predictive value of AMH in cancer survivors is limited due to 
incomplete knowledge of factors that influence AMH concentrations (Abusief et 
al., 2012; van Dorp et al., 2014). There is also limited information on how 
changes in AMH relate to changes in serum gonadotropin levels (e.g. follicle 
stimulating hormone) affecting fertility in women, and the predictive value of AMH 
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in assessing reproductive potential in young cancer survivors (Lunsford et al., 
2014).  
One of the primary regulators of reproductive function is the hypothalamic-
pituitary-adrenal (HPA) axis. Precise levels of glucocorticoids are required for 
proper ovarian function (Whirledge & Cidlowski, 2010). At homeostatic levels, 
cortisol contributes to steroid biosynthesis and maintenance of gonadotropin 
release; at elevated levels, it suppresses gonadotropin-releasing hormone 
(GnRH) secretion, reduces pulsatile LH secretion, and increases rates of follicle 
atresia (Breen & Mellon, 2014; Kalantaridou et al., 2010; Whirledge & Cidlowski, 
2010; Whirledge & Cidlowski, 2013). It is well established that psychological 
stress impairs reproductive function by activating the HPA axis (Louis et al., 
2011; Lynch, Sundaram, Maisog, Sweeney, & Buck Louis, 2014). Stress is also 
associated with increased concentrations of pro-inflammatory cytokines, such as 
interleukin-6 (IL-6), which may reflect reduced sensitivity to the anti-inflammatory 
effects of cortisol (Rohleder, Aringer, & Boentert, 2012; Sribanditmongkol, Neal, 
Patrick, Szalacha, & McCarthy, 2014). Increased IL-6 levels diminish aromatase 
activity within ovarian follicles, inhibiting steroidogenesis and follicle maturation 
(Taghavi et al., 2014). 
Cancer survivors experience high rates of psychological stress and HPA 
dysregulation (Oancea et al., 2014; Taylor, Absolom, Snowden, & Eiser, 2012; 
Zeltzer et al., 2009). As both higher rates of psychological stress and 
reproductive dysfunction are observed in cancer survivors, this study explored 
the relationship between psychological stress and biomarkers of ovarian function 
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in young cancer survivors. The purpose of this study was to explore 
relationships between perceived stress, HPA activity, and ovarian function 
in a sample of female survivors of childhood cancer. 
Specific Aims 
 
 
Aim 1: To describe the relationship between perceived stress and HPA activity in 
female childhood cancer survivors.  
Aim 2: To explore the relationship between perceived stress, biomarkers of HPA 
activity, gonadotropin levels, and AMH in female childhood cancer survivors.  
Significance to vulnerable populations 
 
 
“The term ‘vulnerability’ is used to identify individuals and groups at risk of 
harm” (Spiers, 2000, p. 715). Thus, vulnerable individuals or groups are defined 
based on a real or perceived likelihood of experiencing an adverse outcome due 
to the nature of their circumstances. The definition of a cancer survivor starts 
from the time of diagnosis; accordingly, in the United States, there are more than 
420,000 survivors of cancer diagnosed before the age of 21, which is 
approximately one in every 750 individuals (Tonorezos et al., 2015). The number 
of cancer survivors is growing because there have been improvements in the 
early detection and treatment of cancer. However, the cure is not an end to 
health concerns; many survivors face lifelong challenges to their health due to 
the late effects of cancer treatment. Over two thirds of survivors exhibit at least 
one chronic health condition 5 to 14 years after diagnosis (Phillips et al., 2015). 
At risk of numerous adverse health outcomes, cancer survivors make up a 
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vulnerable population, with distinct and highly variable needs based on cancer 
diagnosis, treatment, and duration.  
CCS often do not receive adequate risk-based survivorship care as they 
transition from pediatric oncology to adult care. Despite the growth of 
survivorship clinics, a recent study by Zheng et al. (2015) found that the majority 
of CCS (72.2%) did not attend a clinic even at 10 years post-diagnosis. 
Researchers offer potential explanations for this discrepancy; CCS do not 
receive adequate education regarding the risks of treatment, providers lack 
sufficient knowledge of risks and fail to recommend proper long-term 
surveillance, and the transfer to adult care lacks standardization (Kremer et al., 
2013; Phillips et al., 2015; Szalda et al., 2016; Zheng, Sint, Mitchell, & Kadan-
Lottick, 2015).     
As a response, survivorship research has emphasized the importance of 
developing personalized follow-up care plans based on individual risk so as to 
prevent chronic disease and improve quality of life in this population (Salz et al., 
2015). In order to provide appropriate individualized follow-up for cancer 
survivors, clinicians need tools to help them to stratify risk. However, in order to 
develop effective risk models for the prediction of late-effects, it is necessary to 
have sufficient knowledge of each variable included in the models (Salz et al., 
2015).  
One effect of cancer treatment that is particularly concerning for cancer 
survivors is reproductive dysfunction. Female cancer survivors are at increased 
risk of premature ovarian insufficiency and fertility problems, and this effect of 
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treatment is associated with significant psychological distress, negatively 
impacting quality of life in this population (Terenziani et al., 2014). And yet, 
studies consistently demonstrate that cancer survivors receive inadequate fertility 
care, which consists of a thorough evaluation of infertility risk and counseling on 
options for the preservation of fertility and the treatment of infertility (Barton et al., 
2013; Noyes, Knopman, Long, Coletta, & Abu-Rustum, 2011; Salih et al., 2015). 
Barton et al. (2013) found that compared to sibling controls, cancer survivors 
were approximately half as likely to be treated for infertility. Kim et al. (2016) 
found that survivors who received fertility counseling prior to treatment were 
more likely to pursue fertility care post treatment. However, the majority (73%) 
did not recall receiving sufficient information regarding risks of cancer treatment 
on future fertility or options for fertility preservation (Kim et al., 2016). One of the 
primary reasons for this disparity is the difficulty in quantifying risk of reproductive 
dysfunction after cancer treatment due to the lack of a sensitive biological marker 
of ovarian function (Barton et al., 2013).  
This study contributes to our knowledge of AMH as a biomarker of ovarian 
reserve in a population at high risk for reproductive dysfunction. Existing 
biomarkers of reproductive function, such as FSH, may not change until infertility 
is advanced. AMH levels may be important in predicting risk for infertility post 
treatment early enough that interventions to promote fertility are likely to be 
successful (Gordon, Kanaoka, & Nelson, 2015).  
Cancer survivors also report increased levels of perceived stress and 
demonstrate alterations in HPA activity. The effects of chronic stress on ovarian 
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reserve are poorly understood.  This study therefore sought to increase the value 
of AMH as a biomarker of ovarian reserve by exploring the association between 
stress, gonadotropins, and AMH in a population of female survivors of childhood 
cancer. The study’s findings will be used to inform future research to improve 
clinical decision-making based on an individual’s vulnerability to the effect of 
cancer treatment on reproductive function.  
Significance to nursing knowledge development 
 
 
 The late effects of cancer and survivorship care reflect 8 of the top 20 
ranked priorities in oncology nursing research (LoBiondo-Wood et al., 2014).The 
goal of survivorship care is to individualize care to maximize quality of life. The 
ability to tailor treatment plans depends on the availability of accurate biomarkers 
that can reliably predict vulnerabilities to the late effects of cancer (Knobf et al., 
2014). Cancer survivors are at increased risk of infertility and reproductive 
dysfunction; however the mechanism underlying this late effect is not well 
understood (Barton et al., 2013). Fertility is a high priority for survivors of 
childhood cancer and is correlated with quality of life in this population (McLaren 
& Bates, 2012).  
Further research is needed to increase knowledge of factors contributing 
to reproductive dysfunction to improve prediction models for the risk of this late 
effect of cancer and its treatment. The knowledge gained in this study will allow 
patients, researchers and clinicians to collaborate in addressing the complex and 
multi-factorial etiology of reproductive dysfunction in female cancer survivors 
(Bhatia et al., 2015; Woodruff, 2013). Targeted interventions to prevent a 
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premature decline in ovarian functioning will decrease the prevalence of 
reproductive dysfunction and its associated financial and psychological burden to 
patients.  
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Chapter 2. Review of the Literature 
 
 
Chapter 2 consists of two parts. Part I includes a description of life history 
theory and how it will be used to structure the study’s main concepts and explore 
relationships between them. Part II will review the research on AMH as a 
biomarker of the ovarian reserve, its current uses in reproductive medicine, and 
its promising potential as a predictor of fertility post treatment in cancer survivors.   
Part I: Theoretical Framework:  
Life History Theory 
 
 
The theoretical framework used to guide this study is life history (Ellis, 
2013; Whirledge & Cidlowski, 2013). Rooted in evolutionary biology, life history 
theory was developed to explain variation in life history strategies, which are 
resource allocation strategies adopted by organisms to optimize survival and 
reproduction throughout the life course and across varying environmental 
conditions. The task of all organisms is essentially the same, to distribute 
material and energy resources to competing life functions: bodily maintenance, 
growth and reproduction. Because resources are limited, an organism must 
make trade-offs, prioritizing their use in one domain at the expense of other 
competing domains (Ellis, Figueredo, Brumbach, & Schlomer, 2009). Life 
history traits, characteristics that determine rates of bodily maintenance, 
reproduction, and growth, are the primary units of analysis in life history theory. 
Both individually and collectively, life history traits provide a window into an 
organism’s life history strategy and the developmental continuum that results 
from a chain of resource allocation decisions (trade-offs). The main life history 
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traits are age and size at maturity, reproductive investment, reproductive 
lifespan, and aging (Stearns, 2000). 
Influences on Life History Strategies 
 
 
Life history traits are influenced by an organism’s genetic characteristics 
and environmental conditions. These traits form the organism’s life history 
trajectory or continuum. Based on the availability of extrinsic and intrinsic 
resources, the organism will coordinate tradeoffs so as to optimize its overall 
fitness. “A synchronized optimization of tradeoffs is therefore at the heart of what 
constitutes a coherent and coordinated [life history] strategy” (Ellis et al., 2009, p. 
212). While life history strategies are varied, general patterns, or continua, can 
be observed. These continua have been described as taking either a ‘slow’ or 
‘fast’ course, dependent on environmental conditions.  
Ellis describes two types of environmental influence that can shape an 
organism’s life history strategy: environmental harshness and environmental 
unpredictability. “Environmental harshness indexes the rates at which external 
factors cause disability and death at each age in a population” (Ellis et al., 2009, 
p. 206). While classical life history theory defines harshness as the rate of 
mortality in a population, Ellis expanded the concept to include non-fatal injury, 
disease, and other sources of stress, as these can also significantly impact 
reproductive success, and therefore the optimal allocation of resources to 
growth, survival and reproduction. Environmental unpredictability is defined as 
“the rates at which environmental harshness varies over time and space” (Ellis et 
al., 2009, p. 207). While environmental harshness will likely favor some life 
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history strategies over others (selective evolution), environmental unpredictability 
limits any one strategy from having an advantage over another since these 
conditions are largely unavoidable.  
In addition to environmental influence on resource allocation decisions, 
individual characteristics (i.e. genetic and biological factors) impact an 
organism’s life history strategy. As would be anticipated, this results in 
considerable variability, and for this reason, life history trajectories cannot be 
easily divided into slow and fast tracks. Instead, an organism’s life history 
strategy is often a mixture of slow and fast traits. However, identifying general 
patterns that give rise to “clusters of correlated traits” (Ellis et al., 2009, p. 212) 
may improve prediction of future traits as well as increase understanding of 
current ones.  
HPA axis: Regulator of Life History Strategies 
 
 
 Early evolutionary biologists were able to demonstrate that organisms 
make tradeoffs in response to changing environmental conditions and that these 
tradeoffs influence the life course of an organism, but they struggled to identify 
the biological mechanisms that allow organisms to make tradeoffs. Identifying 
these mechanisms is vital to understanding the sources of variation in life history 
strategies (Stearns, 2000). One of the primary mechanisms by which an 
organism responds to changing environmental conditions is the hypothalamic-
pituitary-adrenal (HPA) axis (Ellis, 2013). Environmental challenges or stressors 
activate the HPA axis and increase glucocorticoid secretion, directing resources 
to vital physiological activities such as energy mobilization, cardiac output, and 
	 13	
cognition, and away from less vital functions. Because reproduction is 
energetically costly, when resources are limited, an organism is likely to prioritize 
survival over reproduction, delaying fertility until environmental conditions are 
more ideal. The HPA axis, as a primary mediator of resource allocation 
decisions, plays an important role in determining an organism’s life history traits.  
The HPA axis plays a prominent role in the regulation of the hypothalamic-
pituitary-gonadal (HPG) axis through glucocorticoids, which have both supportive 
and suppressive effects on reproductive function. This complex and 
synchronized neuroendocrine cross talk between the HPA and HPG axes allows 
tradeoffs to occur. At homeostatic levels, glucocorticoids contribute to steroid 
biosynthesis and maintenance of gonadotropin release. During acute stress, 
endogenous glucocorticoids counteract the suppressive effects of prostaglandins 
on reproductive function, thus protecting gonadotropin secretion. This suggests 
that threshold glucocorticoid levels are necessary to maintain adequate 
gonadotropin release (Whirledge & Cidlowski, 2010). Elevated glucocorticoid 
levels suppress reproduction at multiple levels along the HPG axis. Increasing 
glucocorticoid levels down-regulate gonadotropin releasing hormone (GnRH) 
synthesis and decrease GnRH pulsatility, inhibiting the LH surge and delaying 
ovulation, and increasing the rate of ovarian follicle atresia (Whirledge & 
Cidlowski, 2010, 2013).  
Strengths and Weaknesses of Life History Theory 
 
 
Life History theory examines an organism’s life history strategy as a 
dynamic process. The capacity of organisms to adapt to changing environments 
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and adjust life history traits to enhance overall fitness is referred to as 
developmental plasticity (Ellis & Del Giudice, 2014). Developmental plasticity is 
beneficial from an evolutionary perspective. It acknowledges that a single life 
history strategy is unlikely to afford an organism maximal fitness in every 
environment. The ‘best’ strategy for survival and reproduction varies as a 
function of one’s environment and thus a strategy that promotes success in some 
environmental contexts may lead to failure in others (Ellis & Del Giudice, 2014).  
Life history theory contrasts with other prevailing models of toxic stress 
and allostatic load in that it takes into account individual differences in 
developmental adaptation. Ellis and Del Giudice describe models of toxic stress 
as falling short in addressing the variation in life history strategies, since they 
operate on the assumption that chronic stress is fundamentally maladaptive. This 
paradigm, while compelling in the examination and prediction of chronic illness, 
fails to capture the ability of stress response systems to adaptively regulate 
development (Ellis & Del Giudice, 2014). Overall, life history theory offers an 
advantage over other models in its balanced perspective of stress within the 
context of environment and human development. 
Life history theory offers an adequate framework for examining an 
organism’s resource allocations in response to competing physiological demands 
(i.e. survival and reproduction) in the face of changing environmental conditions. 
However, life history theory does not comprehensively explain variation in human 
life history traits. It offers a primarily biological framework for examining 
phenotypic variation, as a complex interplay of biological, environmental, and 
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genetic influences on the human organism. Stearns, the father of life history 
theory, examined phenotypic variation within the context of plant and animal life. 
Ellis and Giudice expanded Stearns’ work by applying life history principles to 
human biology. Their work generated a series of testable hypotheses regarding 
the effects of varying environmental conditions on human life history traits. Life 
history theory does not take into account the effect of social context and personal 
choice on biological processes. While human fertility is contingent upon 
biological, environmental and genetic factors, it cannot be fully explained by 
these influences.  
In order to examine the effects of higher level influences such as social 
context and personal choice on human fertility, biological and environmental 
influences need to be better understood. Despite the limitation of life history 
theory as a biobehavioral framework, it is well suited for the current exploratory 
study examining associations between biobehavioral measures of stress and 
ovarian function. Life history theory has been successfully employed in other 
studies to explore variability in reproductive function and lifespan (Bleil et al., 
2012).  
Application of Life History Theory to Study’s Main Concepts 
 
 
Life history theory provides an ideal framework for exploring factors that 
affect life history traits such as reproductive lifespan. A description of how the 
main life history constructs will be conceptualized and measured in the current 
study follows. A complete description of measures will be presented in Chapter 3. 
As stated above, the purpose of this study was to explore relationships 
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between perceived stress, HPA activity, and ovarian function in a sample of 
female survivors of childhood cancer. 
1. The life history trait that was the main outcome of interest for this study 
was ovarian function. As a concept, it was examined both as current and 
“potential” ovarian function. Current ovarian function was measured using 
serum gonadotropin levels (LH and FSH), serum reproductive hormones 
(estrogen), and menstrual cycle characteristics (regularity, age at 
menarche). Because an organism allocates resources for both current and 
predicted future environments, “potential” ovarian function was also 
measured using ovarian reserve (AMH). This concept is described in 
greater detail in the second part of this chapter. 
2. The resource allocation strategy was conceptualized as HPA activity and 
measured using salivary cortisol and IL-6 and hair cortisol. The HPA axis 
is the mechanism by which an organism takes in information regarding 
environmental conditions and makes tradeoffs to meet current demands 
while also attempting to predict and prepare for future environments.  
3. Environmental influences on ovarian function were conceptualized as 
cancer specific influences and perceived stress. Cancer specific 
influences included cancer diagnosis and treatment type. Stress is “a state 
of threatened or perceived as threatened homeostasis” (Nicolaides, 
Kyratzi, Lamprokostopoulou, Chrousos, & Charmandari, 2015). Perceived 
stress will be measured using the Perceived Stress Scale (Cohen, 
Kamarck, & Mermelstein, 1983).  
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Figure 1: Conceptual-Theoretical-Empirical Model for the Study 
 
Contribution of this study to Life History Theory 
 
 
While it is well established that psychological stress interrupts normal 
reproductive functioning (An, Sun, Li, Zhang, & Ji, 2013; Kalantaridou et al., 
2010; O’Connor et al., 2011; Whirledge & Cidlowski, 2013), the biological 
mechanisms underlying this effect are poorly understood (Bleil et al., 2012; 
Lynch, Sundaram, Buck Louis, Lum, & Pyper, 2012). In this study, we explored 
the influence of chronic stress on ovarian function with the goal of improving our 
understanding of variation in life history strategies (Stearns, 2000). The findings 
expand our knowledge of anti-Müllerian hormone (AMH), a biomarker of ovarian 
reserve. Biomarkers provide insight into life history traits, and give us a window 
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into the resource allocation decisions that constitute an organism’s life history 
trajectory. This study contributes to life history theory by furthering our 
understanding of AMH, a biomarker of ovarian reserve. This knowledge may be 
used to improve the biomarker’s ability to reliably predict the development of 
reproductive life history traits among female CCS. 
Philosophical Underpinnings 
 
 
 A philosophical framework informs the researcher’s understanding of 
reality (ontology), what can be known about reality and how knowledge of reality 
is attained (epistemology). While all scientific inquiry makes implicit claims about 
the nature of reality, unless these philosophical foundations are made explicit, 
research risks superficiality and incongruity. A solid philosophical foundation 
informs the conduct of research, ensuring that the right questions are asked and 
promoting coherence in the research aims, methodology and interpretation of the 
findings (Walsh & Evans, 2014).  
 This study was based on a post-positivist philosophical framework. 
Positivist epistemology is the philosophical framework that informs modern 
science. Positivist inquiry assumes the existence of an objective reality, which 
can be observed and directly perceived through the senses. In this framework, 
knowledge gained about reality is always true and generalizable, and truth is 
dependent not on belief but on knowable facts present in external reality (Clark, 
1998). Positivism rejects the existence and influence of unobservable 
phenomena. The positivist researcher therefore is able to assume an atheoretical 
and unbiased perspective in the research process. While an appealing 
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philosophical framework for the conduct of empirical research, positivism is 
unrealistic in its conceptualization of uncertainty.  
 There is an increasing shift to the post-positivist philosophical framework 
in scientific inquiry. Post-positivism shares the positivistic view that metaphysical 
realities are outside the realm of science, but differs from positivism in that it 
adopts a realist perspective of science, recognizing that unobservable 
phenomena, aspects of reality not directly perceivable or measurable, may 
explain observable phenomena (Clark, 1998). Post-positivist inquiry permits 
theoretical explanations of reality. Thus, in addition to the positivist requirement 
for precision in the measurement of observable phenomena, post-positivist 
inquiry incorporates evidence that can be inferred about unobservable 
phenomena (e.g. evidence obtained through self-report, questionnaires, etc…). 
The post-positivist framework assumes that the “researching human, with or 
without instruments, must shape the research process” (Clark, 1998, p. 1246). 
Post-positivism not only acknowledges but also adjusts for uncertainty in the 
research process, allowing for greater realism in the conduct of scientific inquiry 
and the interpretation of findings. As a consequence, knowledge gained through 
post-positivistic inquiry is contextually bounded and not generalizable to all 
cases.  
Post-positivism aligns well with the truths sought in biological nursing 
research (Letourneau & Allen, 1999). The post-positivist framework supports the 
view that truth is unknowable and that the aim of scientific inquiry is to make 
“warranted assertions”, which represent probabilities about human behavior 
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rather than universal laws governing behavior. Scientific claims are warranted 
when there is sufficient objective evidence about the phenomena under study, 
and when these claims demonstrate coherence and consistency through time 
and critical evaluation. In addition to permitting greater realism in the conduct of 
research, post-positivism also supports critical multiplism, recognizing that there 
is no correct or perfect method and that research questions can and should be 
approached through multiple perspectives.   
 The post-positivist framework best reflects the mode of inquiry used to 
conduct this study. First, the study’s purpose was informed by life history theory, 
which provided an explanatory framework for examining the relationship between 
the study’s main variables (stress, HPA activity, ovarian function). Second, the 
study was exploratory, permitting uncertainty regarding the nature of the 
relationship between the variables. And finally, the statistical methodology 
(discussed in chapter 3) selected for this study was Bayesian structural equation 
modeling (SEM) because it integrates uncertainty about the model parameters, 
appropriate for exploring the relationship between stress and ovarian function in 
a small sample of female cancer survivors.  
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Part II: Literature Review 
The Ovarian Reserve 
 
 
The Ovarian Reserve and Anti-Müllerian Hormone  
 
 
The woman’s reproductive lifespan is determined by the size of the 
primordial follicle pool, or the ovarian reserve. The ovarian reserve is established 
during fetal life when germ cells populate the ovary and form primordial follicles 
(Dunlop & Anderson, 2014). These follicles consist of oocytes surrounded by a 
single layer of squamous granulosa cells, and remain in the phase of the first 
meiotic division until puberty. At birth, the number of primordial follicles is 
estimated at 1 million. This number decreases steadily during a female’s lifespan 
and is reduced to approximately 300,000 at menarche. Throughout a female’s 
reproductive years, follicles are recruited from the primordial pool and progress 
through the various stages of follicle growth. At the start of each menstrual cycle, 
one dominant follicle is selected for ovulation (Visser, de Jong, Laven, & 
Themmen, 2006).  
At present, there are is no way to directly assess the ovarian reserve; 
however, there are several biomarkers that provide an indirect measurement of 
its size based on the assumption that the number of growing follicles is correlated 
with the non-growing primordial follicle pool (Dunlop & Anderson, 2014). The 
association between these indirect measures and the number of non-growing 
follicles has been confirmed in histological studies (Hansen, Hodnett, Knowlton, 
& Craig, 2011; Kevenaar et al., 2006).  
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One biomarker that has shown considerable promise in the field of 
reproductive medicine is anti-Müllerian hormone (Dewailly et al., 2014). Anti-
Müllerian hormone (AMH) is a dimeric glycoprotein and a member of the 
transforming growth factor β family of growth and differentiation factors (Dewailly 
et al., 2014). Initially, AMH, also known as Müllerian inhibiting substance (MIS), 
was studied within the context of male sexual differentiation (Dewailly et al., 
2014; Visser et al., 2006). AMH is produced by the Sertoli cells of the testes, and 
induces regression of the Müllerian ducts, the initial clustering of embryonic cells 
from which the female reproductive tract develops (Visser et al., 2006). However, 
AMH also plays a role in ovarian follicle growth, specifically in regulating the pace 
of follicle recruitment and selection. AMH is expressed in granulosa cells of small 
growing follicles with its strongest expression in preantral and small antral 
follicles between 5-8mm in diameter (Jeppesen, Anderson, Kelsey, Christiansen, 
Kristensen, Jayaprakasan, Campbell, et al., 2013). AMH is no longer expressed 
by granulosa cells during FSH-dependent stages of follicle growth or by atretic 
follicles, degenerated follicles that do not ovulate during the menstrual cycle 
(Broekmans et al., 2008; Dewailly et al., 2014). 
The role of AMH in follicle growth was first characterized in studies of 
AMH-deficient mice (Visser et al., 2007). These studies demonstrated that AMH 
acts as an inhibitor of primordial follicle recruitment (Durlinger et al., 1999, 2002). 
AMH deficient mice had more growing follicles and an increased rate of oocyte 
degeneration and follicle atresia (Visser et al., 2007), indicating that in the 
absence of AMH, primordial follicles are recruited at a faster rate, leading to a 
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premature depletion of the follicle pool. Another consequence of AMH absence is 
an increased sensitivity of growing follicles to FSH. AMH has an inhibitory effect 
on FSH and therefore plays an important role in the selection of the dominant 
follicle (Durlinger et al., 2001; Sacchi et al., 2016; Visser & Themmen, 2014; 
Visser, de Jong, Laven, & Themmen, 2006).  
AMH: Validated Measurement and Normative Age Ranges 
 
 
Until recently, FSH and inhibin B were the gold standard measures of the 
ovarian reserve. However, changes in FSH and inhibin B levels are not 
detectable in serum until there is a significant reduction in the follicle pool 
(Steiner, 2013), making timely detection and intervention challenging. AMH levels 
decline before other biomarkers of the ovarian reserve, and are therefore one of 
the earliest detectable changes in the process of ovarian aging (Sills, Alper, & 
Walsh, 2009). Several prospective longitudinal studies involving normo-ovulatory 
women have found that declining AMH concentrations predict with reasonable 
accuracy the onset of menopause (Broer et al., 2011; van Disseldorp et al., 
2008). The hormone is ideal as a research and clinical measure because 
concentrations do not fluctuate significantly across the menstrual cycle, and are 
independent of FSH, LH, and E2 levels (Hehenkamp et al., 2006; La Marca et al., 
2010; Shaw et al., 2011). AMH assays have been developed and serum levels 
correlate with the number of developing follicles in the ovary (Didier Dewailly et 
al., 2014).  
Kelsey et al. (2011) generated the first validated model of AMH in healthy 
females from conception until menopause. Their findings demonstrate that AMH 
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rises steadily until its peak at mean age of 24.5 years, at which point it declines 
until menopause. The model was generated utilizing data from studies of women 
without a diagnosis of infertility or chronic illness. According to their model, 34% 
of the variation in AMH is due to age alone (Kelsey, Wright, Nelson, Anderson, & 
Wallace, 2011). La Marca et al. (2010) established normative AMH ranges based 
on age. In order for AMH values to be clinically interpreted, an established 
nomogram with normative age ranges is vital. La Marca et al. (2010) 
acknowledge the need for more studies to refine these ranges and establish 
standardized values for use in research and clinical/diagnostic assessment.  
Current Uses of AMH in Reproductive Medicine 
 
 
 AMH has already demonstrated considerable clinical potential, most 
significantly in the field of assisted reproductive technology. Since ovarian 
reserve correlates with the size of the remaining follicular pool, it is thought to be 
associated with reproductive potential. The variable response to in vitro 
fertilization (IVF) treatment is thought to be related to variability in the ovarian 
reserve (Reijnders et al., 2016). Diminished ovarian reserve is predictive of poor 
response to gonadotropin therapy, therefore limiting the possibility of pregnancy 
(Iliodromiti, Kelsey, Wu, Anderson, & Nelson, 2014). AMH concentrations are 
also useful for predicting ovarian hyperstimulation syndrome, which is a 
potentially life-threatening condition (Dewailly et al., 2014). Currently there is 
insufficient evidence to base treatment decisions within assisted reproductive 
technology solely on a test of ovarian reserve (Iliodromiti et al., 2014). However, 
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tests of ovarian reserve have proven useful for tailoring treatment and pre-IVF 
treatment counseling (Nelson, 2013).  
 Since AMH regulates the pace of follicle growth by inhibiting initial 
recruitment from the primordial follicle pool and dominant follicle selection, it also 
may have potential application in understanding the pathophysiology of ovarian 
dysfunction (Broekmans et al., 2008). One area of particular interest is polycystic 
ovary syndrome (PCOS). PCOS is the most common female reproductive 
disorder and occurs in up to 10% of all women. The three diagnostic hallmarks of 
the syndrome include oligo/amenorhhea, clinical or biological signs of 
hyperandrogenemia, and polycystic ovaries assessed by transvaginal ultrasound 
(Broekmans et al., 2008).  Polycystic ovarian morphology is characterized by an 
increased number of intermediate-sized follicles. This suggests an increased rate 
of initial follicle recruitment coupled with arrested follicle maturation. Several 
studies have demonstrated that serum AMH concentrations are markedly 
increased in PCOS patients, which is consistent with the increase of AMH-
producing preantral and small antral follicles (Broekmans et al., 2008). Thus, 
AMH may serve as a serological biomarker of PCOS (Iliodromiti et al., 2013).  
Factors Associated with AMH Concentrations  
 
 
While ovarian reserve naturally declines with age, age alone is not 
predictive of ovarian age or reproductive status. The decline of ovarian reserve is 
primarily due to apoptotic loss of oocytes (programmed cell death) rather than 
ovulation (Tremellen, Kolo, Gilmore, & Lekamge, 2005). Thirty-four percent of the 
variation in AMH concentrations is due to age, meaning that the remaining 66% 
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is due to other factors (Kelsey et al., 2011). Identifying these factors may help to 
elucidate predictors of reproductive dysfunction and disease. Understanding 
factors that influence AMH levels in normo-ovulatory women may also help to 
establish reliable normative age ranges for use in clinical practice and research.  
Several studies have explored the influence of both reproductive and 
lifestyle determinants of AMH concentrations (Dolleman et al., 2013; Freeman et 
al., 2007; La Marca et al., 2010; La Marca, Stabile, Artenisio, & Volpe, 2006; 
Malhotra, Bahadur, Singh, Kalaivani, & Mittal, 2013; Nelson, Stewart, Fleming, & 
Freeman, 2010; Steiner, Stanczyk, Patel, & Edelman, 2010; Tsepelidis et al., 
2007). Oral contraceptive use is associated with lower AMH concentrations 
(Dolleman et al., 2013; Kristensen et al., 2012; Shaw et al., 2011). However, 
some studies have reported no association between oral contraceptive use and 
AMH concentrations (Steiner et al., 2010). Some studies have demonstrated a 
negative correlation between body mass index (BMI) and AMH (Freeman et al., 
2007; Steiner et al., 2010), but again this association has not been consistently 
demonstrated (Dewailly et al., 2014; Dolleman et al., 2013). Pregnancy is 
associated with lower AMH concentrations (Dolleman et al., 2013; Nelson et al., 
2010). Smoking is associated with lower AMH concentrations (Dafopoulos et al., 
2010; Hawkins Bressler et al., 2016).  
Several studies have also demonstrated an association between AMH 
concentrations and menstrual cycle irregularity (Dolleman et al., 2013; Kristensen 
et al., 2012). AMH has been studied extensively within the context of advanced 
reproductive technologies and various pathological conditions, but little is known 
	 27	
about the factors associated with variation of AMH concentrations observed in 
normo-ovulatory women (Dolleman et al., 2013). The first manuscript in this 
dissertation, entitled, “An Integrative Review of Modifiable Biobehavioral Factors 
Associated with Anti-Müllerian Hormone Concentrations” provides an integrative 
review of the biobehavioral predictors of AMH concentrations in normo-ovulatory 
women (Appendix A). 
The relationship between AMH concentrations and reproductive outcomes 
is disputed in the literature.  AMH is considered a useful biomarker of 
reproductive potential in infertile women undergoing assisted reproductive 
technology (Burks et al., 2015; Reijnders et al., 2016). However, its value as a 
predictor of natural fertility is still uncertain (Hagen, Vestergaard, et al., 2012; 
Steiner et al., 2011, 2017; Zarek et al., 2015). This is an important distinction as 
AMH concentrations are applied and interpreted in clinical practice. The 
diagnostic and prognostic value of AMH continues to expand, however more 
research is needed to examine its association with reproductive outcomes in 
healthy populations. 
Stress and the Ovarian Reserve 
 
 
This study explored the effect of chronic stress on ovarian reserve. 
Allsworth et al. (2001) were among the first to investigate the effect of chronic 
stress on the ovarian reserve. They examined whether ovarian hormone levels 
(FSH and estradiol [E2]) indicative of menopausal changes were observed at an 
earlier age among 732 women (ages 36-44) who experienced physical or sexual 
violence compared with women who reported no exposure to violence. More 
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extreme levels of both FSH and E2 in relation to abuse history among 
premenopausal women 41-45 years of age were observed, whereas little 
difference was seen for younger women. Allsworth et al. offer a potential 
explanation for the association between abuse history and ovarian function. 
Stress activates the HPA axis and stimulates glucocorticoid secretion, which in 
turn inhibits the synthesis and release of GnRH, LH, and FSH. However, the 
authors did not include a biomarker of stress in the study and as a result, were 
unable to examine this proposed biological mechanism (Allsworth, Zierler, 
Krieger, & Harlow, 2001).  
Pal et al. (2010) expanded the work of Allsworth et al., examining 
associations between acute (serum cortisol) and chronic (history of abuse and/or 
drug use) psychosocial stress and biomarkers of ovarian reserve (FSH and 
Müllerian-Inhibiting-Substance (MIS), now referred to as AMH) in 89 pre-
menopausal infertile women <42 years of age. Women were considered to have 
diminished ovarian reserve (DOR) if they either demonstrated early follicular 
phase (days 1–3) FSH levels >10 mIU/ml and/or poor ovarian response during 
attempts at ovarian hyperstimulation. Those with chronic stress demonstrated 
reduced ovarian reserve parameters: higher FSH (p = 0.051) and significantly 
lower MIS levels (p = 0.034), and were three times more likely to be diagnosed 
with DOR (p = 0.025). However, no association was observed between serum 
cortisol levels and DOR. The authors concluded that chronic, but not current 
stress, was associated with DOR. They proposed inappropriate HPA activation 
as a plausible explanation for this association (Pal, Bevilacqua, & Santoro, 2010). 
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Because a biomarker of chronic stress was not included in the study, they were 
unable to provide evidence supporting this theory. 
Cancer and Reproductive Dysfunction 
 
 
Cancer survivors are at increased risk of reproductive dysfunction (Barton 
et al., 2013). Cancer treatments cause damage to the ovaries and impair 
reproductive potential through accelerated follicle loss (Lie Fong et al., 2009). 
The proposed mechanism is apoptotic cell death in growing follicles, accelerating 
the movement of follicles from the primordial pool to replace those lost to atresia 
(Letourneau et al., 2013; Lie Fong et al., 2009). Increased follicle atresia 
coincides with a decrease in quantity and quality of oocytes, increasing the risk of 
infertility and spontaneous abortion (Knopman et al., 2010). The degree of risk of 
impaired fertility depends on age at cancer diagnosis (El-Shalakany et al., 2013) 
and the treatment regimen (Anderson & Wallace, 2013; Knopman et al., 2010).  
Many chemotherapeutic agents are known to have cytotoxic effects on the 
ovary, and are associated with premature ovarian failure and chemotherapy-
related amenorrhea (Oktem & Oktay, 2009). Chemotherapy exerts its 
gonadotoxic effects by activating apoptotic machinery in the oocyte and 
enclosing granulosa cells (Oktem & Oktay, 2009). This leads to premature 
depletion of the ovarian follicle pool with a subsequent decline of the ovarian 
reserve (McLaren & Bates, 2012). The highest risk is associated with alkylating 
agents (Barton et al., 2013), and with pelvic radiation (Reinmuth et al., 2013). 
However, the quantification of risk of infertility remains challenging for healthcare 
providers (Barton et al., 2013) due in large part to an incomplete understanding 
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of the factors contributing to long-term reproductive function in this population 
(Abusief et al., 2012).  
AMH in Female Cancer Survivors 
 
 
 Reproductive potential has been identified as a factor significantly 
associated with quality of life in cancer survivors (Kondapalli et al., 2014). AMH 
has shown considerable promise in predicting post-treatment risk for infertility in 
female cancer survivors (Anderson, Rosendahl, Kelsey, & Cameron, 2013). 
Recent studies have demonstrated associations between pre- and post-
treatment AMH concentrations (Anderson & Cameron, 2011; Anderson et al., 
2013; Brougham et al., 2012). Lower pre-treatment AMH concentrations are 
predictive of long term loss of ovarian function (Anderson et al., 2013; Brougham 
et al., 2012).  
Ovarian reserve is decreased in female survivors of childhood cancer 
(Charpentier et al., 2014). Several studies have examined the influence of 
treatment-related and biobehavioral factors on AMH concentrations post-
treatment. Treatment-related factors include the therapeutic regimen 
(Charpentier et al., 2014), the length of exposure (El-Shalakany et al., 2013; 
Reinmuth et al., 2013), and the age of the patient at the time of treatment (Barton 
et al., 2013; El-Shalakany et al., 2013). There is also evidence to suggest that 
cancer pathology may contribute to prematurely reduced AMH concentrations. 
Van Dorp et al. found that compared to healthy age-matched controls, girls newly 
diagnosed with cancer presented with significantly lower serum AMH levels (p < 
0.001) (van Dorp et al., 2014). Biobehavioral factors include obesity (van Dorp et 
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al., 2013) and age at menarche (El-Shalakany et al., 2013). Pre-treatment 
planning and the ability to provide individualized fertility prognoses depends on 
increased understanding of factors associated with the ovarian reserve in female 
childhood cancer survivors. This information can then be used to assist decision-
making regarding treatment options and fertility preservation (Anderson et al., 
2013; Knopman et al., 2010). 
Gaps in the Literature 
 
 
The study of ovarian aging as a biological process spanning many years 
has proven challenging. Premature ovarian aging increases risk for infertility and 
early menopause. In addition to reproductive dysfunction, premature menopause 
is associated with increased risk of osteoporosis and cardiovascular disease 
(Letourneau et al., 2013; Salih et al., 2015). There is great need for a reliable 
biomarker of the ovarian reserve to assist in the early detection of infertility. While 
the number of studies examining AMH as a biomarker of the ovarian reserve has 
increased considerably in the last fifteen years, significant gaps in the literature 
remain. First, the value of AMH as an age-independent predictor of fecundity has 
not yet been established (La Marca et al., 2010). In the context of assisted 
reproduction, AMH provides useful information regarding reproductive potential 
and ovarian responsiveness to hormonal stimulation, but its predictive accuracy 
of live birth is poor (Iliodromiti et al., 2014). In the context of unassisted 
reproduction, only a small number of studies have examined the association 
between AMH and fecundability (Hagen, Aksglaede, et al., 2012; Steiner et al., 
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2017b; Zarek et al., 2015), and these failed to find an association between 
having a low ovarian reserve and a longer time to pregnancy.  
Second, most of the studies that have examined the predictive value of 
AMH have been based on single measurements. Freeman et al. (2012) found 
that the rate of change in AMH levels improved the precision of estimates of time 
to menopause (Freeman, Sammel, Lin, Boorman, & Gracia, 2012). Longitudinal 
studies are needed to determine if the rate of change in AMH levels also 
improves prediction of fertility outcomes. Third, more studies are needed to 
identify the biobehavioral factors that influence serum AMH concentrations in 
order to account for these effects in prediction models (Dolleman et al., 2013). 
And finally, because AMH alone is unlikely to provide enough information to 
predict reproductive potential, more studies are needed to develop and test 
models based on multiple predictors (Venturella et al., 2015). This study 
contributes to the literature by improving our understanding of chronic stress on 
the ovarian reserve in female cancer survivors, a population at high risk of 
prematurely diminished ovarian reserve.  
Preliminary Work 
 
 
In June 2010, the author conducted a pilot study at the Hatfield Clinical 
Research Center at the National Institutes of Health. The study sample was 
obtained using an existing database that included urine cortisol levels from 36 
reproductive age females with and without chronic abdominal pain (CAP).  
Laboratory staff assisted with the analysis of frozen serum samples for AMH 
concentrations using a commercially available assay (AMH GEN II ELISA, 
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Beckman Coulter). Women with CAP had significantly lower 5-hour urinary 
cortisol, a finding that is consistent with literature reporting hypocortisolemia in 
individuals with chronic pain (Generaal et al., 2014). Using contingency table 
analysis, we found that women with clinically abnormal (high or low) AMH levels 
had significantly lower 5-hour urinary cortisol (p = 0.04) compared to women with 
normal AMH levels (Hardy, McCarthy, Fourie, & Henderson, 2016). These 
findings suggest that HPA dysregulation may contribute to the variation of AMH 
levels warranting further exploration of this relationship.  
In the summer of 2017, the author examined patterns of cardiometabolic, 
psychological and reproductive parameters of health in postpartum women and 
examined the ovarian reserve within these patterns (Hardy, Garnier-Villarreal, 
McCarthy, Anderson, Reynolds, unpublished manuscript) (Appendix B). Latent 
class analysis (LCA) was used to classify the subjects of the whole sample 
(heterogeneous) into smaller homogeneous groups in which members are similar 
to each other and different from subjects in other groups. The objective is to 
identify groups underlying the data, when the number of underlying groups is 
unknown (DiStefano, 2012; Kaplan, 2014). The LCA model included the following 
variables: fasting lipids (triglycerides, cholesterol, and HDL), fasting glucose, 
fasting cortisol, lean/obese, breastfeeding status, anxiety, depression, FSH, LH, 
E2, and AMH levels. The best fitting LCA model included 3 classes. For the 3 
class LCA, 32.2% (n=22) of the sample was in Class 1, 43.4% (n=30) of the 
sample was in Class 2, and 24.3% (n=17) of the sample was in Class 3. We 
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found that women (class 3) who had lower ovarian reserve also had less 
favorable cardiometabolic and psychological profiles.  
These findings suggest that cardiometabolic and psychological factors 
may contribute to the process of ovarian aging. While numerous studies have 
examined these factors in association with AMH (Dolleman et al., 2013; La 
Marca et al., 2012), few have explored patterns within and between women as a 
means of identifying subgroups. Accurate group classification would facilitate risk 
stratification and early detection in the context of ovarian aging (Pal et al., 2010). 
The findings from this study provided preliminary evidence to support the 
hypothesis that there are modifiable biobehavioral factors that contribute to 
variation in the process of ovarian aging.  
Study Aims, Research Questions, and Hypotheses 
 
 
Aim 1: To describe the relationship between perceived stress and HPA activity in 
female childhood cancer survivors.  
Research question 1: Is perceived stress associated with HPA activity in female 
childhood cancer survivors?  
Hypothesis: Higher levels of perceived stress will be associated with 
dysregulated HPA activity. 
Research question 2: Is the diurnal pattern of HPA activity (salivary cortisol and 
IL-6) associated with long-term average cortisol secretion (hair cortisol)?   
Hypothesis: Flatter diurnal patterns will be associated with lower long-term 
average cortisol secretion. 
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Aim 2: To explore relationships between perceived stress, biomarkers of HPA 
activity, gonadotropin levels, and AMH in female childhood cancer survivors.  
Research question 1: Is perceived stress associated with ovarian function 
(gonadotropin and AMH levels) in female childhood cancer survivors?  
Research question 2: Is dyregulated HPA activity associated with ovarian 
function (gonadotropin and AMH levels) in female childhood cancer survivors? 
Hypothesis: Increased levels of perceived stress and dysregulated HPA activity 
will be associated with abnormal gonadotropin levels and diminished ovarian 
reserve.  
Study Assumptions 
 
 
This study was based on several assumptions. The first was that stress, a 
complex and multifaceted construct, could be measured through a combination 
of biological and self-report measures. It was assumed that chronic stress could 
be accurately measured with self-report of perceived stress levels over the past 
month, diurnal cortisol patterns (intercept and slope), and hair cortisol levels 
which reflect the average cortisol level over a month or more. Second, the study 
assumed that participants were reliable and trustworthy sources of information 
regarding their medical history and that the participants’ treatment team kept 
accurate medical records regarding their diagnoses and treatments. Third, the 
study assumed that the laboratory testing of hair cortisol, serum gonadotropin 
levels and serum AMH levels was completed and recorded precisely and 
accurately.  
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Chapter 3. Research Design and Methods 
 
 
Sample and Settings 
 
 
The sample for this descriptive, cross-sectional cohort study consisted of 
24 female subjects between the ages of 16 and 35 who were previously treated 
for cancer (including leukemia and brain tumors) at the Edinburgh Children’s 
Cancer Centre, Royal Hospital for Sick Children (RHSC). Sample size and power 
estimates are challenging in an exploratory model of predictors, due to the fact 
that one is not aware of predictor effects and cannot put forth anticipated effect 
sizes.  
Rules-of-thumb regarding appropriate sample sizes were used to best 
estimate the necessary sample size. The subject to variable (SV) ratio has been 
an attempt to ensure that the sample is “large enough” to minimize “parameter 
inflation” and improve “replicability”. While numerous rules-of-thumb exist (Green, 
1991), it has been shown that the power for a test of Cohen’s (1988) effects sizes 
(medium: f2 = 0.15 [R2 = 0.13] to large: f2 = 0.35 {R2 = 0.26]) for partial correlation 
(regression parameters) at approximately 1- b = .80 (Alpha = 0.05) is achieved 
based on Harris’ (1975) rule that N >= 50 + 8m for medium effects, where m = 
the number of predictors. This approximates Cohen’s estimates. Assuming a 
maximum number of predictors around six, to achieve power (0.80, alpha = 0.05, 
two-tailed) a sampling of approximately 41 individuals for six predictors was 
required. Thus in order to achieve a power to detect regression effects slightly 
less than a large effect size, a sample of approximately 50 individuals was 
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needed. Due to several recruitment challenges, obtaining this target sample size 
was not as feasible as originally anticipated. These challenges will be discussed 
in detail in the results and discussion. 
Cancer survivors are seen annually for follow up at the Royal Hospital for 
Sick Children (RHSC) (Wallace, Smith, Kelsey, Edgar, & Anderson, 2014). The 
inclusion criteria were: female patients treated for cancer (including leukemia and 
brain tumors) at the Edinburgh Children’s Cancer Centre, younger than 18 years 
of age at cancer diagnosis and between 16-35 years of age at the time of the 
study visit, at least one year following the conclusion of treatment, and signed 
written informed consent. This age range was selected because subjects are 
likely to be post-pubertal and in the most fertile window of their reproductive 
lifespan. Cancer survivors seen for long-term follow-up at the Royal Hospital for 
Sick Children (RHSC) in Edinburgh, Scotland were selected because of Dr. 
Anderson’s current research on reproductive function and fertility preservation in 
cancer survivors (Wallace et al., 2014). This collaboration minimized burden to 
subjects. In the UK, research subjects aged 16 and older are able to provide 
informed consent. The exclusion criteria were a positive pregnancy test, ovarian 
surgery in the past 6 months, hormonal therapy in the preceding 3 months 
(GnRH agonists, recFSH), alcohol or drug abuse/dependence according to ICD-
10 criteria, and investigational drug received in the past 3 months (90 days).  
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Recruitment and Retention Strategies 
 
 
 One day a month, the RHSC medical staff hold annual review 
appointments for cancer survivors in long-term follow-up. This monthly clinic 
promotes a multi-disciplinary approach to care and encourages long-term follow-
up. Recruitment letters (Appendix 2) were sent to potential study participants two 
weeks prior to their annual review appointment to inform them of the study and to 
invite them to consider participating. Subjects could either send their reply slip by 
mail or inform medical staff of their decision at the monthly clinic.   
Research Sites 
 
 
All data collection occurred at the RHSC. Laboratory analyses were 
conducted at the Queens Medical Research Institute (QMRI). Data analyses 
were conducted at Marquette University. 
Instruments  
 
 
Ovarian function: assessment of ovarian function included serum 
gonadotropin levels (luteinizing hormone (LH), follicle-stimulating hormone 
(FSH)) and AMH. Serum levels of these hormones are routinely measured during 
the annual follow-up appointment as part of standard care at NHS affiliated 
clinics and at regular intervals during in the parent study in Ireland. The 
laboratory results were retrieved from subjects’ medical records. Serum AMH 
levels were analyzed using the Beckman Coulter AMH GEN II ELISA (Beckman 
Coulter Inc., Brea, CA). The AMH Gen II ELISA has a sensitivity of 0.57 pmol/l. 
The validated model of serum anti-Müllerian hormone by Kelsey et al. (2011) and 
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the nomogram with normative values for age published by LaMarca et al. (2012) 
will be used to interpret AMH levels (Kelsey et al., 2011a; La Marca et al., 2012).  
Psychosocial stress was determined using the Perceived Stress Scale 
(PSS-10). Perceived stress is a concept that incorporates an understanding of 
stress as a “cognitively mediated emotional response to an event, not the object 
of the event itself” (Cohen, Kamarck, & Mermelstein, 1983). Perceived stress 
was measured using the Perceived Stress Scale, PSS-10, a self-report 
instrument which measures the degree to which situations in one’s life are 
appraised as stressful over the past month (Cohen, Kamarck, & Mermelstein, 
1983).  
Validation of the PSS-14 
 
 
 Cohen et al. (1983) developed the PSS to determine to what extent the 
respondents found their lives to be “unpredictable, uncontrollable, and 
overloaded”, as these had been consistently found to be central components of 
the experience of stress (Cohen & Williamson, 1988). The items were designed 
for use with community samples with at least a junior high school education. 
Responses to each item range from “never” to “very often” on a 5-point Likert 
scale and a higher score indicates greater stress (Cohen et al., 1983). 
The measure was validated using two samples of college students and 
one sample of adults enrolled in a smoking-cessation program. Cohen et al. 
(1983) first calculated the mean and variance of the PSS-14 scores in each 
sample to determine if there were significant differences between gender and 
age. While mean scores were slightly higher in females than in males, the 
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difference was not statistically significant. They also reported that age was 
unrelated to scores. 
Reliability of the PSS-14 
 
 
Reliability of the measure was tested in each sample using Cronbach’s 
alpha and test-retest correlations. Cronbach’s alpha, a measure of internal 
consistency, was .84, .85, and .86 respectively. Test-retest correlations were 
calculated at two different intervals. In the college students, the time between the 
first and second administration was two days, whereas in the smoking-cessation 
sample, the interval was six weeks. The test-retest correlations were .85 and .55 
for the two-day and the six-week interval respectively. Participants were asked to 
strive for accuracy rather than consistency across time. In this way, the authors 
demonstrated that while the test reliably examines perceived stress, test-retest 
correlations weaken as the time between test administration increases.  
Validity of the PSS-14 
 
 
 Validity was examined using tests of concurrent and predictive validity. To 
test concurrent validity, the CSLES (College Student Life Event Scale) and the 
life-event scale (for the smoking-cessation sample) were used. The authors 
anticipated that perceived stress scores would increase with the number of 
stressful events reported in the life event scales (LES) and that the correlations 
between the scores would be even higher when the impact scores of the events 
were included. As predicted, there was a small to moderate correlation between 
LES and the PSS scores (r = .35-.49) and the correlations increased when 
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including the impact scores. While the authors considered the LES to be the best 
available self-report measure for testing concurrent validity, the authors 
recommend the possibility of using a biomarker of stress such as cortisol for 
future validity testing (Cohen, Kamarck, & Mermelstein, 1983). 
 To examine predictive validity, Cohen et al. (1983) administered a 
depression scale (CES-D), an anxiety scale (SADS), a physical symptom 
checklist (CHIPS), and monitored utilization of health services several months 
before and after the testing session. They predicted that the PSS would be a 
better predictor of depression and anxiety, physical symptomatology, and 
utilization of health services. As anticipated, the PSS was a better predictor of 
depression (r = .65-.76), anxiety (r= .37-.48), utilization of health services (r = .11-
.20), and physical symptomology (r = .52-.70) than the life events scores.  
PSS-10 
 Cohen & Williamson (1988) tested the validity and reliability of the PSS-14 
in a large sample of adults (n = 2,387) in the United States. The authors 
conducted a factor analysis using a principle components method with varimax 
rotation. The analysis revealed a two-factor structure accounting for 41.6% of the 
variance. The PSS-10, a shorter version, was derived by eliminating the four 
items with the lowest factor loadings. The authors conducted a second factor 
analysis with the PSS-10, which resulted in an improvement in both the total 
explained variance (48.9%) and internal reliability (alpha coefficient = .78).  
 To examine construct validity of the PSS-10, Cohen & Williamson (1988) 
examined relations between the PSS scores and other stress measures, health, 
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health service utilization, health behaviors, life satisfaction, and help seeking. 
Similar to the PSS-14, the PSS-10 was moderately correlated with the life event 
scale (r = .32). The PSS scores were weakly correlated with self-reported health 
behaviors, weakly or moderately correlated with self-reported physical illness, 
and moderately correlated with scores on the life satisfaction scale (r = .47). The 
authors conclude that the PSS-10 is as reliable and valid a measure of perceived 
stress as the PSS-14. The PSS-10 also had a tighter factor structure and a 
slightly better internal reliability. They therefore recommend the PSS-10 for use 
in research. 
Utilization of PSS-10 in research 
 
 
 The PSS-10 is one of the most widely used measures of psychological 
stress (E.-H. Lee, 2012). It has been validated for use in numerous populations 
and is currently translated into 25 languages other than English (E.-H. Lee, 
2012). The PSS-10 has been utilized as a measure of perceived stress to 
examine the association between stress and reproductive outcomes (Bleil et al., 
2012; Li, Newell-Price, Jones, Ledger, & Li, 2012; Lynch, Sundaram, Maisog, 
Sweeney, & Buck Louis, 2014b; Schliep et al., 2015), to quantify stress levels in 
cancer survivors (Keir, Swartz, & Friedman, 2007), and to examine the 
effectiveness of interventions to reduce stress in cancer survivors (Loprinzi, 
Prasad, Schroeder, & Sood, 2011). For example, Loprinzi et al. (2011) assessed 
the effect of a SMART (Stress Management and Resiliency Training) program for 
increasing resiliency and decreasing stress and anxiety among breast cancer 
survivors. A total of twelve patients completed the intervention, and eight patients 
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were in the control group. No significant differences in any of the measures were 
noted in the control group. In the intervention group, the PSS score decreased 
from 22.1 ± 5.9 initially to 12.8 ± 6.6 (p = .003). The change in PSS score was 
equivalent in magnitude to other concurrent measures of anxiety and resilience. 
Based on previous use, the PSS-10 is an appropriate measure of stress in 
female cancer survivors.   
HPA Activity 
 
 
HPA activity was determined using measures of salivary cortisol, salivary 
IL-6 and hair cortisol. Analysis of salivary cortisol and IL-6 were performed in Dr. 
Anderson’s lab under the guidance of the Queen’s Medical Research Institute 
(QMRI) staff and in Dr. Bryan Hennessy’s lab under the guidance of the Royal 
College of Surgeons in Ireland (RCSI) staff. Hair (1 cm) will be processed for 
extraction of cortisol in the laboratory of Clemens-Kirschbaum in Dresden, 
Germany as previously described (Kirschbaum, Tietze, Skoluda, & Dettenborn, 
2009). 
Salivary cortisol 
 
 
Cortisol is the main glucocorticoid hormone produced in the adrenal 
cortex. Approximately 90% of cortisol in blood is bound to plasma proteins 
(corticosteroid-binding globulin and albumin), leaving only about 5-10% unbound 
(Kahn, Rubinow, Davis, Kling, & Post, 1988; Kirschbaum & Hellhammer, 1989). 
This latter fraction, which is reflected in salivary cortisol, reflects the biologically 
active corticosteroid that is capable of acting on target tissues (Kirschbaum & 
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Hellhammer, 1989). Cortisol is not secreted continuously, but rather in pulses 
influenced by circadian rhythmicity, evident in its well-characterized diurnal 
pattern with levels highest in the early morning hours and lowest around midnight 
(Kirschbaum & Hellhammer, 1989). 
Advantages  
 
 
Salivary cortisol has many advantages over prior measures used to 
examine HPA activity. In comparison to serum cortisol, salivary cortisol is 
noninvasive, providing an accurate measure of HPA activity without the risk of 
provoking the stress response and potentially compromising the findings (Raff, 
2009). It is easy to collect, making it convenient in both the clinical and research 
settings, especially in cases when repeated sampling is required. Studies have 
reported high compliance with home collection of salivary cortisol with minimal 
burden to participants (Bergen et al., 2012).  
Validity and Reliability 
 
 
Validity of salivary cortisol has been established by examining correlations 
with plasma cortisol levels. The linear correlations between salivary and plasma 
cortisol are high, ranging from r = 0.54 to r = 0.97, with most investigators 
reporting correlation coefficients of r ≥ 0.90. The lower correlations were reported 
in studies comparing salivary cortisol levels with total plasma cortisol levels 
(Kirschbaum & Hellhammer, 1989). Since salivary cortisol levels reflect unbound 
cortisol, correlations with total plasma cortisol levels would yield much lower 
coefficients (Inder, Dimeski, & Russell, 2012). Reliability is assay-dependent. A 
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commercially available Enzyme-Linked Immuno-Sorbent Assay (ELISA) kit was 
used for the quantification of cortisol in saliva (Salimetrics, Suffolk, UK KIT 1-
3002). This cortisol assay kit has a lower detection limit of 7 ng/dl. The mean 
intra-assay coefficient is 5.7% and the mean inter-assay coefficient is 10%.  
Influences on cortisol levels 
 Saliva flow rate and viscosity do not significantly affect salivary cortisol 
levels, making the measure robust in a variety of clinical and research conditions 
(Kirschbaum & Hellhammer, 1989). While there is considerable variation, most 
studies recommend participants not eat, drink, or brush their teeth prior to 
sample collection. There is evidence that habitual smoking increases salivary 
cortisol levels as well as exercising within 30 minutes of collection (Kirschbaum & 
Hellhammer, 1989). During pregnancy, cortisol levels are elevated due to the 
estrogen-induced rise in cortisol binding globulin and up-regulation of the 
maternal HPA axis (Jung et al., 2011). Similarly, cortisol binding globulin levels 
are elevated in women taking estrogen-containing oral contraceptives (Raff, 
2009).  Salivary cortisol is not sex-dependent, however concentrations may 
decline with age (Inder et al., 2012). Because cortisol is a stable molecule, saliva 
samples can be stored in a home refrigerator at 4-8° for up to 7 days, after which 
they can be frozen and stored at -20° or -80° for up to 12 months without 
depreciation of concentrations (Inder et al., 2012).  
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Use in research 
 
 
Salivary cortisol has been used in numerous studies as a reliable measure 
of the stress response and HPA activity (An et al., 2015). Chronic stress is 
associated with alterations in the cortisol awakening response (Dedovic & Ngiam, 
2015; Révész et al., 2013), and blunting of the morning-evening diurnal slope 
(Carvalho et al., 2015; Garland, Beck, Lipschitz, & Nakamura, 2014; Ho, Fong, 
Chan, & Chan, 2013; Schrepf et al., 2015). It has been used to measure HPA 
activity in cancer survivors and other populations (Du et al., 2013; Ho et al., 
2013; Sephton et al., 2013). 
Salivary IL-6 
 
 
Interleukin-6 (IL-6) is one of the major cytokines that stimulates HPA 
activity in response to inflammatory stress and is thought to play a role in the 
mechanisms linking psychosocial stress with increased risk of chronic disease 
(Sjögren, Leanderson, Kristenson, & Ernerudh, 2006). Chronic stress is 
associated with elevated levels of pro-inflammatory cytokines, which may reflect 
reduced sensitivity to the inhibitory effects of cortisol (Sribanditmongkol et al., 
2014).  
Validity and Reliability 
 
 
Unlike salivary cortisol, salivary IL-6 has not been shown to correlate with 
serum/plasma levels of IL-6. Salivary IL-6 is thought to reflect localized rather 
than systemic inflammation (Izawa, Sugaya, et al., 2013). However, Izawa et al. 
demonstrated elevated salivary IL-6 concentrations post-TSST (Trier Social 
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Stress Test) when compared to baseline concentrations (p < .01), indicating a 
close association between salivary IL-6 and psychosocial stress. They also 
demonstrated significant correlations between salivary IL-6 and salivary cortisol 
(p < .05) post-TSST. This association was not seen at baseline, suggesting that 
the correlation between the inflammatory response and HPA activity is specific to 
stressful conditions (Izawa, Sugaya, et al., 2013).  
Izawa et al. also described the relationship between IL-6 and cortisol as 
dependent on proximity to and duration of the stressor. Following an acute 
stressor, both IL-6 and cortisol remain elevated for approximately 30-60 minutes. 
Cortisol then suppresses IL-6 production, changing their relationship from a 
positive to an inverse correlation. However, in chronic stress, hypocortisolism 
may occur causing salivary IL-6 to remain elevated (DeSantis et al., 2012; 
Nikkheslat et al., 2015). Thus, salivary IL-6 is particularly useful in helping to 
distinguish between acute and chronic stress when collected in conjunction with 
salivary cortisol (Izawa, Sugaya, et al., 2013). Salivary IL-6 has a diurnal pattern 
similar to that of cortisol, peaking in the morning immediately after awakening 
and then gradually declining into the afternoon and evening. However, unlike 
salivary cortisol, salivary IL-6 peaks again at midnight before going to bed 
(Izawa, Miki, Liu, & Ogawa, 2013).  
A commercially available Enzyme-Linked Immuno-Sorbent Assay (ELISA) 
kit was used for the quantification of salivary IL-6 (Salimetrics, Suffolk, UK KIT 1-
3602). This IL-6 assay kit has a lower detection limit of 7 ng/dl, intra-assay 
coefficient of 4.8% and mean inter-assay coefficient of 6.6%. 
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Hair cortisol 
 
 
Psychosocial stress has also been associated with elevated levels of 
cortisol in hair (Russell et al., 2012; Wells et al., 2014). Hair has a predictable 
growth rate of 1 cm/month; the most proximal 1 cm segment to the scalp 
approximates the last month’s cortisol production, the second most proximal 
segment the month prior to that, and so on (Russell et al., 2012). Hair cortisol 
provides several advantages over current measures of cortisol. It permits a 
retrospective analysis of cortisol secretion, allowing researchers to examine 
cortisol secretion before an event occurred (Stalder & Kirschbaum, 2012). Hair is 
also easy and non-invasive to collect; a sample of hair is cut from the vertex 
posterior region of the scalp as close to the skin with scissors (Raul, Cirimele, 
Ludes, & Kintz, 2004). Only a small amount (about 10mg) is needed to extract 
cortisol concentrations. Sample storage is convenient; hair cortisol can be stored 
at room temperature in aluminum foil for extended periods of time (Raul et al., 
2004).  
Protocol for hair cortisol analysis 
 
 
 To extract cortisol from hair, the sample is weighed and then cut into 
segments correlating with the time period of interest. Then, the hair is finely 
minced with scissors, and incubated overnight in a solvent such as methanol. 
The resulting solution is evaporated until the sample is dry and methanol is 
removed from the sample. Then the sample is reconstituted in a solution such as 
phosphate buffered saline (PBS). Following the extraction, an ELISA is used for 
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cortisol quantification (Raul et al., 2004; Russell et al., 2012; Sauvé, Koren, 
Walsh, Tokmakejian, & Van Uum, 2007).  
Validation of hair cortisol assay  
 
 
Cortisol was first measured in human hair by Raul et al. (2004) using liquid 
chromatography-mass spectrometry analysis and then further validated by Sauve 
et al. (2007) using an ELISA. The methodology and results of both studies will be 
summarized.  
Measurement range 
 
 
Raul et al. (2004) performed liquid chromatography-mass spectrometry 
analysis on 44 hair samples from 17 men and 27 women. Ages ranged from 2 to 
90 years old (mean 36 years old). Four hair color categories were distinguished; 
black, brown, grey and blond (Raul et al., 2004). None of the analyzed samples’ 
concentrations were below the limit of quantification of 5 pg/mg, defined as the 
“lowest reported quantitative value, within the established acceptable error of the 
essay” (Rifai, Gillette, & Carr, 2006). The limit of detection, defined as “the lowest 
value that exceeds the measurand value obtained with a blank sample” (Rifai et 
al., 2006), was 1 pg/mg. Linearity, which “refers to the range of measurand 
values over which there exists a constant relationship between observed and 
expected values” (Rifai et al., 2006), was between 1 and 500 pg/mg. Cortisol 
concentrations ranged from 5.2 to 91 pg/mg with a mean value of 19 pg/mg. 
Concentrations of cortisol were not different based on groups (age, natural hair 
color).  
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Sauve et al. (2007) were the first to use a modified saliva ELISA to 
measure cortisol concentrations in human hair (Sauvé et al., 2007). They used a 
sample of 39 non-obese subjects, 19 male and 20 female, to develop and 
validate an assay for the measurement of cortisol in human hair. For each 
subject, hair, urine, saliva and serum samples were collected for cortisol 
analysis. Sauve et al. (2007) also examined the effect of hair color (n=12) and 
sample location (n=14) (e.g. posterior vertex) on cortisol concentrations, as well 
as the difference between hair cortisol concentrations in hair that had been dyed 
(n=14) and hair that was untreated (n=25).  
Hair cortisol levels were not normally distributed, but after log 
transformation, the distribution was normal. The reference range for cortisol 
levels in hair of healthy non-obese individuals was 17.7-153.2 pg/mg of hair with 
a median of 46.1 pg/mg. Hair cortisol concentrations did not differ significantly 
based on natural hair color. However, hair that was dyed before sample 
collection (n=14) had lower cortisol levels (p < .05) than hair that was untreated 
(n=25) (Sauvé et al., 2007). 
Accuracy and Precision 
 
 
Accuracy is the “closeness of agreement between the value of a 
measurement and the true concentration of the measurand in the sample” (Rifai 
et al., 2006). Raul et al. (2004) examined accuracy using calibration curves. To 
obtain calibration curves for cortisol concentrations under 20 pg/mg, the authors 
could not use blank hair (physiological concentrations being sometimes below 20 
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pg/mg). For this reason, they used melanin to obtain a “blank” hair as close as 
possible to human hair (Raul et al., 2004).  
Sauve et al. (2007) determined accuracy by examining recovery, 
calculated by adding various concentrations of cortisol to the hair sample and 
comparing the measured amount with the added amount (Rifai et al., 2006).  The 
mean extraction recovery of 80 ng/ml and 2 ng/ml cortisol standards (n=5) from 
PBS was 87.4% and 83.6% respectively. When hair samples were spiked with 
100 ng/ml, 50 ng/ml and 2 ng/ml (n=6) cortisol standards, incubated and 
extracted, the mean extraction recoveries were 87.9%, 88.9% and 87.4%, 
respectively (Sauvé et al., 2007).  
Precision is the “closeness of agreement between independent test results 
obtained under stipulated conditions” (Andreasson et al., 2015, p. 3). Raul et al. 
(2004) examined precision through repeatability. Intra-day repeatability (CV 
value) was 11% for cortisol (at 7 pg/mg). Sauve et al. examined the precision of 
the ELISA assay using two hair samples with an average (about 60 pg/mg) and a 
high cortisol level (about 600 pg/mg). The intra-assay coefficients of variation for 
these samples were 7.2% and 6.0%, respectively. Inter-day precision had a 
coefficient of variation of 10.6% for the sample of average concentration and 
7.6% for the sample of high cortisol content (Sauvé et al., 2007). The mean 
coefficient of variation of hair cortisol levels from samples obtained from the 
vertex posterior of 14 individuals was 15.6%. The mean coefficient of variation for 
cortisol levels from hair samples taken from various parts of the head was 30.5%. 
	 52	
Based on these results, Sauve et al. (2007) recommend hair samples be taken 
from the vertex superior in order to obtain consistent results. 
Validity 
 
 
Sauve et al (2007) established validity of the hair cortisol ELISA assay by 
examining correlations between hair cortisol concentrations and concentrations 
of cortisol in urine, saliva, and serum. There was a correlation between hair 
cortisol levels and 24-hr urine cortisol (r=0.33; P=0.041) and between serum and 
salivary cortisol (r=0.58; P=0.0016). The strong correlation between saliva and 
serum cortisol can be explained because both matrices reflect short-term cortisol 
secretion. One explanation for the weaker correlation between hair cortisol and 
urinary cortisol is the difference in the time frames that are reflected by the 
measurements: urine represents cortisol secretion during one day, whereas hair 
cortisol levels represent levels during 1-2 months (Sauvé et al., 2007). 
Stability reliability 
 
 
 Stalder et al. (2012) examined patterns of intra-individual stability in hair 
cortisol levels in two independent study groups. In study I, hair was collected 
from 45 participants at two time points one year apart from each other. In study 
II, 64 participants provided hair samples at three time points occurring at two-
month intervals. In both studies, relevant psychosocial variables and hair-related 
variables were also assessed. Results of both studies consistently revealed 
strong test-retest associations for repeated hair cortisol measurements (‘r’s 
between 0.68 and 0.79, ‘p’s <0.0001). The authors concluded that hair cortisol 
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concentrations demonstrate a considerable degree of intra-individual stability 
(Stalder et al., 2012).  
Validity in known hypercortisolemic conditions 
 
 
Several studies have demonstrated validity of hair cortisol by examining 
cortisol concentrations in individuals with known hypercortisolemic conditions. 
D’Anna-Hernandez et al. (2011) examined associations between hair and 
salivary cortisol throughout pregnancy and in the first three months postpartum. 
Cortisol levels are known to increase throughout pregnancy (D’Anna-Hernandez, 
Ross, Natvig, & Laudenslager, 2011). Findings demonstrated a significant effect 
of pregnancy phase on hair cortisol levels (p = 0.003), with levels higher in the 
third trimester relative to the first trimester (p < 0.001). Overall mean salivary and 
hair cortisol levels calculated across all time points were significantly correlated 
(p = 0.047).   
Association between hair cortisol and self-report measures 
 
 
Several studies have also examined the association between hair cortisol 
and self-report measures of stress, with variable results. Wells et al. (2014) used 
a pooled database from diverse community samples to examine associations 
between hair cortisol concentrations and self-reported measures of stress as well 
as mental health measures. Two centimeters of hair (reflecting the last two 
months) were collected from participants for analysis of cortisol. Stress was 
measured using the PSS-10 and the Chronic Stress Scale. To measure mental 
health, the following data was collected: depression and anxiety (using screening 
	 54	
questions taken from the DSM-IV); drug, alcohol and antidepressant use; 
smoking status; WHO Disability Assessment (WHO-DAS II) (to assess limitations 
in activities and daily functioning); and intimate partner aggression.  
 Hair cortisol concentrations (HCC) were significantly related to the use of 
antidepressants, hazardous drinking, smoking, disability and aggression by 
partner, after controlling for confounders. Correlations of HCC with self-reported 
chronic stress and perceived stress were small and both were non-significant 
after controlling for confounders. The authors provide several possible 
explanations for the lack of association between HCC and self-report measures 
of stress. The first explanation they offer is that HCC and self-report measures of 
stress such as the PSS-10 do not reflect the same time frame. Second, they offer 
the explanation that the relationship between hair cortisol and self-report 
measures of stress may not be linear. They explored alternate models, and found 
that HCC increased at higher levels of perceived stress but decreased at the 
highest levels of stress, suggesting an inverse U relationship (Wells et al., 2014).  
Conclusions 
 
 
 The Perceived Stress Scale-10 is a valid and reliable measure of stress of 
an individual’s perceived stress over the past month. Salivary cortisol and IL-6 
are measures of current HPA activity whereas hair cortisol reflects integrated 
cortisol secretion over the past month. Together they can be used to measure 
biological and behavioral levels of stress, providing a more complete picture of 
the stress response. These measures were used in this study to examine the 
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associations between chronic stress and ovarian function in female cancer 
survivors.  
Data Collection Schedule and Procedures 
 
 
 Recruitment began by sending letters of invitation to female cancer 
survivors in long-term follow-up, two weeks prior to their annual review 
appointment. Letters included a Patient Information Sheet and a reply slip 
(Appendix E). By returning the reply slip, patients agreed to be contacted by the 
research team. This manner of recruitment prevented patients from feeling any 
obligation to participate. After consenting to be contacted, patients were 
interviewed over the phone to determine eligibility to participate in the study. If 
eligibility requirements were met and the patient agreed to participate, a 30-
minute study visit at the RHSC was scheduled at a mutually agreed upon time. 
The study visit was scheduled within a week of the subject’s annual review visit. 
Written consent was obtained from subjects at the study visit. Each subject was 
assigned a unique study ID and data was entered into an SPSS file on an 
encrypted computer in a locked office.  
Procedure Data Collection 
 
 
Data was collected in this order: saliva, demographic and PSS-10 
questionnaires, hair. Salivette collecting devices and detailed instructions for 
collection of samples were provided to participants at their annual review 
appointment. Subjects were instructed not to eat, consume caffeine or exercise 
for 30 minutes prior to sample collection (Schrepf et al., 2015). Subjects were 
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instructed to record the date/time of saliva collection and to refrigerate samples 
immediately following collection to preserve sample integrity. Subjects provided 
four timed saliva samples: the first sample was collected before going to bed on 
the night prior to the study visit, the second immediately upon awakening the 
morning of their visit before getting out of bed, and the third and fourth were 
collected 30 minutes after the second sample. Subjects were instructed to bring 
the four saliva samples to the study visit. Samples were labeled with a unique 
subject study ID. Saliva samples were stored at the RHSC at -20 C. Dr. 
Anderson’s research nurse picked them up within a week of collection and 
brought them to the QMRI, where they were centrifuged and stored at -80 C.  
During the study visit, subjects provided demographic information 
including age, ethnicity/race, years of formal education, marital status, 
employment status, number of pregnancies and live births, and income status 
(Appendix D). Subjects then completed the PSS-10, a 10-item questionnaire, 
which measures perceived stress over the past month (Cohen et al., 1983). 
Lastly, subjects provided a sample of hair for measurement of hair cortisol. A 
small sample of hair, 20mg (100-150 strands), was taken from the vertex 
posterior of the participant’s scalp using a new pair of thinning shears (Hoffman, 
Karban, Benitez, Goodteacher, & Laudenslager, 2014; Van Uum et al., 2008). 
Hair length was recorded and proximal ends of the hair samples were marked. 
Hair samples were stored in aluminum foil for protection before processing 
(Hoffman et al., 2014) and labeled with a unique subject study ID. Wells et al. 
(2014) reported that 95% of 247 women consented to hair sampling conducted in 
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this manner. To minimize variation in sample collection, research nurses were 
trained on how to collect and store hair samples. 
The following clinical characteristics were retrieved from subjects’ medical 
records: age at cancer diagnosis, cancer type, treatment type and duration, age 
at completion of treatment, comorbidities, prescription medications, and 
reproductive history (age at menarche, last menstrual period, menstrual cycle 
regularity, and parity). Reproductive hormone levels (AMH, FSH, LH and E2), 
measured as part of routine care at the annual review visit, were also retrieved 
from subjects’ medical records. This data was used to describe the sample 
characteristics and explore subgroup effects on associations between variables 
(aim 1).    
Amendment to Data Collection Procedures 
 
 
During data collection, it was discovered that many subjects travel a great 
distance to the hospital for clinic visits. Therefore, to reduce the burden of 
participation, subjects were given the option to receive a research packet in the 
mail if they were unable to return to the Royal Hospital for Sick Children for a 
separate study visit because of the travel distance. Since the current methods 
already required subjects to collect saliva samples at home, the main change 
was that subjects who decided to receive a research packet in the mail also self-
collected a hair sample. In a study of 70 multi-ethnic breast cancer survivors, 
Ramirez et al. examined the feasibility of self-collection of hair samples and 
demonstrated that it was a reliable and non-invasive way to measure cortisol 
(Ramirez et al., 2017). Participants were instructed on how to collect the hair 
	 58	
sample after consenting to participate in the study. They were also asked to 
complete the PSS-10 at home. Biological samples and questionnaires were 
labeled with the subject’s study ID so as to ensure confidentiality. No identifying 
information was included in or on the research packet. The research packet 
included prepaid return packaging and an ice pack so that subjects could return 
samples and questionnaires to the Royal Hospital for Sick Children for 
processing. Clements & Parker (1998) demonstrated that salivary cortisol 
concentrations of samples frozen immediately after collection and samples sent 
on ice were highly correlated (Clements & Parker, 1998). 
Data Analysis and Interpretation 
 
 
Means and standard deviations or frequency distributions, as appropriate, 
for all demographic and clinical variables were reported to describe the sample 
and reveal distributional characteristics.  
Latent Growth Curve Modeling was used to examine diurnal cortisol 
patterns. Bayesian Structural Equation Modeling was used to explore the 
relationship between perceived stress and HPA activity and to explore 
relationships between perceived stress, biomarkers of HPA activity, gonadotropin 
levels, and AMH.  
Latent Growth Curve Modeling  
 
 
Latent Growth Curve Modeling was used to define diurnal cortisol change 
over time (three time points). Growth curve modeling (GCM) examines change 
as a trajectory and assumes that trajectories vary across participants (Barker, 
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Rancourt, & Jelalian, 2013). This method was selected since chronic stress is 
characterized by a persistent and unstable trajectory of HPA activity 
(Hellhammer, Wüst, & Kudielka, 2009). Change processes are determined by 
combining the underlying pattern of growth (slope) with the initial or baseline 
measurement (intercept). The intercept and slope of this trajectory were then 
incorporated into the structural equation model as independent predictors of 
ovarian function. GCM was selected instead of more commonly utilized methods 
of analyzing diurnal cortisol (e.g. area under the curve, cortisol awakening 
response) because it permits a robust examination of change in small samples.  
GCM was evaluated as yit = λintηint + λslpηslp + et, where yit represents the 
observations for each subject i at each time t. λint represents the vector of fixed 
values that define the latent intercept, this is λint = [1,1,1], while λslp represents the 
vector of fixed values that define the linear slope, this is λslp = [0, 9.3, 9.8]. This 
represents the average time between the first observation to the second (9.3 
hours), and from the first observation to the third observation (9.8 hours). ηint 
represents the latent intercepts, while ηslp represents the latent slope, for which 
we estimate the respective mean and variance. The means represent the 
average starting point and average change over time, while the respective 
variance represents how much the subjects vary from the respective mean. 
Lastly, et represents the residual variance at each time point t, this indicates that 
the GCM is estimated without the assumption of homogeneity of variance over 
time, the residual variance is allowed to differ over time.  
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Bayesian analysis 
 
 
In Bayesian analysis, statistical inferences are drawn from parameter 
values that could give rise to the observed data (Scheines, Hoijtink, & Boomsma, 
1999). The term prior is used to refer to the expected parameter distribution 
based on theory or previous research. The posterior distribution is the parameter 
distribution that results from multiplying the prior distribution by the likelihood (as 
observed in the sample data). The posterior distribution describes the behavior of 
the parameters conditional on the data. Because the Bayesian framework makes 
inferences from the posterior distribution, it allows researchers to make direct 
inferences about the parameters given the observed data. The posterior 
distribution describes both the best estimate given the data, and the level of 
uncertainty about the respective parameter by the width of it, typically 
represented by the credible interval (Yuan & MacKinnon, 2009).  
The Bayesian framework is an appropriate method for small sample sizes. 
Frequentist methods rely on the asymptotically correct estimation methods, 
basing the inference in function of the null hypothesis (Wagenmakers et al., 
2008). Bayesian inference bases the inference on the observed data, which 
allows estimation of parameters with small samples in conditions where 
frequentist estimation fails (Lee & Song, 2004).  
The Bayesian approach requires specification of prior distributions for 
each of the model parameters (Palomo, Dunson, & Bollen, 2007). The selection 
of the prior distribution is important because the posterior distribution is informed 
by the prior distribution and the likelihood of the data (Palomo et al., 2007). The 
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prior distribution incorporates information drawn from previous empirical studies 
or theory regarding the model parameters. Given the exploratory nature of this 
study, we first examined the model parameters using weakly informed priors. 
Weakly informed priors are not intended to guide the parameters, but instead 
provide information to delimitate the most likely data space for the parameters. 
Means/intercepts have a prior µ~N(0,100); the standard deviations have a prior 
δ~half-cauchy(0,2.5); the regressions have a prior β~N(0,50); and the 
correlations have a prior ρ~U(-1,1).  
Strong hypotheses are tested by model comparison. A model without 
constraints was compared to a model with constraints in the regressions (β), 
constraining if the β is positive or negative (according to theory). These 
constraints are set by specifying the respective β prior as a truncated normal 
(e.g: β~N(0,50)T(0,)) not allowing β to be above/below 0. Model comparison 
allowed us to evaluate if the model with directional constraints fit the data better 
than the unconstrained model. If the directional constraint model fit better, it is 
evidence that the β should be directional. The models were compared with 
Information Criteria Leave-One-Out (LOO), and Widely Applicable (WAIC)  
(Vehtari, Gelman, and Gabry, 2016; Gelman et al., 2013; Raftery, 1993; Kass, 
and Raftery, 1995). The theoretical model including the hypothesized 
directionality of the associations is presented in Figure 1. 
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Bayesian Structural Equation Modeling 
 
 
Structural Equation Modeling (SEM) provides a broad framework for 
modeling relationships with multivariate outcomes (Palomo et al., 2007). The 
purpose of SEM is to test a theory by specifying a model that represents 
predictions about the theory’s constructs measured with appropriate observed 
variables (Kline, 2016, p. 10). The outcome of SEM is a set of model parameters 
for hypothesized effects given the data. From these parameters, a set of logical 
implications result about the nature of the relationship or non-relationship 
between the variables (Kline, 2016, p. 10). While SEM typically includes an 
approximation of unobserved or latent constructs as well as an estimation of the 
structure of the relationships among these observed constructs, in this study we 
used a special case of SEM called path analysis. In path analysis, every variable 
in the model is directly measured or observed (Bryan, Schmiege, & Broaddus, 
2007). While latent variables account for unreliability of measures and 
uncertainty in the model, they can also complicate a model, especially when the 
sample size is small. Path analysis was selected instead of multiple linear 
regression because it allowed us to test multiple relationships between variables, 
with multiple outcomes, conforming to the hypothesized model in this study. 
Establishing relationships including multiple paths and outcomes allowed us to 
test the presence of relationships accounting for the relationships with other 
variables of interest (Kline, 2015).  
Bayesian SEM was selected because it facilitates greater precision in 
estimating the posterior distribution of the parameters for small samples. 
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Additionally, Bayesian SEM offers the advantage of incorporating previous 
knowledge about the model’s parameters through the use of priors. Thus, 
Bayesian SEM provided an excellent framework for exploring the relationships 
between this study’s variables, allowing for an appropriate degree of uncertainty 
when estimating the model’s parameters (Scheines et al., 1999). We ran a series 
of path analysis models with salivary cortisol intercept and slope, PSS, Hair 
cortisol, BMI, Age, Age at diagnosis, and Age at menarche as predictors and with 
AMH, E2, FSH, and LH, as outcomes. 
Because the aim of the study was to explore relationships between 
variables, the analysis was not strictly confirmatory. If the data did not fit the 
model specified, alternative models were tested. The purpose of exploring 
various models was to provide additional information about the plausible 
relationships between the variables of interest and make recommendations for 
future model testing.  Data augmentation was used to account for missing data. 
Missing data was treated simultaneously as a parameter and data, filling any 
missing data points with the most likely value given the posterior distribution. At 
each iteration of the estimation, likely values were imputed for the missing data. 
These likely values were drawn from the posterior distribution estimated at that 
point in the iterations. In later steps of the estimation, the likely values were used 
as data in the path analysis, and this process continued until the model had 
converged (Merkle, 2011).  
Data analysis was conducted in R (R Core Team, 2017). Bayesian path 
analysis was run with the R package blavaan (Merkle & Rosseel, 2016), which 
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estimates the model with the general Bayesian software JAGS (Plummer, 2003). 
Convergence of the Markov chains was determined using the potential scale 
reduction factor (PSRF), also known as univariate R-hat (see Gelman & Rubin, 
1992). It was determined that the model converged when R-hat was lower than 
1.10 for every parameter (Brooks & Gelman, 1998). The models were run with 3 
chains, keeping the last 5000 iterations from each chain to build the posterior 
distributions. Model comparison with LOO and WAIC were done with loo R 
package (Vehtari, Gelman, and Gabry, 2016b); smaller values for LOO and 
WAIC represent a better fit. 
Protection of Human Subjects 
 
 
Human Subjects Involvement and Characteristics, and Design 
 
 
The goal of the proposed study was to explore relationships between 
perceived stress, biomarkers of (hypothalamic-pituitary-adrenal) HPA activity, 
and ovarian function in female survivors of childhood cancer. This population was 
selected because female survivors of childhood cancer are at increased risk of 
experiencing a premature decline in ovarian function. Additionally, cancer 
survivors have higher levels of stress and HPA dysregulation. The association 
between HPA dsyregulation and ovarian function in cancer survivors has not 
been examined. The present study sought to fill this research gap so as to better 
understand factors associated with this late effect of cancer treatment. 
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Ethics approval in Scotland 
 
 
 The South East Scotland Research Ethics Committee approved the 
study. Approval included recruitment materials and methods, consent forms, and 
data collection protocols. The South East Scotland Research Ethics Committee 
approved any changes made to the study protocol before they were 
implemented. 
IRB Oversight 
 
 
Marquette University’s Institutional Review Board (IRB) reviews and 
approves research involving the use of human subjects under the jurisdiction of 
Marquette University. The IRB is charged with the responsibility of ensuring the 
adequacy of the research plan, to minimize risks and to maximize the potential 
benefits for human subjects who participate in research, based on federal and 
state regulations as well as institutional policies. The proposed study was 
approved by Marquette University’s IRB.  
Data Management 
 
 
Data management was compliant with the most current guidelines of the 
Complete Health Insurance Portability and Accountability Act (HIPAA) of 1996 
and in full conformance with the principles of the “Declaration of Helsinki”, in 
accordance with the principles laid down in the Convention of the Council of 
Europe for the protection of human rights and dignity of the human being with 
regard to the application of biology and medicine. 
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Original patient names and hospital barcodes were de-identified by using 
a new, independent numbering system for all study related documentation (ie 
pseudo-anonymisation). A link-list was established and kept separate from other 
study documentation. The link-list was only accessible by the Principal 
Investigator (Theresa Hardy), Dr. Anderson, Dr. Wallace, and Rachel McAndrew 
(oncology research nurse). Theresa Hardy was granted an NHS Lothian visiting 
researcher passport giving her access to clinical data once participants 
consented to participate in the study.  
Data Protection 
 
 
 All personal information was kept separate from the research record. 
Consent forms (Appendix F) were stored in locked filing cabinets in locked NHS 
premises at the Department of Pediatric Oncology, RHSC. Consent forms were 
stored on the NHS premises until the completion of the study. No identifying 
information will be stored on secure University computers, with all relevant files 
accessed only by the researchers and protected by passwords. Computer-stored 
data will be on password-protected computers/servers without identifying 
information.  
Potential Risks 
 
 
 The risks to subjects are minimal. The time required to collect saliva 
samples at home as well as involvement in the study may be an inconvenience 
to subjects. The collection of hair samples may cause some discomfort to 
subjects. However, previous researchers have found taking a small hair sample 
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from the vertex to be very acceptable (personal communication from Dr. Jodi 
Ford, Ohio State University, Columbus, Ohio, July 2015). The PSS-10 is a 
measure of stress perceived over the past month. As subjects recall stress, they 
may experience some distress.  
Adequacy of Protection Against Risk 
 
 
Recruitment and Informed Consent 
 
 
All recruitment materials and procedures were reviewed and approved by 
the South East Scotland Research Ethics Committee and the Marquette 
University IRB prior to initiating data collection. The letter of invitation (Appendix ) 
sent to potential subjects included a description of the study, what was involved if 
they agreed to take part, and an explanation of risks. Written informed consent 
was obtained at the annual review appointment. Potential subjects had the 
opportunity to ask questions before providing consent. Participants were allowed 
to withdraw from the study at any point. Any patients identified as participating in 
ongoing interventional research were not recruited.  
Protection Against Risk 
 
 
The primary risk of the proposed study was risk of disclosure of personal 
data, which was minimized by the data management and security measures 
described above. Risk of harm associated with biological specimen collection 
was minimized by adhering closely to study procedures and allowing subjects to 
withdraw from the study at any point. NHS staff were available to treat any 
adverse effects due to study collection procedures, and any subject that 
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expressed emotional distress as a result of recalling perceived stress were 
referred to a member of the interdisciplinary care team.  
Potential Benefits of the Proposed Research to Human Subjects 
 
 
Any relevant clinical information obtained during the course of the study 
was made available to participants during routine care.  
Importance of the Knowledge to be Gained 
 
 
The findings from this study will be used to improve knowledge of factors 
associated with fertility and ovarian function in female survivors of childhood 
cancer, which may inform decision-making prior to and after treatment of cancer 
in young women. Reproductive potential is a major concern for cancer survivors. 
The knowledge gained from this study will directly contribute to quality of life for 
female cancer survivors. Potential risks to subjects are minimal and reasonable 
in relation to the importance of the knowledge that will be obtained.  
 
 
 
 
 
 
 
 
 
	 69	
Chapter 4: Results 
 
 The findings from this study are presented in the manuscript entitled, 
“Chronic Stress and Reproductive Function in Female Childhood Cancer 
Survivors” and can be found in Appendix C.  
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Chapter 5: Discussion, Implications, and Conclusion 
 
 
 In this chapter, the main findings from this dissertation will be summarized. 
The strengths and limitations of the study and the implications for nursing 
practice, education and research will be discussed. 
Chronic Stress and Reproductive Function in Female Childhood Cancer 
Survivors 
 
 
In this study, we examined the association between chronic stress and 
ovarian function in childhood cancer survivors. The hypothalamic-pituitary-
adrenal (HPA) axis is one of the primary regulators of reproductive function 
(Shannon Whirledge & Cidlowski, 2013b). As high levels of psychological stress 
and HPA dysregulation have been observed in childhood cancer survivors 
(Oancea et al., 2014; Taylor et al., 2012; Zeltzer et al., 2009), we hypothesized 
that increased psychological stress and HPA dysregulation would be associated 
with lower levels of gonadotropins and anti-Müllerian hormone (AMH), a 
biomarker of the ovarian reserve. We found that perceived stress was negatively 
associated with ovarian function, and that biomarkers of HPA activity were 
positively associated with ovarian function in female childhood cancer survivors. 
The findings from this study provide preliminary evidence supporting the 
hypothesis that chronic stress negatively impacts ovarian function and may 
contribute to infertility in female childhood cancer survivors. 
While many cancer survivors encounter impaired fertility after treatment, 
few studies have examined predictors of the ovarian reserve in childhood cancer 
survivors other than diagnosis and treatment-related factors. Pre-treatment 
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planning and the ability to provide individualized fertility prognoses depends on 
increased understanding of factors associated with the ovarian reserve in this 
population (Anderson et al., 2013; Knopman et al., 2010). The findings from this 
study provide the foundation for further research examining factors that 
contribute to risk for post-treatment reproductive dysfunction in female childhood 
cancer survivors.  
Strengths of the study 
 
 
This exploratory study has several strengths. First, this study involved 
interdisciplinary collaboration, bringing together expertise from oncology, 
reproductive endocrinology and nursing to examine factors associated with post-
treatment reproductive function with the aim of improving quality of life for 
childhood cancer survivors (Kremer et al., 2013). Second, we used Bayesian 
structural equation modeling to address the study’s aims, a useful approach for 
small sample sizes. Bayesian inference is based on the observed data, 
permitting estimation of parameters with small samples in conditions where 
frequentist estimation fails (Lee & Song, 2004). Third, while the sample size was 
small, the association between chronic stress, measured as both perceived 
stress and HPA activity, and ovarian function has not been previously examined 
in childhood cancer survivors. As this population is at higher risk of infertility, the 
findings from this study provide the foundation for further hypothesis testing.  
And last, this study demonstrates the feasibility of examining factors that 
contribute to reproductive function in this population. Of those asked to 
participate in the study, all but one consented. The participants expressed 
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interest in contributing to research in this area. Contrary to our concern that 
cancer survivors might be reluctant to provide a hair sample, no one refused to 
participate for this reason. Hair cortisol has not been utilized as a measure of 
chronic stress in childhood cancer survivors; this study demonstrates that this 
measure may be a useful non-invasive biomarker of chronic stress in this 
population. 
Limitations of the study 
 
 
Several aspects of data collection may have impacted the study’s internal 
validity. Clinical and demographic information was collected using self-report. To 
reduce the potential for recall bias, we verified information using medical records. 
The Perceived Stress Scale (PSS-10) also relies on subject recall. However, the 
PSS-10 is the most widely used measure of perceived stress and has 
demonstrated good to excellent reliability in varied populations (Sheldon Cohen 
et al., 1983). The measure has also been utilized to reliably measure stress 
appraisal in cancer survivors (Golden-Kreutz, Browne, Frierson, & Andersen, 
2009).  
 As the Royal Hospital for Sick Children was far away for many patients, 
participants were given the choice to self-collect hair and saliva samples at home 
rather than returning to the hospital for a study visit. Participants were provided 
with a prepaid packet and an ice pack to return the samples; postal 
transportation of samples may have affected sample integrity. However, 
Clements & Parker (1998) demonstrated that salivary cortisol concentrations of 
samples frozen immediately after collection and samples sent on ice were highly 
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correlated (Clements & Parker, 1998). In addition, the amendment allowed 
participants to self-collect hair samples. In a study of 70 multi-ethnic breast 
cancer survivors, Ramirez et al. examined the feasibility of self-collection of hair 
samples and demonstrated that it was a reliable and non-invasive way to 
measure cortisol (Ramirez et al., 2017). And finally, the majority of samples had 
undetectable IL-6 levels, so we were unable to include this measure in the 
analysis. IL-6 is less stable, and sample integrity may have been affected by 
collection procedures (Izawa, Miki, et al., 2013). 
 There are also several factors that may have impacted the study’s 
external validity. The study design was cross-sectional and relied on a 
convenience sample. Due to the small sample, we were unable to adjust for 
hormonal contraceptive use in the overall model. Hormonal contraceptive use is 
associated with increased production of corticotropin-binding-globulin and 
subsequent decreases in unbound cortisol levels (Stephens, Mahon, McCaul, & 
Wand, 2016). In addition, due to the wide variety of pediatric cancer diagnoses in 
the sample, we could not adjust for cancer diagnosis and treatment-related 
factors in the model. Several studies have found a significant effect of diagnosis 
and treatment-related factors on post-treatment ovarian function, including the 
cancer pathology itself (Van Dorp et al., 2014), the therapeutic regimen 
(Charpentier et al., 2014) and the length of exposure (El-Shalakany et al., 2013; 
Reinmuth et al., 2013). Another limitation is that due to the great distance that 
many of the participants needed to travel, we were unable to time study visits to 
coincide with a specific menstrual cycle phase. For this reason, we were unable 
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to adjust gonadotropin and reproductive hormone levels to account for menstrual 
cycle phase. 
Integrative Review 
 
 
The majority of the studies examining AMH as a biomarker of the ovarian 
reserve have been conducted in women diagnosed with infertility or polycystic 
ovary syndrome. AMH has been proposed as a biomarker of the ovarian reserve 
for use in reproductive medicine; in order to improve its accuracy as a reliable 
biomarker, more studies examining AMH in healthy samples are needed. The 
gaps in this area have limited the ability of AMH to reliably predict reproductive 
outcomes/ reproductive potential in healthy samples, thus significantly limiting the 
utility of the biomarker (Steiner et al., 2017a; Zarek et al., 2015). An increased 
understanding of factors associated with AMH concentrations in healthy women 
will provide greater context for the clinical evaluation and interpretation of AMH 
concentrations.  
An integrative review was conducted with the purpose of summarizing the 
evidence regarding the modifiable biobehavioral factors associated with AMH 
concentrations in healthy reproductive age women. We found that various 
reproductive (contraceptive use, parity), biological (obesity, cardiometabolic) and 
behavioral (smoking, alcohol and caffeine consumption) factors have been 
examined in association with AMH concentrations. Among the studies included in 
the review, hormonal contraceptive use was most often examined. The majority 
found lower AMH levels in hormonal contraceptive users compared to non-users. 
Previous contraceptive use, however, was not associated with lower AMH levels 
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after contraceptive use was discontinued, suggesting a reversible effect. Given 
the current level of evidence, clinicians and researchers should be cautious when 
interpreting AMH levels during hormonal contraceptive use. Among the other 
factors examined, findings were mixed. The findings from the integrative review 
demonstrate that our understanding of the modifiable biobehavioral factors 
influencing AMH concentrations is incomplete and further research is needed.  
Latent Class Analysis 
 
 
In order to establish AMH as a reliable biomarker of the ovarian reserve, it 
is vital to explore how it behaves within the context of other health parameters. In 
addition to the primary study, we performed a second study exploring the 
feasibility of using Latent Class Analysis (LCA) to identify subgroups based on 
cardiometabolic (lipids, BMI, cortisol), psychological (depression, anxiety) and 
reproductive factors (FSH, LH, E2, AMH). We used stored postpartum blood 
samples of 69 women from a prospective cohort study examining mood and 
weight changes in pregnant women in Edinburgh, Scotland. We were able to 
identify three subgroups with unique class characteristics based on the factors 
included in the LCA, specifically focusing on AMH in our discussion of class 
characteristics. While the sample size was small, the findings of this exploratory 
study provide the foundation for further hypothesis testing regarding the effect of 
cardiometabolic and psychological parameters on reproductive health and 
fertility. In addition, it demonstrates that LCA is a feasible approach for identifying 
subgroups based on underlying patterns of cardiometabolic, psychological, and 
reproductive factors. While the findings of the study require validation in larger 
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cohorts, it demonstrates the potential of using LCA to examine AMH or other 
biomarkers in the context of other significant parameters of health, including 
cardiometabolic and psychological factors. 
Implications for nursing practice  
 
 
The findings from these studies have several important implications for 
oncology and woman’s health nursing practice. Reproductive dysfunction is a 
major concern for cancer survivors, and is highly correlated with quality of life in 
this vulnerable population (Cherven et al., 2015; Knopman et al., 2010; 
Kondapalli et al., 2014; Letourneau et al., 2013). However, studies have 
demonstrated that cancer survivors are about half as likely to be treated for 
infertility as their siblings (Barton et al., 2013). While the reasons for this 
discrepancy are not fully understood, healthcare providers may perceive fertility 
treatments to be less successful in this population. Additionally, knowledge 
regarding factors that contribute to risk for post-treatment reproductive 
dysfunction is incomplete (Knight et al., 2015; Letourneau et al., 2013). The 
guidelines from The American Society for Clinical Oncology recommend that 
options for fertility preservation be discussed with cancer patients at the earliest 
opportunity (Knight et al., 2015; Letourneau et al., 2013). Oncology nurses play 
an important role in advocating for cancer survivors, helping to initiate 
conversations regarding future fertility as early as possible and discussing factors 
that may mitigate the risk for post-treatment reproductive dysfunction. The 
findings from this study also suggest that there may be modifiable factors such 
as chronic stress that contribute to risk for infertility post-treatment. Oncology 
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nurses can minimize the potential burden of late effects by educating patients 
regarding their risk and what actions can be taken prior to or after treatment to 
reduce this risk (McClellan et al., 2013).  
This research also has important implications for woman’s health nursing. 
Many women seek out information regarding their fertility potential. The 
integrative review provides nurses with an evidence-based summary of 
modifiable biobehavioral factors associated with AMH, a biomarker of the ovarian 
reserve. AMH is increasingly used in reproductive medicine as a biomarker of 
fertility lifespan and reproductive potential (Didier Dewailly et al., 2014). While it 
has demonstrated significant value in the context of assisted reproduction, its 
value as a predictor of natural fecundity has not been established (Hagen, 
Vestergaard, et al., 2012; Steiner et al., 2017a; Zarek et al., 2015). Therefore, 
nurses can discuss with women the current limitations in the clinical interpretation 
of AMH levels, given the present level of evidence.  
Implications for nursing education and research 
 
 
 Understanding how to interpret biobehavioral data is vital to the nursing 
role. The studies included in this dissertation demonstrate the importance of 
understanding how biology and behavior interact to influence patient outcomes. 
Nursing education should emphasize a biobehavioral approach to health so as to 
prepare nurses to provide individualized care to patients, taking into account 
biological data while also considering the ways in which lifestyle and environment 
contribute to disease risk. Nursing research should continue to utilize 
biobehavioral methodology to address questions related to human health and 
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disease, integrating a depth of understanding regarding the pathophysiological 
mechanisms of disease with a thorough comprehension of human behavior, 
lifestyle and environment.  
The nursing profession is tasked with health promotion and disease 
prevention. For this reason, nurses need an understanding of disease risk and 
the tools available to help identify or measure that risk (e.g. biomarkers). As a 
biomarker of the ovarian reserve, AMH provides a window into the process of 
ovarian aging. In addition to increased risk of infertility, ovarian aging is 
associated with increased risk of cardiovascular disease, osteoporosis and mood 
disturbances (F. J. Broekmans, Soules, & Fauser, 2009). Thus, the applications 
of AMH as a biomarker of ovarian age extend well beyond reproductive health 
and may provide insight into women’s’ overall health (Pal, Bevilacqua, Zeitlian, 
Shu, & Santoro, 2008). Nursing education and research should continue to utilize 
and improve tools such as AMH to promote reproductive health and prevent the 
burden of infertility.  
Future research 
 
 
It is well established that stress disrupts reproductive function (Shannon 
Whirledge & Cidlowski, 2013b). The proposed explanatory mechanism is HPA 
dysregulation. As childhood cancer survivors are exposed to significant early life 
stress and are at higher risk of infertility due to the gonadotoxicity of 
chemotherapy, we sought to explore the relationship between stress, HPA 
activity and ovarian function in this population. The findings of this study provide 
preliminary evidence to support a negative association between perceived stress 
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and ovarian function in female childhood cancer survivors. Our findings also 
provide evidence to support the role of the HPA axis in regulating reproductive 
function. We found a positive association between the salivary cortisol intercept 
and slope and AMH as well as a positive association between hair cortisol and 
AMH, suggesting that threshold glucocorticoid levels are required to maintain 
reproductive function. These findings are consistent with other studies that have 
demonstrated an association between hypocortisolism and increased risk for 
adverse outcomes in cancer survivors (Cuneo et al., 2017).  
The HPA axis mediates resource allocation decisions and plays an 
important role in determining an organism’s life history traits. In this study, we 
sought to explore the association between HPA activity and the ovarian reserve 
in female childhood cancer survivors in order to increase our understanding of 
how pediatric cancer influences life history traits, specifically reproductive 
function. Biomarkers of HPA activity may provide valuable information regarding 
increased risk for infertility in this population. Additional studies with larger 
samples are needed to further explore this hypothesis.  
More research is also needed to examine the biobehavioral factors 
associated with AMH as a biomarker of the ovarian reserve. Longitudinal studies 
are needed to examine the influence of biobehavioral exposures over time. In 
addition, randomized controlled trials are needed to examine the effect of lifestyle 
modification (i.e. stress reduction programs, smoking cessation, weight loss) and 
pharmacological intervention on the ovarian reserve and to determine whether an 
	 80	
improvement in AMH concentrations is associated with subsequent improvement 
in reproductive outcomes.  
This dissertation examined the association between biobehavioral factors 
and the ovarian reserve. The mechanisms contributing to diminished ovarian 
reserve are complex, and in addition to biobehavioral factors, include 
environmental and genetic factors. Further research is needed to examine how 
biology, genetics and environment interact to impact reproductive lifespan and 
fertility. Epigenetic changes have been proposed as the link between 
biobehavioral exposures and reproductive disorders. Further research is needed 
to examine epigenetic influences on the ovarian reserve in order to obtain a 
better understanding of how environmental and biobehavioral exposures 
contribute to infertility. Findings from this research can be used develop reliable 
risk models incorporating environmental, lifestyle, and genetic factors for the 
early detection of infertility. With a better understanding of the mechanisms 
contributing to the ovarian reserve, nurse scientists can contribute to the 
development of novel therapeutic interventions for the treatment of infertility.  	
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Abstract 
 
 
Objective: Anti-Müllerian hormone (AMH) is an emerging biomarker of ovarian 
reserve. There is inadequate understanding of the modifiable biobehavioral 
factors contributing (AMH) concentrations in normo-ovulatory women. The 
purpose of this integrative review was to provide a summary of the modifiable 
biobehavioral factors associated with AMH concentrations. 
Data Sources: An electronic literature search was conducted in PubMed using 
the following search terms: “anti-Müllerian hormone” NOT “polycystic ovarian 
syndrome” NOT “cancer” NOT “endometriosis” NOT “assisted reproductive 
technology”. 
Study Selection: Studies were included in the review if the population studied 
was healthy reproductive age women (ages 19+), the exposure was a modifiable 
biobehavioral factor, the outcome was serum AMH, and the biobehavioral factor 
was examined in 2 or more studies.   
Data Extraction: For each study, the first author, year of publication, study 
design, sample size, age range, groups, covariates and main finding were 
summarized and organized by factor. 
Data Synthesis: A total of 39 studies were included in the final review. Studies 
were published between 2007-2017. Sample sizes ranged from 20-2320. Study 
designs included cross-sectional, prospective cohort, retrospective cohort, and 
case-control. The main biobehavioral factors relating to AMH levels that emerged 
from the review were contraceptive use (n=14), parity (n=5), BMI (n=11), 
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cardiometabolic factors (n=4), smoking (n=10), alcohol consumption (n=4) and 
caffeine (n=3) consumption.  
Conclusion: Our understanding of the modifiable biobehavioral factors 
influencing AMH concentrations is incomplete. Increased understanding of the 
biobehavioral factors associated with AMH levels will improve the quality of care 
for women at risk for infertility. 
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Introduction 
 
 
Scientists continue to search for reliable and clinically useful biomarkers in 
the field of reproductive medicine (Palmer & Barnhart, 2013). The process of 
ovarian aging that eventually culminates in menopause spans approximately ten 
years, and there are few biomarkers that determine reproductive age. One 
biomarker that has received considerable attention in the field of reproductive 
medicine is anti-Müllerian hormone (AMH). A woman’s reproductive age is 
determined by the size of the primordial follicle pool, referred to as the ovarian 
reserve. Circulating AMH levels are recognized to reliably reflect the size of the 
primordial follicle pool, making AMH a promising non-invasive marker of the 
ovarian reserve (Hansen et al., 2011).  
Longitudinal studies involving normo-ovulatory women have found that 
serum AMH concentrations accurately predict the onset of menopause (Broer et 
al., 2011; van Disseldorp et al., 2008). The hormone is ideal as a research and 
clinical measure because, unlike follicle stimulating hormone (FSH)-- another 
biomarker of the ovarian reserve—serum AMH concentrations remain relatively 
stable across the menstrual cycle, are independent of gonadotropin levels 
(Hehenkamp et al., 2006; La Marca et al., 2010; Shaw et al., 2011) and correlate 
with the number of developing follicles in the ovary (Dewailly et al., 2014). Age 
remains the strongest determinant of ovarian reserve, and 34% of the variation in 
AMH levels can be attributed to age alone (Kelsey, Wright, Nelson, Anderson, & 
Wallace, 2011). Although normative age ranges for AMH have been established, 
there is considerable variation within the same age range (Konishi, Nishihama, 
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Iida, Yoshinaga, & Imai, 2014; La Marca et al., 2012; Lie Fong et al., 2012; 
Nelson, Messow, Wallace, Fleming, & McConnachie, 2011). To improve the 
clinical application of AMH as a reliable biomarker of the ovarian reserve, further 
research is needed to understand factors other than age that contribute to the 
observed variations in AMH levels in healthy women. 
 AMH has proven utility in the field of assisted reproductive medicine 
(Iliodromiti et al., 2014), but its value in predicting natural fecundability is less 
clear (Hagen, Vestergaard, et al., 2012; Steiner et al., 2017b; Zarek et al., 2015). 
AMH is widely used in reproductive medicine to counsel women regarding their 
future fertility, and many women struggling to conceive have sought out 
information regarding risk factors that contribute to a premature decline in AMH 
concentrations. While several studies have examined factors associated with 
AMH concentrations, the bulk of data comes from studies involving infertile 
women, or women diagnosed with polycystic ovary syndrome (PCOS). It is 
unclear if modifiable biobehavioral factors contribute to AMH concentrations in 
normo-ovulatory women. A greater understanding of AMH levels in the healthy 
female population will help to refine normative age ranges for use of this 
biomarker of the ovarian reserve in clinical practice and research. The purpose of 
this integrative review is to provide a summary of the modifiable biobehavioral 
factors associated with AMH concentrations. 
Function of AMH 
 
 
Anti-Müllerian hormone (AMH), a member of the TGF-β family, is a 
product of granulosa cells of pre-antral ovarian follicles. AMH plays a role in 
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ovarian follicle growth, specifically in regulating the pace of follicle recruitment 
and selection. AMH is expressed in granulosa cells of small growing follicles with 
its strongest expression in preantral and small antral follicles between 5-8mm in 
diameter (Jeppesen, Anderson, Kelsey, Christiansen, Kristensen, Jayaprakasan, 
Campbell, et al., 2013). AMH is no longer expressed by granulosa cells during 
FSH-dependent stages of follicle growth or by atretic follicles, degenerated 
follicles that do not ovulate during the menstrual cycle (Frank J. Broekmans et 
al., 2008; Didier Dewailly et al., 2014). 
The role of AMH in follicle growth was first characterized in studies of 
AMH-deficient mice (Visser et al., 2007). These studies demonstrated that AMH 
acts as an inhibitor of primordial follicle recruitment (Durlinger et al., 1999, 2002). 
AMH-deficient mice had more growing follicles and an increased rate of oocyte 
degeneration and follicle atresia (Visser et al., 2007), indicating that in the 
absence of AMH, primordial follicles are recruited at a faster rate, leading to a 
premature depletion of the follicle pool. Another consequence of AMH absence is 
an increased sensitivity of growing follicles to FSH. AMH has an inhibitory effect 
on FSH and therefore plays an important role in the selection of the dominant 
follicle (Durlinger et al., 2001; Sacchi et al., 2016; Visser & Themmen, 2014; 
Visser, de Jong, Laven, & Themmen, 2006).  
Methods 
 
 
This review was conducted using the guidelines for integrative reviews 
(Whittemore & Knafl, 2005). The integrative review methodology was selected 
because it provides a framework for summarizing evidence from studies with 
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diverse methodologies. An electronic literature search was conducted in PubMed 
on January 17, 2018 using the following search terms: “anti-Müllerian hormone” 
NOT “polycystic ovarian syndrome” NOT “cancer” NOT “endometriosis” NOT 
“assisted reproductive technology”, using filters: females, humans, English. To 
focus the review, studies conducted in the pediatric/adolescent population were 
excluded. Titles and abstracts, if necessary, of all resulting citations were read. 
The full text of all potentially eligible studies was read to determine whether 
studies met the eligibility criteria. Reference lists of included studies were also 
searched in order to identify any relevant studies missed in the primary search.  
Studies were included if they met the following criteria:  
1) The population studied was healthy reproductive age women. The 
population was considered “healthy” if they were not identified as having 
an infertility diagnosis or any other disease process that could potentially 
alter AMH levels.  
2) The exposure was a modifiable biobehavioral factor, involving the 
interaction of biological and behavioral processes (Webster).  
3) The outcome was serum AMH and was measured in all study participants. 
4) The biobehavioral factor was examined in 2 or more studies.   
The primary author selected and read all studies. Studies were grouped 
by the biobehavioral factors that emerged from the literature search. For each 
study, the first author, year of publication, study design, sample size, age range, 
groups, covariates and the main finding are summarized and organized by factor 
(Tables 1-7).  
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Results 
 
 
The search strategy resulted in 408 studies. The search strategy is 
provided in Figure 1. Using the search criteria described above, fifty studies were 
selected from the primary search. After reading the full text of all 50 studies, 17 
were excluded for the following reasons: the factor was only examined in one 
study (n=8), examined associations between AMH and non-modifiable risk 
factors (n=6), examined an intervention (n=1), population with illness (1), AMH 
examined as predictor (n=1). Six studies were added from the reference lists of 
included studies. A total of 39 studies were included in the final review.  
 Studies were published between 2007-2017. Sample sizes ranged from 
20-2320. Study designs included cross-sectional, prospective cohort, 
retrospective cohort, and case-control. The main biobehavioral factors relating to 
AMH levels that emerged from the review were contraceptive use (n=14), parity 
(n=5), BMI (n=11), cardiometabolic factors (n=4), smoking (n=10), alcohol 
consumption (n=4) and caffeine (n=3) consumption.  
Reproductive factors 
 
 
 Several studies examined whether reproductive factors were associated 
with a woman’s ovarian reserve trajectory (Daan & Fauser, 2015). Reproductive 
factors that have been examined in relation to AMH levels are contraceptive use 
(n=14) and parity (n=5).  
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Contraceptive Use 
 
 
Hormonal contraceptive use was examined in the greatest number of 
studies (n=14). Contraceptive use suppresses ovarian follicle growth by inhibiting 
gonadotropin secretion via exogenous administration of reproductive hormones. 
Ten studies found a significant inverse association between AMH levels and 
current hormonal contraceptive use. In a recent large retrospective cohort study, 
Marsh et al. (2016) examined factors associated with AMH in 1,654 African 
American women (23-34 years). In a multivariable model adjusting for BMI, 
history of abnormal menstrual bleeding, history of a thyroid condition, and history 
of seeking care for difficulty conceiving, current hormonal contraceptive use 
(27.5%) was inversely associated with AMH levels (β = -0.290, 95% CI -0.408, -
0.171), p < .0001 (Marsh et al., 2016). Five studies were cross-sectional and 
examined whether there were was a significant difference in AMH levels between 
users and non-users of oral contraceptives. In all five studies, oral contraceptive 
use was associated with significantly lower AMH levels (Bentzen et al., 2012; 
Birch Petersen et al., 2015; Dolleman et al., 2013; Kristensen et al., 2012; Shaw 
et al., 2011). One study was retrospective and also found a significant inverse 
association between oral contraceptive use and AMH levels (p < 0.001) (Kerkhof 
et al., 2010). 
Two of the studies were prospective and examined AMH levels pre- and 
post- oral contraceptive use (Arbo, Vetori, Jimenez, Freitas, & Lemos, 2007; 
Kallio et al., 2013). Arbo et al. (2007) examined AMH levels pre- and one month 
post administration of the oral contraceptive pill (OCP) in 20 normo-ovulatory 
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infertile women (male factor or tubal occlusion). AMH levels were significantly 
reduced after pituitary suppression, with a median (inter-quartile range) of 3.02 
ng/mL (1.21–6.39) before OCP and 2.22 ng/mL (0.9–3.11) after OCP, p < 0.04 
(Arbo et al., 2007). 
Kallio et al. (2013) measured AMH levels in 42 women in Finland (20–33 
years) prior to contraceptive administration and at 5 and 9 weeks post 
administration in three groups (OCP, transdermal patch, or vaginal ring). In 
addition to examining the effect of hormonal contraceptive use on AMH levels, 
the authors examined whether the effect differed depending on route of 
administration. They found significant decreases in AMH levels after 9 weeks in 
all groups: OCP (3.88 ± 3.0 vs. 1.91 ± 1.5 ng/mL, p < .001), transdermal (3.86 ± 
3.6 vs. 1.96 ± 1.3 ng/mL, p < .001), and vaginal ring (4.27 ± 3.5 vs. 2.25 ± 1.2 
ng/mL, p < 0.001). However, they found no significant difference between the 
groups, demonstrating that combination (estrogen plus progestin) hormonal 
contraceptive use lowers AMH levels regardless of the route of administration 
(Kallio et al., 2013).   
In the last study, van den Berg (2010) examined AMH levels in 25 Dutch 
women in the hormone free interval (either using the standard 21-/7- day regimen 
or an extended regimen) of a contraceptive cycle and two consecutive natural 
cycles. There was a significant increase in AMH levels between the hormone free 
interval of the contraceptive cycle and the consecutive natural cycles (p = 0.005). 
The authors demonstrate that AMH levels are suppressed in the hormonal 
contraceptive cycle and that levels increase after use of contraceptive is stopped. 
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In contrast, four studies found no association between AMH levels and 
contraceptive use. In a prospective case-control study, Deb et al. (2012) 
compared the AMH levels of 34 subjects who had been using the combined OCP 
(30 mcg of ethinylestradiol and 150 mcg of levonorgestrel) for more than a year 
with 36 control subjects who had not used any form of hormonal contraceptive in 
the last year and found that AMH levels did not differ significantly between the 
two groups. However, the study did not adjust for age (18-35 years), making it 
difficult to determine the strength of the evidence.  
Contrary to the study by Kallio et al. (2013), Li et al. (2011) compared 
AMH levels pre- and 3-4 months post- administration of five different hormonal 
contraceptive types in 95 women. The five types included the (1) combined oral 
contraceptive (COC) (Microgynon-30®, n=23); (2) combined injectable 
contraceptive (CIC) (Cyclofem®, n=23); (3) progestogen-only contraceptive pill 
(POP) (Cerazette®, n=9); (4) progestogen-only injectable (POI) (Depo-Pro- 
vera®, n=20); and (5) levonorgestrel intrauterine system (LNG-IUS) (Mirena®, 
n=20).  There was no significant difference between pre- and post-treatment 
serum AMH levels in all the treatment groups (p > .05). However, the authors 
made no adjustment for age (25-50 years), and did not provide complete 
statistics, making it difficult to evaluate the strength of the findings (H. W. R. Li, 
Wong, Yeung, Ho, & Ng, 2011).  
Similarly, Streuli et al. (2013) compared AMH levels in 24 women divided 
into three groups, (1) control group; (2) 0.02 mg of ethinylestradiol (EE) plus 0.15 
mg of desogestrel (DSG) orally (Mercilon); and (3) 0.015 mg of EE and 0.12 mg 
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of etonogestrel, the active metabolite of DSG, through a vaginal ring (Nuvaring). 
They also found no significant differences in AMH levels pre- and one month 
post- administration of hormonal contraceptives (Streuli et al., 2008). 
 Finally, Kucera et al. (2016) compared AMH levels in females who had 
used hormonal contraceptives for a period of at least 10 years and had ceased 
use 1 year prior to sample collection (n=105) with females who had never used 
hormonal contraceptives. The median concentration of AMH in the group of long-
term users of hormonal contraceptives was 2.89 ng/ml. The median 
concentration of AMH in the group of women who had never used contraceptives 
was 3.37 ng/ml. There was no statistically significant difference between the 
groups (p = 0.3261) (Kucera, Ulcova-Gallova, & Topolcan, 2016). 
While there is contradictory evidence regarding the association between 
hormonal contraceptive use and AMH levels, the majority of the studies found an 
inverse association between AMH levels and hormonal contraceptive use. The 
findings from several small studies (Deb et al., n=34; Streuli et al., n=24) included 
in this review suggest that short-term administration of oral contraceptives (less 
than 3 months) has a limited impact on AMH levels (H. W. R. Li, Wong, et al., 
2011; Streuli et al., 2008). In contrast, many studies found lower serum AMH 
concentrations with long-term hormonal contraceptive use, suggesting that 
hormonal contraceptive use suppresses follicle development (Bentzen et al., 
2012). However, several studies also found that AMH levels recover after 
ceasing hormonal contraceptive use and that there was no significant difference 
in AMH levels between those who never used hormonal contraceptives and 
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those who previously used them, suggesting that the ovarian suppression 
induced by long-term hormonal contraceptive use is temporary (Dolleman et al., 
2013; Kucera, Ulcova-Gallova, & Topolcan, 2016; La Marca et al., 2010; Van 
Den Berg et al., 2010). More research is needed to clarify the association 
between various characteristics of contraceptive use (duration, type, etc…) and 
AMH levels, as well as a more precise timeline of the return to normal AMH 
levels once hormonal contraceptive use is discontinued.  
Parity 
 
 
 Several studies examined the association between parity and AMH 
concentrations (n=5). In a study of 294 women, Bragg et al. found that women 
with two (p < 0.05) and three or more (p < 0.01) children had significantly lower 
AMH levels than those with no children. However, they were unable to exclude 
women with PCOS from the study. Since PCOS is characterized by abnormally 
elevated AMH concentrations and subfertility, this may have skewed the results. 
In a sample of 420 women, Whitworth et al. (2015) found that women with the 
highest parity had 20% lower AMH concentrations (95% CI = −39% to 6%) than 
nulliparous women.  
Contrary to these studies, Dolleman et al. (n = 2,320) found that higher 
parity was associated with higher age-specific AMH levels (p < .02). However, 
after adjusting for contraceptive use, cycle irregularity, pregnancy, and current 
smoking, parity was no longer significant (Dolleman et al., 2013). In a cross-
sectional study of 186 women, Moini et al. (2016) found that multiparous women 
had significantly higher AMH levels than nulliparous women (Moini, 
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Hedayatshodeh, Hosseini, & Rastad, 2016). The mean AMH level was 2.53 ± 
1.90 ng/ml in nulliparous women and 3.54 ± 1.42 ng/ml in women with children (p 
< .0001), suggesting that increased parity is associated with increased AMH 
levels. And finally, in a cross-sectional study of 277 women, La Marca et al. 
(2010) found no association between parity and AMH levels (La Marca et al., 
2010).  
Resolution of conflicting findings regarding the effects of parity on AMH 
requires further studies. Higher parity may result in later age at natural 
menopause by suppressing follicle recruitment and ovulation (during pregnancy), 
thus preserving the follicle pool and resulting in later menopause (Gold et al., 
2001). This explanation is consistent with the findings from the studies by 
Dolleman et al. and Moini et al. In contrast, studies that found lower AMH levels 
in women with higher parity posit that this association may be explained by the 
costly energetic investment required for pregnancy at the expense of future 
reproductive potential (Bragg, Kuzawa, Ahustin, Banerjee, & McCade, 2012). 
Biological factors 
 
 
Obesity 
 
 
 Obesity inhibits reproductive function by altering the secretion of 
gonadotropin releasing hormone, which disrupts the ovarian follicular 
environment and leads to anovulation (Halawaty, ElKattan, Azab, ElGhamry, & 
Al-Inany, 2010; Klenov & Jungheim, 2014; Moy, Jindal, Lieman, & Buyuk, 2015; 
Vryonidou, Paschou, Muscogiuri, Orio, & Goulis, 2015b). Eleven studies 
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examined the correlation between BMI and AMH. Six observed an association 
(Bernardi et al., 2017; Bleil et al., 2014; Dafopoulos et al., 2010; Freeman et al., 
2012; Steiner et al., 2010; Su et al., 2010) and five  did not (Bentzen et al., 2013; 
Dolleman et al., 2013; Halawaty et al., 2010; La Marca et al., 2010; Sahmay et 
al., 2012).  
Bernardi et al. (2017) conducted one of the largest studies examining the 
relationship between BMI and AMH in 1,654 African American women. At 
enrollment, 19.8% of participants were underweight or normal, 20.7% were 
overweight and 59.5% were obese. When current BMI was analyzed as a 
continuous variable (15.9-79.4 kg/m2), there was a significant inverse relationship 
with AMH levels in the age-adjusted and the multivariable linear regression 
model, after adjusting for current hormonal contraceptive use, history of a thyroid 
condition, abnormal menstrual bleeding and menstrual cycle length. When 
current BMI was analyzed as a categorical variable, there was also a significant 
association between AMH and BMI, with the strongest association observed in 
the group with the highest BMI. This study provides convincing evidence due to 
its large sample size and inclusion of participants with a wide range of BMIs. 
 In a prospective study of 20 women, Steiner et al. examined AMH 
concentrations in obese (37.3 ± 6.0 kg/m2) and non-obese (21.9 ± 1.6 kg/m2) 
women and found that AMH levels were 34% lower in the obese group (2.9 ± 2.1 
vs. 4.4 ± 1.8 ng/mL, p < .05). Similarly, in a prospective study of 122 late 
reproductive age women, Freeman et al. found that obese women had 65% 
lower mean AMH levels than non-obese women (29.9 ± 8.6 kg/m2) (geometric 
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mean: 0.016 ng/mL versus 0.046 ng/mL, p < .034). In a cross-sectional study of 
947 women, Bleil et al. (2014) found that AMH decreased by 1.5% with every unit 
increase in BMI after adjusting for age, smoking, parity, hormonal contraception, 
age at menarche, psychological stress, educational attainment, and income (p < 
0.0001) (Bleil et al., 2014). And finally, in a small comparative study (n=36), Su et 
al. (2010) found that AMH levels in obese women were 77% lower on average 
than in normal weight women after adjusting for age, race, smoking, and alcohol 
use, (p = 0.02). 
Five studies found no association between AMH and BMI. In a study of 
527 Danish women, Bentzen et al. (2013) found no significant association 
between BMI (median 22 kg/m2) and AMH (p = 0.53) after adjusting for oral 
contraceptive use, smoking and prenatal exposure to smoking. In a comparative 
study, Halawaty et al. (2010) examined differences in AMH levels between 50 
women with BMI between 30-35 kg/m2and 50 age-matched controls with BMI 
<30 kg/m2 and found no significant difference between the groups. In another 
comparative study, Sahmay et al. (2012) found no statistically significant 
difference in AMH levels between obese (>30 kg/m2) and non-obese (<30 kg/m2) 
participants. However, out of the 259 participants in the study, only 37 were 
obese. In the studies by Halawaty et al. and Sahmay et al., individuals were 
grouped using arbitrary BMI cut points (>30 kg/m2 and <30 kg/m2). Comparing 
obese women to groups that include normal and overweight women is unlikely to 
detect differences in AMH levels, particularly given what we know regarding the 
disruptive effects of adipose tissue on hormone metabolism (Klenov & Jungheim, 
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2014). Additionally, neither of these studies adjusted for age, which has a 
significant effect both on AMH and BMI. The last two studies were cross-
sectional. In one, the range in BMI was not reported (La Marca et al., 2012), and 
in the other, the mean BMI of the sample did not cover a broad range, 24.3 ± 3.9 
(Dolleman et al., 2013). 
There are several theories that may explain the relationship between AMH 
and obesity. Obesity is characterized by alterations in adipocyte-hormone 
secretion and insulin resistance (Crujeiras & Casanueva, 2015). Leptin, an 
adipokine required for activation of gonadotropin releasing hormone secretion, is 
present in high concentrations in obesity, and may directly inhibit gonadal 
functions and contribute to lower AMH levels (Crujeiras & Casanueva, 2015). 
Adinopectin, an adipokine that contributes to oocyte maturation and granulosa 
cell proliferation, is decreased in obesity and may contribute to lower AMH levels. 
Insulin resistance may contribute to granulosa cell dysfunction and alter AMH 
concentrations (Bernardi et al., 2017; Park et al., 2010). Another possibility is that 
AMH metabolism is altered in obese women (Freeman et al., 2007). Decreased 
levels of AMH in obese women may point to impaired follicular function; however, 
the association between AMH and BMI was not observed in all studies (Freeman 
et al., 2007). More research is needed to examine the association between BMI 
and AMH levels and to clarify the explanatory mechanisms behind this 
association.  
Cardiometabolic 
 
 
Four studies examined the association between AMH and cardiometabolic 
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factors (Bleil, Gregorich, McConnell, Rosen, & Cedars, 2013; Park et al., 2010; 
Tehrani, Erfani, Cheraghi, Tohidi, & Azizi, 2014; Zhu, Wang, Chen, Ji, & Xiong, 
2017). In a study of 951 women, Bleil et al. (2013) observed that the number of 
cardio-metabolic risk factors was higher in women with low compared to high 
AMH levels and that women with low AMH levels had increased risk of high-
density lipoprotein (HDL) <50 mg/dL, increased waist circumference, and 
hypertension. However, associations were no longer significant after controlling 
for BMI (Bleil, Gregorich, et al., 2013).  
In a longitudinal study of 1,015 women by Tehrani et al. (2014), 
cholesterol and low-density lipoprotein (LDL) profiles were less favorable in 
women with lower age-specific AMH levels. While there were no significant 
differences in baseline cardiovascular risk factors, during the follow-up period, 
total cholesterol increased for those with the lowest age-specific AMH levels, 
while it decreased for those with the highest age-specific AMH levels (p < .001); 
the average decrease in LDL for those with the lowest age-specific AMH levels 
was less than for those with the highest age-specific AMH levels (p < .004) 
(Tehrani et al., 2014). And last, in a prospective study of 120 healthy women, 
Park et al. used the Homeostatic Model Assessment of Insulin Resistance 
(HOMA-IR) to examine the association between insulin resistance and ovarian 
reserve and found an inverse association between HOMA-IR and AMH levels (r = 
-0.343, p < .001) (Park et al., 2010).  
While numerous studies have found evidence of increased cardiovascular 
disease risk with advancing gynecological age (Tehrani, Behboudi-Gandevani, 
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Ghanbarian, & Azizi, 2014), few studies have examined potential associations 
between premenopausal cardiovascular risk factors and the process of ovarian 
aging (de Kat, Broekmans, Laven, & van der Schouw, 2015). The studies 
included in this review provide preliminary evidence that variability in 
reproductive aging may be related to cardiometabolic risk factors in pre-
menopausal women, however more research is needed to examine this 
association (Maria E Bleil, Gregorich, et al., 2013).  
Behavioral factors 
 
 
Smoking 
 
 
 Toxins from smoking may have detrimental effects on the ovarian follicle 
pool and increase rates of follicle atresia, leading to decreased antral follicles and 
alterations in ovarian hormones (Schuh-Huerta et al., 2012). The association 
between smoking and AMH levels was examined in 10 studies. Two observed an 
inverse association (Dolleman et al., 2013; Plante, Cooper, Baird, & Steiner, 
2010), one observed higher AMH levels in smokers vs non-smokers (Schuh-
Huerta et al., 2012) and seven observed no association (Bentzen et al., 2013; 
Dafopoulos et al., 2010; Hawkins Bressler et al., 2016; J. Kline, Tang, & Levin, 
2016; Lambert-Messerlian, Plante, Eklund, Raker, & Moore, 2016; Waylen, 
Jones, & Ledger, 2010).  
In a cross-sectional study of 284 women, Plante et al. (2010) examined 
AMH levels in current smokers (defined as actively smoking within the previous 
two years), past smokers (defined as a history of smoking with cessation 
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occurring at least two years before the study), and passive smokers (defined as 
currently living with someone who smoked in their home). They found that 
current smokers, but not past smokers, had 44% lower AMH levels than the 
reference group (participants with neither active nor former or passive smoke 
exposure), p = 0.04. They also found that within current smokers, those who 
smoked 15 cigarettes or more per day tended to have lower AMH levels than 
those who smoked fewer than 15 cigarettes per day, but this difference was not 
statistically significant (p = 0.08). Dolleman et al. (2013) also found lower AMH 
levels in current smokers in comparison to never smokers (p = 0.02), and no 
association with previous smoking. When examining duration of smoking, they 
found an inverse association between AMH levels and 10+ pack-years (β = -7.0, 
P = .003).  
Of the studies that found no association, Hawkins Bressler et al. was one 
of the largest with 1,654 African American participants. This study provided one 
of the most in depth analyses of various characteristics of smoking including age 
at initiation, cessation and duration. Most women (73%) never smoked regularly, 
7% formerly smoked, and 19% were current smokers. Among current smokers, 
only 4% smoked a pack or more a day. The average age of smoking initiation 
was 18 (±4) years, cessation was 25 (±4) years, and the average duration of 
smoking was 6 (±5) years, none of which were associated with AMH levels (p > 
.05) (Hawkins Bressler et al., 2016). In another study of 137 women, of which 59 
(43%) smoked 8.6 ± 5.9-pack years (range 2–20 pack years), Dafoupoulos et al. 
found an inverse association between smoking and AMH levels; this association 
	118	
was no longer significant after adjusting for age, BMI, and reproductive hormones 
(Dafopoulos et al., 2010).  
Waylen et al. examined the association between AMH and smoking in 335 
women. Of these, 202 were non-smokers, 86 were ex-smokers and 47 were 
current smokers. No statistically significant difference was observed in serum 
AMH concentrations in women with a history of smoking compared with those 
that had never smoked. However, a trend towards a decrease in both previous 
and current smokers was observed (Waylen et al., 2010). Several other cross-
sectional studies examined the association between smoking and AMH levels 
and also found no association (Bentzen et al., 2013; J. Kline et al., 2016; 
Lambert-Messerlian et al., 2016; Shaw et al., 2011). Contrary to these studies, 
Schuh-Huerta et al. (2012) found higher AMH levels in a sample of 947 smokers 
vs nonsmokers, 33.5 ± 2.4 versus 27.4 ± 1.7 pM (p = 0.038) and found that 
neither current nor previous smoking was associated with overall lower ovarian 
follicle counts. It is unclear why AMH levels would have been elevated in 
smokers in this study.  
While a greater number of studies found no association between AMH and 
smoking, the two studies that included smoking duration in the analyses of 
smoking did observe an association between the duration of smoking and AMH 
levels. More research is needed to clarify the association between smoking and 
AMH levels. 
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Alcohol consumption 
 
 
Four studies examined the association between alcohol consumption and 
AMH levels. In a cross-sectional study of 420 women, Whitworth et al. (2016) 
found lower AMH levels among women who drank alcohol (−21%, 95% CI=−36% 
to −3%) (Whitworth et al., 2016). In another cross-sectional study of 1654 
women, Hawkins Bressler et al. (2016) found that those who binge drank twice a 
week or more had 21% lower AMH levels compared with those who never drank 
(95% CI= -41% to 7%), but found no association between drinking alcohol and 
AMH levels in non-binge drinkers (Hawkins Bressler et al., 2016). Hawkins 
Bressler et al. hypothesized that the association between binge drinking and 
lower AMH levels may be due to alcohol-induced alterations in hepatic 
catabolism of estradiol or gonadotropins and the subsequent impact on 
hypothalamic-pituitary axis signaling. Alternatively, they also hypothesized that 
repeated large-volume alcohol exposures may overwhelm the protective 
mechanisms of the granulosa complex and contribute to lower AMH levels 
(Hawkins Bressler et al., 2016). Two studies found no association between 
alcohol consumption and AMH levels (Dolleman et al., 2013; J. Kline et al., 
2016).  
Caffeine consumption 
 
 
Three studies examined the association between caffeine consumption 
and ovarian reserve. Whitworth et al. (2016) found lower AMH levels among 
women who drank coffee (−19%, 95% CI −31% to −5%). Two studies of 2320 
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and 477 women found no association between caffeine consumption and AMH 
levels (Dolleman et al., 2013; J. Kline et al., 2016). In a review of epidemiologic 
evidence concerning the association between caffeine consumption and 
reproductive health, Peck et al. (2010) concluded that there was insufficient 
evidence to support a relationship between caffeine intake and reproductive 
outcomes (Peck, Leviton, & Cowan, 2010).  
Discussion 
 
 
 This integrative review provides a summary of the evidence regarding the 
association between modifiable biobehavioral factors and anti-Müllerian hormone 
levels in reproductive age women. Various reproductive (contraceptive use and 
parity), biological (obesity, cardiometabolic) and behavioral (smoking, alcohol 
and caffeine consumption) factors have been examined in association with 
serum anti-Müllerian hormone concentrations.  
Among the studies included, most often examined was hormonal 
contraceptive use (n=14). While several studies found no association, the 
majority (n=10) found lower AMH levels in hormonal contraceptive users 
compared to non-users. Previous contraceptive use, however, was not 
associated with lower AMH levels after contraceptive use was discontinued. 
These findings suggest that if contraceptive use affects serum AMH levels, the 
effect is reversible. Given the current level of evidence, clinicians and 
researchers should be cautious when interpreting AMH levels during 
contraceptive use; and it is important that future researchers examine how long 
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after discontinuing hormonal contraceptive use AMH returns to age-adjusted 
normal levels. 
Among the biological factors examined, obesity was examined the most 
(n=11). However, the evidence regarding the association between BMI and AMH 
is contradictory. Six observed an association between increased BMI and lower 
AMH levels, and five found no association. There was considerable variation in 
the way BMI was measured and categorized. Several of the studies examined 
BMI as a continuous variable and several examined it as a categorical variable. 
The studies examining BMI as a categorical variable used different cut-points 
making it difficult to compare the findings (Bentzen et al., 2013; Freeman et al., 
2007; Steiner et al., 2010). 
There is insufficient evidence regarding the association between AMH 
levels and cardiometabolic risk factors; however, the studies included in this 
review suggest that women with lower AMH levels are more likely to have less 
favorable cardiometabolic profiles. And finally, the evidence regarding the effect 
of lifestyle factors (smoking and alcohol/caffeine consumption) is inconclusive. 
However, studies that observed an association between smoking and AMH 
levels found lower AMH levels in current smokers but no association with 
previous smoking, suggesting a reversible effect.  
In order to facilitate direct comparison between studies and increased 
precision in determining effect sizes, there is a need to incorporate standardized 
and consistent measures of biobehavioral exposures. There was significant 
variation in how exposures were defined and measured (i.e. duration, quantity, 
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categorization, etc…). In addition, greater consistency in adjustment for 
covariates is needed, as this will improve our understanding of the combined 
effect of multiple factors as well as their total contribution to variation in the 
process of ovarian aging. Chronic disease risk is best explained by the 
synergistic effect of multiple factors, and this is likely also the case with the 
process of ovarian aging. The studies included in the review were all cohort, 
cross-sectional or case-control studies. These study designs limit the ability to 
detect effects and conclusions drawn are based only on associations. 
Longitudinal studies are needed to account for fluctuations in biobehavioral 
exposures over time, and to permit an examination of the mechanisms behind 
the associations between biobehavioral exposures and AMH levels.  
The focus of this integrative review was to summarize the evidence 
regarding modifiable biobehavioral factors associated with AMH levels in women 
of reproductive age.  While age at menopause is highly heritable, the rate of 
change in AMH levels improves the precision of estimates of time to menopause 
(Freeman et al., 2012). Therefore, it is helpful to also consider the evidence 
regarding these same biobehavioral factors and onset of menopause. In a large 
multi-ethnic study examining factors associated with age at natural menopause 
(n=14,620), Gold et al. found that ever using hormonal contraceptives was 
associated with later age at natural menopause (Gold et al., 2001). However, in 
another study that examined more specific characteristics of hormonal 
contraceptive use in relation to age at natural menopause, de Vries et al. found 
that long-term (>3 years) use of high dose oral contraceptives and long-term 
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(>11 years) overall oral contraceptive use were associated with an earlier age at 
menopause (adjusted HR = 1.12; 95% CI 1.03–1.21 and HR = 1.13; 
respectively). The use of lower dose oral contraceptives had no influence on 
menopausal age (de Vries et al., 2001). As regards parity, Gold et al. reported 
that higher parity was associated with later age at menopause (Gold et al., 2001).  
The evidence regarding the relationship between BMI and age at 
menopause has been conflicting. In the study by Gold et al., in unadjusted 
models, women with lower BMI were more likely to be pre-menopausal, and 
women with higher BMI were more likely to be surgically amenorrheic (Gold et 
al., 2001). However, in adjusted models, BMI was not a significant predictor of 
age at menopause. The relationship between cardiometabolic factors and age at 
menopause has also proven complex to unravel. While it is widely accepted that 
postmenopausal status is associated with increased risk for cardiovascular 
disease, recent studies have demonstrated that premenopausal CVD risk factors 
may play a more important role in determining postmenopausal risk than 
previously thought (de Kat et al., 2017). It has been hypothesized that the 
processes of ovarian aging and cardiovascular disease risk have a synergistic 
relationship (de Kat, Verschuren, Eijkemans, van der Schouw, & Broekmans, 
2016).  
In a systematic review examining the association between smoking and 
age at menopause, a reduction in age at menopause was greater among current 
smokers than among former smokers, suggesting that the detrimental effect of 
smoking on ovarian follicles may be salvageable (Parente, Faerstein, Keller, & 
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Werneck, 2008). And in a recent systematic review and meta-analysis examining 
the association between alcohol consumption and age at menopause, Taneri et 
al. (2016) found that low and moderate alcohol consumption (more than one 
drink per week (RR = 0.60; 95% CI 0.49–0.75) and three or fewer drinks per 
week (RR = 0.75; 95% CI 0.60–0.94) were associated with later menopause 
onset, compared to non-drinkers. They suggest that low to moderate alcohol 
intake may reflect moderate lifestyle habits, which could explain the positive 
association between moderate intake and age at menopause (Taneri et al., 
2016).  
Many of the factors shown to influence AMH levels may also influence age 
at menopause.  More research is needed to better understand the effects of 
these factors on AMH and whether serum AMH concentrations accurately predict 
the onset of menopause (Broer et al., 2011; van Disseldorp et al., 2008).    
Conclusion 
 
 
It is clear from this integrative review that our understanding of the 
modifiable biobehavioral factors influencing AMH concentrations is incomplete. 
Increased understanding of the biobehavioral factors associated with AMH levels 
will improve the quality of care for women at risk for infertility. Many reproductive 
age women seek evidence-based information regarding their fertility status There 
is a great need for a reliable biomarker to improve early detection of infertility risk 
and address gaps in reproductive healthcare.  Greater understanding of factors 
affecting AMH levels will aid in the development of evidence-based information 
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for improved patient education as well the development of effective interventions 
for the prevention and treatment of infertility. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Search Strategy 
 
 
408 Records 
identified 
through 
Pubmed 
Inclusion 
criteria: 
1. Reproductive 
age (19+) 
2. AMH as 
outcome 
3. Healthy 
females 
4. Human 
5. English 
17	excluded:		1. Only	one	study	(n=8)	2. Intervention	(n=1)		3. Non-modifiable	(n=6)	4. Illness	(n=1)	5. AMH	outcome	(n=1)		
50 records  
6 added from 
references lists 
of included 
publications 
39	included	in	the	final	review	
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Table 1: Hormonal Contraceptive Use  
Inverse association (n=10) 
Author et 
al. (date) 
Desig
n 
N (age) Race/ 
Ethnicity 
Groups Covariates Finding 
Bentzen 
(2012) 
CC 732 
(21-41) 
Denmark 228 
users, 
504 non-
users 
Age • AMH 29.8% lower in OCP users 
(p < .001, 95% CI 19.8%; 38.5%) 
 
 
 
Birch-
Peterson 
(2015) 
CC 887 
(19-46) 
Denmark 244 
users, 
643 non-
users 
Age, smoking, 
BMI, maternal 
age at 
menopause, 
preterm birth, 
maternal 
smoking 
• AMH 20% lower in OCP users 
(p < 0.001, 95% CI 8.4%; 30.3%).  
 
 
 
 
 
 
Dolleman 
(2013)  
CC 2,320 
(37.3 ± 
9.2) 
The 
Netherlands 
1194 
previous,  
908 
current, 
218 
never 
Age, cycle 
regularity, 
OCP use, age 
at menarche, 
parity 
• Current OCP users had 
significantly lower AMH levels 
than women who had never used 
OCP  
(β = -9; p < .0001) 
• Previous OCP use was not 
associated with lower AMH levels 
(β = -0.3; p = .9) 
 
Arbo 
(2007) 
PC 20 
(29.1 ± 
4.1) 
Brazil Pre and 
post 
OCP use 
(1 month) 
No • AMH levels were significantly 
reduced with OCP use 
Median (inter-quartile range) 
3.02 ng/mL (1.21–6.39) before 
OCP and 2.22 ng/mL (0.9–3.11) 
after OCP (p < .04) 
 
Shaw 
(2011) 
CC 135 
(41 ± 
2.48) 
USA 14 Users, 
121 non-
users 
Age • Median AMH level in OCP users 
was 3.00 pmol/L (95% CI, 2.07–
3.86), compared with 4.57 pmol/L 
(95% CI, 3.86–5.21) in nonusers 
(p < .001) 
 
Kristensen 
(2012) 
CC 256 
(19-20) 
Denmark 180 
users, 76 
non-
users 
No • Median AMH in users was 2.5 
ng/mL (95% CI, 1.5–3.5), 
significantly lower than the median 
AMH level in nonusers 2.9 ng/mL 
(95% CI, 1.8–4.3), (p < .01) 
 
Kallio 
(2013) 
PC 42 
(20-33) 
Finland 13 OCP, 
15 
transder
mal, 14 
vaginal 
No • Significant decreases in serum 
AMH levels after 9 weeks in all 
groups: OCP (3.88 ± 3.0 vs. 1.91 
± 1.5 ng/mL, p < .001), 
transdermal (3.86 ± 3.6 vs. 1.96 ± 
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ring 1.3 ng/mL, p < .001), and vaginal 
ring (4.27 ± 3.5 vs. 2.25 ± 1.2 
ng/mL, p < .001) 
 
van den 
Berg 
(2010) 
PC 25 
(26.3 ± 
6.2) 
The 
Netherlands 
Hormone 
free 
interval, 
natural 
cycle 
Age • Significant increase in AMH in 
natural cycle vs. hormone free 
interval of contraceptive cycle, (p 
= .005) 
 
 
 
Kerkhof 
(2010) 
RC 279 
(18-24) 
The 
Netherlands 
Users, 
non-
users 
Age, birth 
weight, fat 
mass, age at 
menarche and 
SES 
• OCP use inversely associated 
with AMH in each model (p < 
0.001) 
 
 
 
Marsh  RC 1654 
(23-34) 
USA: 
African 
American 
Current 
users, 
non-
users 
Age, BMI • Current OCP use (27.5%) 
inversely associated with AMH 
levels (β = -0.290 (-0.408, -0.171), 
(p < .0001) 
 
No association (n=4)  
Author 
et al. 
(date) 
Desig
n 
N (age) Race/ 
Ethnicity 
Groups Covariates Finding 
Deb et al. 
(2012) 
Case-
control 
70 
(18-35) 
UK 34 Use for 
≥1 year; 
36 no use 
for ≥1 
year 
No • No significant difference between 
groups (p = .44) 
 
 
 
Li et al. 
(2011) 
PC 95 
(26-50) 
Hong Kong Pre and 3 
months 
post 
contracept
ive use (5 
types) 
No • No significant difference pre and 
post contraceptive use in all 
treatment groups (p > 
.05)(statistics not provided) 
 
 
 
Streuli 
(2008) 
PC 24 
24.1 
(3.5) 
Switzerland OCP, 
vaginal 
ring, 
control 
No • No significant difference between 
groups. Mean AMH levels for 
controls, 4.4 (SD ± 1.2) and 4.2 
(SD ± 1.4) ng/mL for first and 
second cycles; for OC, 5.0 (SD ± 
2.0) and 6.2 (SD ± 3.0) ng/mL; 
and for vaginal ring, 4.9 (SD ± 
3.3) and 5.5 (SD ± 4.1) ng/mL. 
 
Kucera 
(2016) 
CC 
 
149 
(23-34) 
Czech 
Republic 
(23-34) 
Long-term 
users, 
non-users 
No • No significant difference between 
groups. Median for users 2.89 
ng/mL, for non-users 3.37 ng/mL 
	128	
(p = .3261). 
Note: Abbreviations: CC, Cross-sectional; PC, Prospective cohort; RC, Retrospective cohort; OCP, Oral 
Contraceptive Pill; BMI, Body Mass Index; AMH, Anti-Müllerian hormone; CI, Confidence Interval; OR, Odds 
Ratio; SD, Standard Deviation 
 
 
Table 2: Parity 
Lower AMH associated with higher parity or no association (n=3) 
Author et al. 
(date) 
Design N (age) Race/ 
Ethnicity 
Groups Covariates Finding 
Bragg (2012) PC 294 Philippines 1, 2, 3+ 
children 
Age, BMI, 
smoking 
status  
• The overall 
association with parity 
was significant (F 
(3,286) = 4.25, p < 
0.01). Women with 2 
or 3+ pregnancies had 
50% of a SD decrease 
in AMH. 
 
Whitworth 
(2015) 
CC 420 
(20-30) 
South Africa Nulliparous, 
1, 2 
children 
Age, BMI, 
parity, 
education 
• Compared with 
nulliparous women, 
women with one 
previous birth had 
21% lower AMH 
concentrations (95% 
CI −36 to −3%), and 
women with two or 
more previous births 
had 30% lower AMH 
concentrations (95% 
CI −46% to −10%). 
 
La Marca 
(2010)  
CC 277 
(18-50) 
The 
Netherlands 
Nulliparous, 
1+ 
Age • No significant 
association between 
parity and AMH levels. 
 
Higher AMH associated with higher parity (n=2) 
Author et al. 
(date) 
Design N (age) Race/ 
Ethnicity 
Groups Covariat
es 
Finding 
Dolleman 
(2013) 
CC 2320 
(37.3 ± 
9.2) 
The 
Netherland
s 
Continuous 
variable 
Age, 
cycle 
regularity, 
HC use, 
age at 
menarche 
• Higher parity 
associated with 2 
percentiles higher 
AMH. 
 
Moini (2016) CC 186 
(20-35) 
Iran Nulliparous
, 
multiparous 
Age, BMI, 
age at 
menarche
, cycle 
regularity, 
• Higher AMH in 
multiparous women. 
The mean of AMH was 
2.53 ± 1.90 ng/ml in 
nulliparous women and 
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duration 
of 
menses 
3.54 ± 1.42 ng/ml in 
women with children, 
which showed a 
significant difference 
between the groups (p 
< 0.0001). 
 
Note: Abbreviations: CC, Cross-sectional; PC, Prospective cohort; HC, Hormonal Contraceptive; BMI, Body 
Mass Index; AMH, Anti-Müllerian hormone; CI, Confidence Interval; SD, Standard Deviation 
 
Table 3: BMI  
Inverse association (n=6) 
Author et al. 
(date) 
Design N 
(Age) 
Race/ 
Ethnicity 
Groups Covariates Finding 
Steiner (2010) PC 20 
(18-35) 
USA <25 kg/m2 
(n=10), >30 
kg/m2 
(n=10) 
No • AMH levels were 34% 
lower in the obese group 
(2.9 ± 2.1 vs. 4.4 ± 1.8 
ng/mL, p < 0.05) 
 
Bleil (2014) CC 947 
(25-45) 
USA Continuous 
variable 
BMI, 
smoking, 
parity, HC, 
age at 
menarche, 
psychologica
l stress, 
education, 
and income 
• With every unit increase 
in BMI, AMH decreased 
by 1.5% (p < .0001) 
 
 
 
 
 
 
 
Dafoupoulos 
(2010) 
PC 137 
(20-49) 
Greece Continuous 
variable 
Age, BMI, 
reproductive 
hormones 
• BMI and AMH associated 
without adjusting for age 
(r = -0.345, p < 0.05) 
 
Freeman (2007) PC 122 
(45.8 ± 
5.2) 
USA ≤30 kg/m2, 
>30 kg/m2, 
continuous 
variable 
BMI, age, 
menopausal 
status and 
race 
• Obese women had mean 
AMH levels that were 
65% lower than AMH 
levels of non-obese 
women (geometric mean: 
0.016 ng/mL versus 
0.046 ng/mL; geometric 
mean ratio = 0.35; 95% 
CI 0.13, 0.92; p < .034) 
 
Bernardi (2017) RC 1654 
(23-34) 
USA: 
African 
American 
<18.5kg/m2
= 
underweight
, ≥18.5 to 
24.9 kg/m2 
= normal,  
25 to 29.9 
Current HC, 
history of a 
thyroid 
condition, 
abnormal 
menstrual 
bleeding, 
• When current BMI was 
analyzed as a continuous 
variable, there was a 
significant inverse 
relationship with AMH in 
the age-adjusted and the 
multivariable linear 
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kg/m2= 
overweight, 
≥30 kg/m2= 
obese 
Continuous 
and 
menstrual 
cycle length 
regression models. 
When current BMI was 
analyzed as a categorical 
variable, the beta 
coefficients for each BMI 
group increased with 
increasing BMI, with the 
strongest association 
between AMH and BMI 
being observed among 
those with the highest 
BMI. 
 
Su (2010) CC 36 
(40-52) 
USA <25 kg/m2 
(n=18) 
>30 kg/m2 
(n=18) 
Age, BMI, 
race, 
smoking, 
alcohol use 
• AMH levels in obese 
women were 77% lower 
on average than in 
normal weight women (p 
= 0.02) 
 
No association (n=5) 
Author et al. 
(date) 
Design N (Age) Race/  
Ethnicity 
Groups Covariates Finding 
Bentzen (2013) CC 527 
(32.7 ± 
4.1) 
Danish <18 kg/m2, 
18-25 
kg/m2, >25 
kg/m2, >30 
kg/m2 
HC, BMI, 
smoking 
habits and 
prenatal 
exposure to 
smoking 
• No significant 
association found 
between BMI and 
serum AMH (p = 0.53). 
 
 
 
 
Dolleman 
(2013) 
PC 2320 
(37.3 ± 
9.2) 
The 
Netherlands 
Continuous 
variables 
Age, cycle 
regularity, 
HC use, age 
at menarche, 
parity 
• No significant 
association between 
BMI and AMH (β = -
0.2; p = 0.16) or waist 
circumference and 
AMH (β = -0.09, p = 
0.12) 
 
La Marca 
(2012)  
CC 416 
(18-50) 
Italy Continuous 
variable 
Age • AMH levels and BMI 
were significantly and 
negatively correlated 
(r = -0.1; p = 0.03), but 
not correlated after 
adjusting for age 
 
Sahmay (2012) CC 259 
(27-45) 
Turkey <30 kg/m2 
(n=222), 
>30 kg/m2 
37 
No • AMH levels were 3.46 
± 2.79 ng/ml in non-
obese participants and 
3.79 ± 2.93 ng/ml in 
obese participants. No 
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significant correlation 
was found between 
the levels of AMH and 
BMI (p > 0.05). 
 
Halawaty 
(2010) 
CC 100 
(40-48) 
Egypt <30 kg/m2, 
30-35 
kg/m2 
No • There was no 
correlation between 
BMI and serum AMH. 
•  
Note: Abbreviations: CC, Cross-sectional; PC, Prospective cohort; HC, Hormonal Contraceptive; BMI, Body 
Mass Index; AMH, Anti-Müllerian hormone; CI, Confidence Interval;  
 
Table 4: Smoking  
Inverse association (n=2)  
Author et al. 
(date) 
Design Sample 
size 
(Age) 
Race/ 
Ethnicity 
Groups Covariates Finding 
Dolleman 
(2013) 
CC 2320 
(37.3 ±  
9.2) 
The 
Netherlands 
Current, 
previous, 
never 
Age, cycle 
regularity, 
OC use, 
age at 
menarche, 
parity 
• Current smoking was 
associated with 3.6 
percentiles lower age-
specific AMH values (p = 
.02) in comparison to never 
smokers. Significant effect 
of duration of smoking on 
AMH levels seen after 10+ 
pack-years (β = -7.0, p = 
.003). No significant effect 
of previous smoking. 
 
Plante (2010) CC 284 (38-
50) 
USA Current, 
previous, 
passive, 
never 
Age, BMI • Current smokers, but not 
past smokers, had 44% 
lower AMH values than did 
the reference group 
(participants with neither 
active nor former or 
passive smoke exposure); 
p = 0.04. 
 
No association (n=8) 
Author et al. 
(date) 
Design Sample Race/ 
Ethnicity 
Groups Covariates Finding 
Dafoupoulos 
(2010) 
CC 137 
(20-49) 
Greece Smokers, 
non-
smokers 
Age, BMI, 
reproductive 
hormones 
• Pearson’s correlation 
showed that AMH 
levels were negatively 
correlated with smoking 
(r = -.807, p < .001), not 
significant in multiple 
linear regression. 
 
Bentzen CC 527 Denmark Current, Age • No significant effect of 
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(2012) (21-41) previous, 
never 
current or previous 
smoking on AMH 
values (p = .9). 
 
Waylen 
(2010) 
RC 335 
(24-48) 
UK Current, 
previous, 
never 
Age • A decreasing trend was 
observed, but not 
significant: Geometric 
mean: Never: 1.074 
(0.925–1.245), 
Previous: 0.955 
(0.760–1.199), Current: 
0.869 (0.638–1.183). 
 
Kline (2016) CC 477 
(19-45) 
USA Current, 
previous, 
never 
Age • Neither current nor 
former smoking was 
associated with AMH 
levels.  
 
Hawkins 
Bressler 
(2016) 
RC 1654 
(23-34) 
USA 
African 
American 
Current, 
previous, 
never 
Age, BMI, 
current HC 
use 
• AMH not associated 
with current or previous 
smoking, age at 
initiation, duration, or 
passive exposure (p > 
.05) 
 
Lambert 
Messerlian 
(2016) 
PC 45 
(18-45) 
USA Current 
Not 
smoking 
Age, BMI • AMH not associated 
with smoking 
 
 
Schuh-Huerta 
(2012) 
CC 432 
(25-45) 
USA Smokers, 
non-
smokers 
Age, HC 
use 
• AMH was significantly 
higher in smokers than 
non-smokers AMH 
levels were 33.5+2.4 
versus 27.4+1.7 pM (p 
< 0.038) in Caucasians. 
 
Shaw (2011) CC 135 
(41 ± 2.5) 
USA Current,  
Previous, 
never 
Age • No significant 
association between 
age and smoking status 
 
Note: Abbreviations: CC, Cross-sectional; PC, Prospective cohort; RC, Retrospective cohort; HC, Hormonal 
Contraceptive; BMI, Body Mass Index; AMH, Anti-Müllerian hormone; CI, Confidence Interval 
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Table 5: Cardiometabolic  
Inverse association (n=4) 
Author et 
al. (date) 
Design Sample Race/ 
Ethnicity 
Groups Covariates Finding 
Tehrani 
(2014) 
PC 1015 
(20-50) 
Iran Continuous 
variables 
Age, BMI, 
menopause 
status 
• Total cholesterol net 
changes per year 
were higher in 
women with the 
lowest age-specific 
AMH but not in 
women with the 
highest age-specific 
AMH (p < 0.001). 
Over time, 
cholesterol and LDL 
profiles were less 
favorable in women 
with lower age-
specific AMH levels. 
 
Park 
(2010) 
PC 120 
(37.24 ± 
5.48) 
Korea HOMA-IR Age • There was a 
significant 
association between 
HOMA-IR and AMH 
levels, increase of 
HOMA-IR 
associated with 
decrease in AMH 
levels (r = -0.343, p 
< .001) 
 
Zhu 
(2017) 
CC 109 
(23-41) 
Chinese >30, <30 
years old 
NA • In women 30 years 
or older, increases 
in triglycerides were 
associated with 
increased AMH 
level; however, the 
effect of triglycerides 
vanished with 
adjustment for 
testosterone level. 
 
Bleil 
(2013) 
CC 951 
(25-45) 
USA Categorical
: 
number of 
cardio-
metabolic 
risk factors  
Age, smoking, 
race/ethnicity,
age at 
menarche, 
past use HC, 
and parity 
• The number of 
cardio-metabolic risk 
factors was 52.1% 
higher among 
women with low 
compared to high 
AMH levels and 
46.0% higher among 
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women with mid 
compared to high 
AMH levels.  
 
Note: Abbreviations: CC, Cross-sectional; PC, Prospective cohort; HC, Hormonal Contraceptive; BMI, Body 
Mass Index; AMH, Anti-Müllerian hormone 
 
Table 6: Alcohol  
Inverse association (n=2) 
Author et al. 
(date) 
Design N 
(Age) 
Race/ 
Ethnicity 
Groups Covariates Finding 
Whitworth 
(2016) 
CC 420 
(20-30) 
South 
Africa 
Yes/No 
Alcohol 
drinker 
Age, BMI, 
parity, 
education 
• AMH levels were 
significantly lower 
among women who 
drank alcohol 
(−21%, 95% CI 
−36% to −3%). 
 
Hawkins 
Bressler 
(2016) 
RC 1654 
(23-34) 
USA: 
African 
American 
Drinkers, 
non-
drinkers, 
binge 
drinkers 
Age, BMI, 
current HC 
• Those who binge 
drank twice a week 
or more had 21% 
lower AMH levels 
compared with those 
who never drink 
(95% CI, -41 to 7). 
 
No Association (n=2) 
Author et al. 
(date) 
Design Sample 
size 
(Age) 
Race/ 
Ethnicity 
Groups Covariates Finding 
Kline (2016)  CC 477 
(19-47) 
USA Days/week 
drink 
alcohol 
Age • No significant 
association between 
alcohol consumption 
and AMH levels 
 
Dolleman 
(2013) 
CC 2320 
(37.3 ± 
9.2) 
The 
Netherlan
ds 
Daily, 
drinks per 
day 
Age, cycle 
regularity, HC 
use, age at 
menarche, 
parity 
• No significant 
association between 
alcohol consumption 
and AMH levels (β=-.4; 
p = .74) 
 
Note: Abbreviations: CC, Cross-sectional; RC, Retrospective cohort; HC, Hormonal Contraceptive; BMI, Body 
Mass Index; AMH, Anti-Müllerian hormone; CI, Confidence Interval 
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Table 7: Caffeine  
Inverse association (n=1) 
Author et 
al. (date) 
Design N 
(Age) 
Race/ 
Ethnicit
y 
Groups Covariates Finding 
Whitworth 
(2016) 
CC 
 
420 
(20-30) 
South 
Africa 
Yes/No 
regular 
coffee 
consumption  
Age, BMI, 
parity, 
education 
• Lower AMH levels 
among women who 
drank coffee (−19%, 
95% CI −31% to 
−5%)  
 
 
No Association (n=2) 
Author et 
al. (date) 
Design N 
(Age) 
Race/ 
Ethnicity 
Groups Covariates Finding 
Kline 
(2016)  
CC 477 
(19-47) 
USA Amount of 
caffeine 
Age • No significant 
association between 
caffeine consumption 
and AMH levels 
 
Dolleman 
(2013) 
CC 2320 
(37.3 ± 
9.2) 
The 
Netherlands 
Daily, 
drinks per 
day 
Age, cycle 
regularity, 
OCP use, 
age at 
menarche, 
parity 
• No significant 
association between 
caffeine consumption 
and AMH levels  
 
Note: Abbreviations: CC, Cross-sectional; OCP, Oral Contraceptive Pill; BMI, Body Mass Index; AMH, Anti-
Müllerian hormone; CI, Confidence Interval 
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Abstract 
 
 
The process of ovarian aging is influenced by a complex and poorly 
understood interplay of endocrine, metabolic and environmental factors. The 
purpose of this study was to explore the feasibility of using Latent Class Analysis 
to identify subgroups based on cardiometabolic, psychological and reproductive 
parameters of health and to describe patterns of anti-Müllerian hormone levels, a 
biomarker of the ovarian reserve, within these subgroups. Sixty-nine lean (BMI ≤ 
25kg/m2) and severely obese (BMI ≥ 40kg/m2) postpartum women in Edinburgh, 
Scotland were included in this exploratory study. The best fitting model included 
3 classes; Class 1, n = 23 (33.5%); Class 2; n = 30 (42.2%); Class 3; n = 16 
(24.3%). Postpartum women with lower ovarian reserve had less favorable 
cardiometabolic and psychological profiles. Examining the ovarian reserve within 
distinct subgroups based on parameters of health that affect ovarian aging may 
facilitate risk stratification in the context of ovarian aging. 
Key Words: Ovarian reserve, latent class analysis, cardiometabolic, 
psychological 
 
 
 
 
 
 
 
	146	
The ovarian reserve--the number of remaining ovarian follicles--declines 
gradually over a women’s reproductive lifespan and natural menopause occurs 
when the ovarian reserve is depleted (Daan & Fauser, 2015). Anti-Müllerian 
hormone (AMH) plays a role in ovarian follicle growth, specifically in regulating 
the pace of follicle recruitment and selection (Visser et al., 2007). Plasma levels 
of AMH reflect the continuous non-cyclic growth of small ovarian follicles, and 
therefore mirror the size of the remaining follicle pool (Dewailly et al., 2014; 
Jeppesen et al., 2013). Considerable variation in the age at natural menopause 
suggests that factors other than chronological age contribute to the depletion of 
the ovarian follicle pool over time (van Disseldorp et al., 2008).  
While numerous studies have examined the effect of biobehavioral factors 
on AMH concentrations (Dolleman et al., 2013; La Marca et al., 2012b), few have 
explored patterns within and between women with proven fertility as a means of 
identifying subgroups. Accurate group classification would improve the clinical 
interpretation of serum AMH concentrations and facilitate risk stratification in the 
context of ovarian aging (Pal et al., 2010). As cardiovascular, metabolic, and 
psychological factors have each been shown to have an effect on the ovarian 
reserve (Balkan, Cetin, Usluogullari, Unal, & Usluogullari, 2014; Bleil et al., 2012; 
Bleil et al., 2012; de Kat, Broekmans, Laven, & van der Schouw, 2015), we 
hypothesized that latent class analysis (LCA) could be used to develop subgroup 
classifications using these factors and that these subgroups would provide a 
useful context within which to examine the complex interplay of variables 
involved in the process of ovarian aging.  
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LCA is a clustering method used to identify patterns in factor 
configurations and has been effectively used to examine co-occurrence patterns 
of risk factors in chronic disease development (Dewailly, Alebić, Duhamel, & 
Stojanović, 2014; Leventhal, Huh, & Dunton, 2014). Rather than providing 
prescriptive clinical guidelines regarding the nature of class structures, we sought 
to elucidate the complex process of ovarian aging by exploring AMH within the 
context of cardiometabolic, psychological and reproductive factors (Henry, 
Dymnicki, Mohatt, Allen, & Kelly, 2015; Leventhal et al., 2014). As the underlying 
mechanisms contributing to premature ovarian aging are not well understood, 
LCA may be a useful method for clarifying how co-occurrence patterns of risk 
factors contribute to subtle changes in ovarian functioning over time (Leventhal et 
al., 2014). We conducted an exploratory study with the purpose of testing the 
feasibility of this hypothesis in a sample of postpartum women in whom 
cardiovascular, metabolic, and psychological factors had been measured during 
pregnancy and postpartum.  
Methods 
 
 
Sample 
 
 
This study used data from a prospective cohort study conducted in 
Edinburgh, Scotland from 2008-2013 examining associations between mood and 
weight changes in lean (BMI ≤ 25kg/m2) and very severely obese (BMI ≥ 
40kg/m2) women with singleton pregnancies (Mina et al., 2015). In the parent 
study, cardiovascular, metabolic, and psychological measures were recorded 
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during pregnancy and 3 months postpartum. For this exploratory cross-sectional 
study, only data collected during the study visit three months postpartum were 
used. This time point was selected to avoid the ovarian suppression that occurs 
during pregnancy and to coincide with the expected recovery of AMH levels 
(Köninger et al., 2015). Women diagnosed with gestational diabetes or polycystic 
ovary syndrome were excluded as these conditions are known to influence AMH 
levels (Iliodromiti et al., 2013; Łebkowska et al., 2016). All samples and data 
were collected with ethical approval (references 08/S1101/39 and 13/ES/0126), 
and with fully informed and written consent from all women.  
Measures 
 
 
Cardiometabolic risk factors included fasting lipids (total cholesterol, high 
density lipoprotein, triglycerides), fasting glucose, fasting morning cortisol and 
BMI (Mina et al., 2015). BMI was used to group women as lean (BMI ≤ 25kg/m2) 
or severely obese (SO) (BMI ≥ 40kg/m2).  
Psychological measures included the Hospital Anxiety and Depression 
Scale (HADS), the State-Trait Anxiety Index (STAI) and the General Health 
Questionnaire (GHQ). The HADS evaluates anxiety and depression symptoms 
(range: 0–21) and has been reported to help in differentiating transient and 
enduring stress during pregnancy (Matthey & Ross-Hamid, 2012). The STAI 
evaluates both state and trait anxiety (range: 20–80 each), and has been 
previously validated in severely obese pregnant women (Gunning et al., 2010). 
The GHQ-12 uses binary scoring (range: 0–15) and has been shown to reliably 
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differentiate stress levels between pregnant and non-pregnant controls 
(Goldberg, 1973; van Bussel, Spitz, & Demyttenaere, 2006). 
Reproductive measures included LH, FSH, estradiol (E2), AMH and 
breastfeeding status. Serum levels of LH, FSH, E2 and AMH were measured in 
stored serum samples in a single batch by electrochemiluminescence 
immunoassay using the Roche Elecsys assay system (West Sussex, UK) 
(reference numbers: 11732234122, 11775863122, 06656021190 and 
06331076190 respectively). The intra-assay coefficients of variation were 6.2-
6.9% for LH, 7.3-8.1% for FSH, 1.5-3.2% for E2, and 5.8-6.9% for AMH.. 
Breastfeeding status at both time points was assessed with a single yes/no 
question: ‘Are you breastfeeding your baby now?’. A ‘yes’ answer included both 
exclusive and non-exclusive breastfeeding. 
Data Analyses 
 
 
To describe the data, means and standard deviations were calculated for 
clinical and demographic variables in the whole sample. A one-way ANOVA was 
used to explore differences in variables between lean vs. very severely obese 
women, and in breastfeeding vs. non-breastfeeding women. The ANOVA was 
conducted to control for the parent study’s primary research questions and to 
identify meaningful differences present in the data. Bonferroni adjustment was 
used, dividing α of 0.05 by the number of variables (n= 12), to account for 
multiple statistical testing with only differences resulting in a p-value lower than 
0.004 considered statistically significant.  
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AMH levels were log-transformed for parametric analysis. Anxiety and 
depression were analyzed using the methods outlined in Mina et al. (2015). 
Briefly, maternal mood outcomes were grouped into ‘anxiety symptoms’ and 
‘depression symptoms’. Anxiety symptoms were represented by Hospital Anxiety 
(HA from the HADS) and both the state and trait components of the STAI. 
Depression outcomes were represented by Hospital Depression (HD, from the 
HADS) and the GHQ. To avoid multiple testing and the need to include a 
Bonferroni correction, the z-score was calculated for each outcome and 
averaged z-scores were used for each symptom group in the analysis. 
Latent Class Analysis (LCA) was used to classify the subjects of the whole 
sample (heterogeneous) into smaller homogeneous classes/groups in which 
members are similar to each other and differentiated from subjects in other 
groups using cardiometabolic, psychological and reproductive factors. The 
objective is to identify groups naturally occurring in the data, when the number of 
underlying groups is unknown (DiStefano, 2012; Kaplan, 2014). LCA assumes 
that the data comes from a mixture of populations that have different probability 
distributions and that the population consists of homogeneous subgroups, in 
which the groups are discrete and mutually exclusive (DiStefano, 2012). The 
results of LCA provide probabilities for the proportion of the population expected 
in each group. Groups are not defined a priori but are rather probabilistic 
(Dewailly, Alebić, Duhamel, & Stojanović, 2014); individuals are allocated to 
groups based on observed values in the indicator variables used to determine 
class membership. Individuals of the same group are similar such that their 
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observed values are assumed to come from the same probability distribution 
(Tein, Coxe, & Cham, 2013). Conditional probabilities describing the mean or 
likelihood of each indicator variable are provided for each class (Henry et al., 
2015). LCA has demonstrated the ability to accurately determine class 
membership in samples as small as 50 (Henry et al., 2015).  As this was an 
exploratory study to examine the feasibility of using LCA to identify subgroups, 
we used a small sample. The LCA model included the following indicator 
variables: age, fasting lipids (triglycerides, cholesterol, and HDL), fasting glucose, 
fasting cortisol, lean/obese, breastfeeding status, anxiety, depression, FSH, LH, 
E2, and AMH levels. All variables were continuous with the exception of 
lean/obese and breastfeeding status; LCA is capable of reliability identifying 
class structures using variables with mixed scales (DiStefano, 2012). 
All analyses were conducted using R 3.3.3 (Core Team, 2017), with the 
package flexmix (Leisch, 2004). This software allowed us to estimate LCA with 
different numbers of classes and compare the fit of each number of classes to 
identify how many classes should be estimated. The LCA was estimated for 1 to 
10 classes, comparing the models with the Bayesian Information Criterion (BIC) 
and Integrated Completed Likelihood Criterion (ICL) (Burnham & Anderson, 
2003). These information criteria penalized the log-likelihood of the model. The 
BIC and ICL are used to select the model from a set of candidate models that 
provides the best balance of model fit, complexity and parsimony, where models 
with lower BIC and ICL present better fit (Burnham & Anderson, 2003). Once the 
number of classes was defined, we looked at the characteristics of each class 
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and the patterns of the variables of interest relative to the ovarian reserve. As the 
primary focus of this study was to establish the feasibility of using LCA to identify 
subgroups, we provide only a brief discussion of class characteristics.  
Results 
 
 
Sixty-nine lean (n=38) and severely obese (n=31) postpartum women with 
mean age 33.97 (SD = 4.1) years were included in the analysis. Forty-seven 
women were breastfeeding and 22 were not breastfeeding. Clinical and 
demographic data and group differences (lean/very severely obese and 
breastfeeding/non-breastfeeding) are summarized in Table 1. As expected, there 
was a significant negative correlation between age and logAMH (r = -0.312, p = 
0.002). 
Information criteria (BIC and ICL) and entropy were used to compare the 
LCA solutions from a different number of classes (Table 2). As the number of 
classes increases, the log-likelihood decreases, and entropy increases. The BIC 
and ICL decreased from 1 to 2 classes, increased minimally from 2 to 3 classes, 
and clearly increased from 4 or more classes. Given that the difference in 
information criteria between the 2 and 3 classes solution was small, we 
examined the parameter estimates for each of these solutions to identify which 
one presented results that were more theoretically fitting.  
The best fitting LCA model with meaningful parameter characteristics for 
each class included 3 classes (Table 3). For the 3-class LCA, 33.5% (n=23) of 
the sample was in Class 1, 42.2% (n=30) of the sample was in Class 2, and 
24.3% (n=16) of the sample was in Class 3. Table 4 shows the variable 
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characteristics for each class. For the continuous variables, the characteristic is 
presented as the average score of that variable within each class, for the binary 
variables (breastfeeding status and lean/obese), the characteristic is presented 
as the probability of presenting that characteristic. Comparisons between the 
classes by cardiometabolic, psychological and reproductive health parameters 
are shown in Table 3.  For the 3-class solution, the entropy is 0.93. Entropy is a 
measure of uncertainty in the classification procedure, indicating how well the 
model predicts membership, with values close to 1 representing better prediction. 
The high entropy (0.93) for this LCA solution shows that the model accurately 
predicts membership.  Each class is summarized briefly below: 
Class 1: Highest mean AMH levels, lowest probability of breastfeeding, 
lowest mean cholesterol levels, lowest mean HDL levels, lowest 
probability of being lean, lowest mean fasting morning cortisol levels, 
lowest mean anxiety scores, lowest mean FSH and LH levels, and highest 
mean E2 levels 
Class 2: Highest probability of breastfeeding, lowest mean triglyceride 
levels, highest mean HDL levels, highest probability of being lean, lowest 
mean depression score, highest mean FSH and LH levels, and lowest 
mean E2 levels 
Class 3: Lowest mean AMH levels, highest mean triglyceride and 
cholesterol levels, highest mean anxiety and depression scores, and 
highest mean cortisol levels 
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Discussion 
 
 
In this study, we used latent class analysis to explore possible subgroups 
of cardiometabolic, psychological and reproductive parameters of health in 
relation to ovarian reserve in a convenience sample of post-partum women. 
Three subgroups were identified.  As expected, there was a negative correlation 
between age and AMH; however, age was not a strong determinant of class 
membership in the LCA. The subgroups identified through LCA provide insight 
into the complex interactions of various health related parameters in relation to 
ovarian reserve and contribute to our understanding of factors other than age 
involved in the process of ovarian aging. LCA offers a feasible approach for 
examining risk factors in the context of ovarian aging.  
Class 1 had the highest mean AMH levels and the lowest mean 
cholesterol levels. Class 3 had the lowest mean AMH levels and the highest 
mean cholesterol and triglyceride levels. Several studies have observed the trend 
toward a less favorable cardiovascular risk profile in women with lower age-
specific AMH levels (Bleil, Gregorich, McConnell, Rosen, & Cedars, 2013; 
Tehrani, Erfani, Cheraghi, Tohidi, & Azizi, 2014). Cardiovascular disease risk 
factors have been suggested to accelerate the process of ovarian aging by 
impairing vascularization of the ovaries and accelerating ovarian decline (de Kat 
et al., 2015). It may be that these processes occur simultaneously and share 
similar underlying mechanisms, such that accelerated ovarian aging increases 
cardiovascular disease risk and increased cardiovascular disease risk 
accelerates ovarian aging (de Kat et al., 2015; Kok et al., 2006).  
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In the present study, the probability of being lean or severely obese did 
not demonstrate a strong class trend in relation to AMH. Given the strong class 
trend of cardiovascular risk factors in relation to AMH, this was an unexpected 
finding since severe obesity is a well-defined risk factor for early onset 
cardiovascular disease. This finding may be explained by the lack of variability in 
cardiometabolic factors observed in the sample, irrespective of BMI. Despite their 
obesity, these women are still relatively young and display a narrow range of 
variability in cardiometabolic factors. This lack of class trend may also be 
explained by the use of a postpartum sample of women; breastfeeding has been 
shown to have a protective effect on cardiovascular health regardless of pre-
conception risk factors (McClure, Catov, Ness, & Schwarz, 2012).  
The suppressive effect of obesity on reproductive function is well 
established (Klenov & Jungheim, 2014; Nelson, Stewart, Fleming, & Freeman, 
2010; Vryonidou, Paschou, Muscogiuri, Orio, & Goulis, 2015). Obesity alters the 
ovarian follicular environment and contributes to anovulation (Klenov & 
Jungheim, 2014; Moy et al., 2015). The effect of obesity on ovarian reserve is 
less well understood (Moy et al., 2015; Sahmay et al., 2012) with conflicting 
results (Malhotra et al., 2013; Moy et al., 2015; Sahmay et al., 2012; Steiner, 
2013). Whether obesity also accelerates follicle loss and perhaps contributes to 
diminished ovarian reserve remains unclear (Klenov & Jungheim, 2014).  
Class 1 had the lowest mean fasting morning cortisol levels and was the 
only class to have cortisol levels within the normal range.  Both the mean cortisol 
levels in class 2 and class 3 were higher than normal. Class 2 had the highest 
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probability of breastfeeding. While few studies have examined hypothalamic 
pituitary adrenal (HPA) activity in breastfeeding, one study found that morning 
salivary cortisol levels were higher in women who predominantly breastfed (Ahn 
& Corwin, 2014). Class 3 had the highest fasting morning cortisol levels. This 
finding may be explained by the increased mean anxiety and depression scores 
as well as less favorable lipid profiles observed in this class (Veen et al., 2009). 
Dysregulation of the HPA axis impairs reproductive function by suppressing 
steroidogenesis and inhibiting gonadotropin release (Schliep et al., 2015). The 
effect of HPA activity on ovarian reserve is less well understood, however 
preliminary studies suggest associations between cortisol and abnormal AMH 
levels (Hardy et al., 2016).  
In addition to the lowest mean AMH levels and a less favorable 
cardiovascular risk profile, class 3 also had the highest mean depression and 
anxiety scores (z-scores). Few studies have examined the association between 
psychological factors and biomarkers of the ovarian reserve (Bleil et al., 2012; 
Pal et al., 2010). Psychological disorders such as depression and anxiety are 
associated with impaired reproductive function (Williams, Marsh, & Rasgon, 
2007) and are also associated with greater cardiovascular and metabolic disease 
risk (Bleil, Bromberger, et al., 2013; Lamers et al., 2012; Nikkheslat et al., 2015).  
Class 2 had the highest probability of breastfeeding and of being lean, the 
lowest mean triglyceride levels, and the highest mean HDL levels. This is 
consistent with a protective effect of breastfeeding on cardiovascular health 
regardless of pre-conception risk factors (McClure et al., 2012). The probability of 
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breastfeeding did not, however, demonstrate a strong class trend in relation to 
AMH. Several studies have reported a suppressive effect of pregnancy on the 
ovarian reserve (Gerli et al., 2015; Köninger et al., 2013; Nelson et al., 2010). 
The effect of breastfeeding is not previously described, although AMH was not 
reduced in women with hyperprolactinaemia-induced amenorrhea (Li, Anderson, 
Yeung, Ho, & Ng, 2011). In this study, there was no significant difference in AMH 
concentrations between breastfeeding and non-breastfeeding postpartum 
women. 
 Consistent with this class also having the highest probability of 
breastfeeding, class 2 had the lowest E2 levels (McNeilly, 1993). Class 2 also 
had the highest gonadotropin levels, a finding that was unexpected and the basis 
for which is unclear. Class 1 had the highest E2 levels and the lowest FSH and 
LH levels. Class 1 also had the highest AMH levels. While AMH does not 
fluctuate significantly across the menstrual cycle, levels are at their highest in the 
late follicular phase, corresponding with rising estradiol levels (Wunder, 
Bersinger, Yared, Kretschmer, & Birkhäuser, 2008). Reproductive hormone 
levels were not able to be timed according to menstrual cycle phase in our 
postpartum sample, so these findings should be interpreted with caution. 
This was an exploratory study with a small sample size. However, this was 
appropriate given that the study was exploratory in nature, it was the first to use 
latent class analysis to explore subgroups of risk profiles for ovarian reserve, and 
was meant to determine the feasibility of this type of analysis for this population.  
It is important to note that the sample consisted of a population of postpartum 
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women with known fertility; most studies examining factors associated with AMH 
concentrations have been conducted in infertile populations.  
While preliminary, the findings from this study can be used as the 
foundation for future analyses of subgroups in relation to the ovarian reserve. 
The findings from this exploratory study should be replicated in larger samples to 
allow for independent validation, as well as in different reproductive contexts to 
examine how these variables behave in other populations. Current evidence 
suggests that the rate of change in AMH concentrations improves the accuracy 
of the biomarker to predict age at menopause (Freeman et al., 2012). Thus, 
longitudinal studies will be necessary to identify additional factors contributing to 
variation in the process of ovarian aging.  
 The process of ovarian aging spans many years, and at present, there are 
few clues, other than chronological age, that indicate where a woman is in her 
reproductive lifespan (Ottinger, 2011). In this study, we explored patterns in 
cardiometabolic, psychological and reproductive factors in relation to ovarian 
reserve and found less favorable cardiometabolic and psychological profiles in 
women with lower ovarian reserve. The findings from this study demonstrate that 
LCA is a feasible and useful approach for examining subgroups based on various 
parameters of health, and sheds light on factors that may contribute to variation 
in serum AMH concentrations, providing a window into what may be the earlier 
stages of ovarian aging. With validation in larger samples, this information could 
be used to develop reliable subgroup classifications to aid in the early detection 
and prevention of premature ovarian aging.  
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Table	1:	Clinical	and	Demographic	Data	
	 Overall	(n	=	69)	
Lean	
(n	=	38)	
Obese	
(n	=	31)	 p-value	
Breastfeeding	
(n	=	47)	
Not	
Breastfeeding	
(n	=	22)	
p-value	
Age	(years)	 33.97	±	4.1	 34.54	±	3.64	 33.27	±	4.56	 0.203	 34.6	±	3.93	 32.66	±	4.24	 0.07	
Anxiety	 0.04	±	1.08	 -0.2	±	1.04	 0.33	±	1.06	 0.039	 -0.05	±	1.07	 0.24	±	1.08	 0.302	
Depression	 -0.08	±	0.95	 -0.38	±	0.86	 0.29	±	0.94	 0.003	 -0.2	±	0.91	 0.17	±	1.01	 0.132	
FSH	(mIU/ml)	 7.02	±	3.56	 7.79	±	3.35	 6.08	±	3.64	 0.046	 7.4	±	3.34	 6.19	±	3.95	 0.188	
LH	(mIU/ml)	 5.19	±	3.93	 4.9	±	4.12	 5.53	±	3.73	 0.513	 5.21	±	4.39	 5.14	±	2.82	 0.952	
E2	(pg/ml)	 40.02	±	38.06	 31.02	±	26.6	 51.04	±	46.71	 0.029	 27.9	±	26.12	 65.91	±	46.52	 <0.0001*	
AMH	(ng/ml)	 2.79	±	2.5	 3.19	±	2.81	 2.3	±	2.0	 0.143	 2.98	±	2.57	 2.4	±	2.36	 0.375	
Serum	cortisol	
(nmol/L)	 855.7	±	556.5	 963.7	±	587	 742.5	±	504.9	 0.168	 867.88	±	537.53	 758.96	±	577.62	 0.446	
Cholesterol	
(mmol/L)	 5.28	±	1.47	 5.57	±	1.51	 4.92	±	1.36	 0.064	 5.29	±	1.36	 5.26	±	1.71	 0.937	
HDL	
(mmol/L)		 1.57	±	0.46	 1.68	±	0.46	 1.44	±	0.43	 0.027	 1.62	±	0.4	 1.46	±	0.56	 0.196	
Triglycerides	
(mmol/L)	 1.12	±	0.81	 1.01	±	0.77	 1.25	±	0.85	 0.234	 1.01	±	0.79	 1.34	±	0.82	 0.115	
• Alpha	level	≤	.0004	considered	significant	
Note:	Anxiety	and	depression	are	z-scores.	Abbreviations:	AMH,	Anti-Müllerian	Hormone;	HDL,	High-Density	Lipoprotein;	FSH,	
Follicle	Stimulating	Hormone;	LH,	Luteinizing	Hormone;	E2,	Estradiol	
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Table	2:	Latent	Class	Analysis:	Three-class	model	characteristics	
	
	
Class	1	(32.2%)	
(n=22)	
	
	
Class	2	(43.4%)	
(n=30)	
	
	
Class	3	(24.3%)	
(n=17)	
	
AMH	
(ng/ml)	 3.83	 2.88	 1.86	
	
Age	
	
33.25	 35.01	 33.08	
Breastfeeding	
(Yes)	 0.47	 0.94	 0.49	
	
Triglycerides	
(mmol/L)	
1.04	 0.64	 1.85	
	
Cholesterol	
(mmol/L)	
4.1	 5.05	 6.53	
	
HDL	
(mmol/L)	
1.22	 1.77	 1.56	
Glucose	
(mmol/L)	 4.73	 4.48	 4.61	
Lean	
	 0.29	 0.73	 0.51	
Anxiety	
(z-score)	 -0.18	 -0.05	 0.33	
Depression	
(z-score)	 0.02	 -0.26	 0.1	
Cortisol	
(nmol/L)	 437.15	 955.91	 974.67	
FSH	
(mIU/ml)	 5.1	 8.13	 6.99	
LH	
(mIU/ml)	 4.34	 5.9	 4.85	
E2	
(pg/ml)	 74.19	 22.85	 37.04	
Note:	For	the	continuous	variables,	the	characteristic	is	presented	as	the	mean	of	that	variable	within	each	class,	for	the	binary	
variables	(breastfeeding	status	and	lean/obese),	the	characteristic	is	presented	as	the	probability	of	presenting	that	
characteristic.	Abbreviations:	AMH,	Anti-Müllerian	Hormone;	HDL,	High-Density	Lipoprotein;	FSH,	Follicle	Stimulating	
Hormone;	LH,	Luteinizing	Hormone;	E2,	Estradiol	
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Table	3:	Comparisons	between	classes	by	health	parameters		
Class		
(mean	AMH	level)	
Class	1	
(3.83	ng/mL)	
Class	2	
(2.88	ng/mL)	
Class	3		
(1.86	ng/mL)	
Cardiometabolic	 • Lowest	cholesterol	
and	HDL	
• Lowest	probability	
of	being	lean	
• Highest	glucose	
• Lowest	cortisol	
• Lowest	
triglycerides	
• Highest	HDL	
• Highest	probability	
of	being	lean	
• Lowest	glucose	
	
• Highest	
triglycerides	and	
cholesterol	
• Highest	cortisol	
	
	
	
	
Psychological		 • Lowest	anxiety	 • Lowest	depression	 • Highest	anxiety	
and	depression	
	
Reproductive	 • Highest	AMH	
• Lowest	probability	
of	breastfeeding	
• Lowest	FSH	and	LH	
• Highest	E2	
• Highest	probability	
of	breastfeeding	
• Highest	FSH	and	LH	
• Lowest	E2	
• Lowest	AMH	
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Abstract 
 
 
Background: Few predictors of post-treatment reproductive function in 
childhood cancer survivors (CCC) have been identified. CCS report high levels of 
psychological stress. The association between stress and ovarian function has 
not been explored in this population. 
Purpose: The purpose of this exploratory study was to explore the relationship 
between perceived stress, biomarkers of HPA activity, gonadotropin levels, and 
anti-Müllerian hormone (AMH) in female CCS. 
Methods: Perceived stress was measured using the Perceived Stress Scale-10. 
HPA activity was measured using salivary and hair cortisol. Ovarian function was 
measured using serum gonadotropin levels and serum AMH levels. Latent 
Growth Modeling was used to determine diurnal cortisol slope and intercept. 
Bayesian Structural Equation Modeling was used to explore the relationship 
between perceived stress, biomarkers of HPA activity and ovarian function.  
Results: Twenty-four female (mean age 21.79 ± 5.68) CCS were included in the 
study. We found an inverse association between perceived stress and ovarian 
function and a positive association between biomarkers of HPA activity and 
ovarian function.  
Conclusion: The findings from this study provide the foundation for further 
research examining factors that contribute to risk for post-treatment reproductive 
dysfunction in female CCS.  
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Background 
 
 
An estimated one in 1000 adults under the age of 35 is a survivor of 
childhood cancer (Blumenfeld, 2012). Due to significant advances in the 
treatment of pediatric cancer, the five year survival rate now exceeds 80% in the 
United States (Barton et al., 2013) with similar statistics worldwide (Reinmuth et 
al., 2013). With an increasing number of survivors, there has been growing 
recognition of the potential late effects of cancer treatment (Kremer et al., 2013). 
Among these, reproductive dysfunction is a major concern for cancer survivors, 
and is highly correlated with quality of life in this population (Cherven et al., 2015; 
Knopman et al., 2010; Kondapalli et al., 2014; Letourneau et al., 2013). Among 
female childhood cancer survivors (CCS), 6.3% suffer from acute ovarian failure 
and another 22.6% suffer from a significant reduction in ovarian function (Salih et 
al., 2015). Female CCS are at risk for persistent chemotherapy-related 
amenorrhea and early menopause; however, not all premenopausal CCS 
experience these effects (Abusief et al., 2012).  
The American Society for Clinical Oncology recommends that providers 
discuss fertility preservation options with cancer patients at the earliest 
opportunity; however, it remains challenging for providers to predict individual 
risk of post-treatment reproductive dysfunction because of the limited knowledge 
of factors associated with this late effect (Knight et al., 2015; Letourneau et al., 
2013). While the etiology of reproductive dysfunction in cancer survivors has 
been discussed (El-Shalakany, Ali, Abdelmaksoud, Abd El-Ghany, & Hasan, 
2013; Letourneau et al., 2013), few predictors of this effect of treatment have 
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been identified (Dewailly, et al., 2014, Anderson et al., 2015). Further research is 
warranted to develop reliable biomarkers to help clinicians accurately identify 
cancer survivors at increased risk for reproductive dysfunction (Abusief et al., 
2012).  
In clinical practice, post-treatment ovarian function is assessed using a 
profile of the hormones follicle-stimulating hormone (FSH) and luteinizing 
hormone (LH), plus the presence or absence of menses. However, neither FSH 
nor menstrual cyclicity post-cancer treatment are reliable predictors of future 
fertility (Knight et al., 2015). Because risk of infertility related to premature 
ovarian failure is directly associated with the size of the ovarian follicle pool 
(ovarian reserve), a biomarker which more closely reflects the number of 
remaining follicles in the ovary would have significant clinical potential.  
Anti-Müllerian hormone (AMH) is one such recently identified biomarker of 
ovarian reserve. Plasma levels of AMH reflect the continuous non-cyclic growth 
of small follicles, and therefore mirror the size of the remaining follicle pool 
(Jeppesen, Anderson, Kelsey, Christiansen, Kristensen, Jayaprakasan, 
Campbell, et al., 2013). Kelsey et al. (2011) developed and validated the first 
model of AMH, mapping out the chronological trajectory of the hormone from 
conception to menopause (Kelsey, Wright, Nelson, Anderson, & Wallace, 2011). 
La Marca et al. then established normative age-ranges to aid in the clinical 
interpretation of AMH values (La Marca et al., 2012).  
Ovarian reserve declines naturally with age; however, recent research 
demonstrates that chronological age alone is not an accurate indicator of 
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reproductive age and that other factors affect the depletion of the ovarian follicle 
pool over time (Dolleman et al., 2013). AMH is prematurely reduced in CCS 
(Anderson & Wallace, 2013; Charpentier et al., 2014; Miyoshi et al., 2013), and 
may be an early marker of significant gonadotoxicity post treatment (Brougham 
et al., 2012; Lie Fong et al., 2009). Several studies have demonstrated the utility 
of pre-treatment AMH concentrations to predict risk of post treatment ovarian 
dysfunction in cancer survivors (Anderson & Wallace, 2013; Lunsford et al., 
2014). However, the predictive value of AMH in cancer survivors is limited due to 
incomplete knowledge of factors that influence AMH concentrations (Abusief et 
al., 2012; Van Dorp et al., 2014). 
One of the primary regulators of reproductive function is the hypothalamic-
pituitary-adrenal (HPA) axis. Cancer survivors have high rates of psychological 
stress and hypothalamic-pituitary-adrenal (HPA) dysregulation (Oancea et al., 
2014; Taylor et al., 2012; Zeltzer et al., 2009). It is well established that 
psychological stress impairs reproductive function by activating the HPA axis, 
which suppresses hypothalamic-pituitary gonadal function (Kalantaridou et al., 
2010; Louis et al., 2011; Lynch, Sundaram, Maisog, Sweeney, & Buck Louis, 
2014; Whirledge & Cidlowski, 2013). Increased HPA activity is associated with 
elevated levels of glucocorticoids, such as cortisol. Precise levels of 
glucocorticoids are required for proper ovarian function (Whirledge & Cidlowski, 
2010). At homeostatic levels, cortisol contributes to steroid biosynthesis and 
maintenance of gonadotropin release; at elevated levels, it suppresses 
gonadotropin-releasing hormone secretion, reduces pulsatile LH secretion, and 
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increases rates of follicle atresia (Breen & Mellon, 2014; Whirledge & Cidlowski, 
2010; Whirledge & Cidlowski, 2013). As both higher rates of psychological stress 
and reproductive dysfunction are observed in cancer survivors, this study 
explored the relationship between psychological stress and biomarkers of 
ovarian function in young cancer survivors. The purpose of this study was to 
explore relationships between perceived stress, HPA activity, and ovarian 
function in a sample of female survivors of childhood cancer. 
Theoretical Framework 
 
 
Life history theory was the framework used to guide this study (Whirledge 
& Cidlowski, 2013). Rooted in evolutionary biology, life history theory was 
developed to explain variation in resource allocation strategies adopted by 
organisms to optimize survival and reproduction throughout the life course and 
across varying environmental conditions. The task of all organisms is essentially 
the same, to distribute material and energy resources to competing life functions: 
bodily maintenance, growth and reproduction. Life history theory posits that the 
allocation of biological resources is a trade-off between survival and 
reproduction.   
Because resources are limited, an organism must make trade-offs, 
prioritizing their use in one domain at the expense of other competing domains 
(Ellis et al., 2009). Life history traits, characteristics that determine rates of bodily 
maintenance, reproduction, and growth, are the primary units of analysis in life 
history theory. Both individually and collectively, life history traits provide a 
window into an organism’s life history strategy and the developmental continuum 
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that results from a chain of resource allocation decisions (trade-offs). The main 
life history traits are age and size at maturity, reproductive investment, 
reproductive lifespan, and aging (Stearns, 2000).  
Early evolutionary biologists were able to demonstrate that organisms 
make tradeoffs in response to changing environmental conditions and that these 
tradeoffs influence the life course of an organism, but they struggled to identify 
the biological mechanisms that allow organisms to make tradeoffs. Identifying 
these mechanisms is vital to understanding the sources of variation in life history 
strategies (Stearns, 2000). One of the primary mechanisms by which an 
organism responds to changing environmental conditions is the hypothalamic-
pituitary-adrenal (HPA) axis (Ellis, 2013). Environmental challenges or stressors 
activate the HPA axis and increase glucocorticoid secretion, directing resources 
to vital physiological activities such as energy mobilization, cardiac output, and 
cognition, and away from less vital functions. Because reproduction is 
energetically costly, when resources are limited, an organism is likely to prioritize 
survival over reproduction, delaying fertility until environmental conditions are 
more ideal. The HPA axis, as a primary mediator of resource allocation 
decisions, plays an important role in determining an organism’s life history traits.  
The HPA axis plays a prominent role in the regulation of the hypothalamic-
pituitary-gonadal (HPG) axis through glucocorticoids, which have both supportive 
and suppressive effects on reproductive function. This complex and 
synchronized neuroendocrine cross talk between the HPA and HPG axes allows 
tradeoffs to occur (Whirledge & Cidlowski, 2010). At homeostatic levels, 
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glucocorticoids contribute to steroid biosynthesis and maintenance of 
gonadotropin release. During acute stress, endogenous glucocorticoids 
counteract the suppressive effects of prostaglandins on reproductive function, 
thus protecting gonadotropin secretion. This suggests that threshold 
glucocorticoid levels are necessary to maintain adequate gonadotropin release 
(Whirledge & Cidlowski, 2010). Elevated glucocorticoid levels suppress 
reproduction at multiple levels along the HPG axis. Increasing glucocorticoid 
levels down-regulate gonadotropin releasing hormone (GnRH) synthesis and 
decrease GnRH pulsatility, inhibiting the LH surge and delaying ovulation, and 
increasing the rate of ovarian follicle atresia (Whirledge & Cidlowski, 2010, 2013).  
 In this study, we hypothesized that chronic stress, operationalized 
as perceived stress (Perceived Stress Scale), and HPA activity, 
operationalized as hair cortisol and diurnal salivary cortisol patterns, would 
be associated with AMH, gonadotropin and reproductive hormone levels. 
This study had the following aims: 
Aim 1: Describe the relationship between perceived stress and biomarkers 
of HPA activity in female cancer survivors.  
Aim 2: Explore the relationship between perceived stress, biomarkers of 
HPA activity, AMH and gonadotropin levels in female cancer survivors. 
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Methods 
 
 
Sample and Settings 
 
 
The sample for this exploratory cross-sectional study consisted of female 
childhood cancer survivors between the ages of 16 and 35 who were previously 
treated for cancer at the Edinburgh Children’s Cancer Centre, Royal Hospital for 
Sick Children (RHSC). This was an exploratory study; sample size calculations 
are challenging in an exploratory model of potential predictors, due to the fact 
that one is not aware of predictor effects, and cannot put forth anticipated effect 
sizes.  
Cancer survivors are seen annually for follow up at the Royal Hospital for 
Sick Children (RHSC) (Wallace et al., 2014). The inclusion criteria were: female 
patients treated for cancer (including leukemia and brain tumors) at the 
Edinburgh Children’s Cancer Centre, younger than 18 years of age at cancer 
diagnosis and between 16-35 years of age at the time of the study visit, at least 
one year out from completing treatment, and signed written informed consent. In 
the UK, research subjects aged 16 and older are able to provide informed 
consent.  
This inclusion age range of 16-35 was selected because subjects are 
likely to be post-pubertal and in the most fertile window of their reproductive 
lifespan. Cancer survivors seen for long-term follow-up at the Royal Hospital for 
Sick Children (RHSC) in Edinburgh, Scotland were selected because of Dr. 
Anderson’s current research on reproductive function and fertility preservation in 
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cancer survivors (Wallace et al., 2014). This collaboration minimized burden to 
subjects and maximized potential findings. The exclusion criteria were a positive 
pregnancy test, ovarian surgery in the past 6 months, hormonal therapy in the 
preceding 3 months (GnRH agonists, recFSH), alcohol or drug 
abuse/dependence according to ICD-10 criteria, and having received an 
investigational drug in the past 3 months (90 days).  
Instruments 
Ovarian function: Assessment of ovarian function included serum 
gonadotropin levels (luteinizing hormone (LH), follicle-stimulating hormone 
(FSH)), estradiol (E2) and AMH. Serum levels of these hormones are 
routinely measured during the annual follow-up appointment as part of 
standard care at NHS affiliated clinics. The laboratory results were retrieved 
from participants’ medical records. Serum AMH levels were analyzed using 
the Beckman Coulter AMH GEN II ELISA (Beckman Coulter Inc., Brea, CA). 
The AMH Gen II ELISA has a sensitivity of 0.57 pmol/l. The validated model 
of serum anti-Müllerian hormone by Kelsey et al. (2011) and the nomogram 
with normative values for age published by La Marca et al. (2012) was used 
to interpret AMH levels (Kelsey et al., 2011b; La Marca et al., 2012b).  
HPA activity was determined using measures of salivary cortisol and 
hair cortisol. Salivary cortisol has been used to measure diurnal HPA activity 
in cancer survivors and other populations (Du et al., 2013; Ho et al., 2013; 
Sephton et al., 2013). Chronic stress is associated with alterations in the 
cortisol awakening response (Dedovic & Ngiam, 2015; Révész et al., 2013), 
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and blunting of the morning-evening diurnal slope (Garland et al., 2014; Ho 
et al., 2013; Schrepf et al., 2015). A commercially available Enzyme-Linked 
Immuno-Sorbent Assay (ELISA) kit was used for the quantification of 
cortisol in saliva (Salimetrics, Suffolk, UK KIT 1-3002). This cortisol assay kit 
has a lower detection limit of 7 ng/dl. The mean intra-assay coefficient is 
5.7% and the mean inter-assay coefficient is 10%. Analysis of salivary 
cortisol was conducted at the Queen’s Medical Research Institute in 
Edinburgh, Scotland under the supervision of Dr. Richard Anderson. 
Chronic stress has also been associated with elevated levels of 
cortisol in hair (Russell et al., 2012; Wells et al., 2014a). Hair has a 
predictable growth rate of 1 cm/month; the most proximal 1 cm segment to 
the scalp approximates the last month’s cortisol production, the second 
most proximal segment the month prior to that, and so on (Russell et al., 
2012). Hair (3 cm) was processed for extraction of cortisol in the laboratory 
of Clemens-Kirschbaum in Dresden, Germany as previously described 
(Kirschbaum et al., 2009). 
Perceived Stress was measured using the Perceived Stress Scale 
(Cohen et al., 1983). The PSS is a 10 item (PSS-10) self-report of life stress 
over the past 4 weeks, and is the most widely used measure of this concept. 
The PSS-10 was designed for use in community samples of subjects with 
education as low as junior high. Good to excellent reliability has been 
observed with the PSS-10 in varied populations (Cohen et al., 1983) with a 
Cronbach’s alpha ranging from .78-.91 (E.-H. Lee, 2012). The measure has 
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been demonstrated to reliably measure stress appraisal in cancer survivors 
(Golden-Kreutz et al., 2009).  
Data Collection  
 
 
 Recruitment was conducted by sending letters of invitation to female 
cancer survivors in long-term follow-up two weeks prior to their annual 
review appointment. After consenting to be contacted, patients were 
interviewed over the phone to determine eligibility to participate in the study. 
If eligibility requirements were met and the patient agreed to participate, a 
30-minute study visit at the RHSC was scheduled at a mutually agreed upon 
time. Written consent was obtained from participants at the study visit. Each 
subject was assigned a unique study ID and data was entered into an SPSS 
file on an encrypted computer in a locked office.  
Data was collected in this order: saliva, demographic and PSS-10 
questionnaires, hair. Salivette collecting devices and detailed instructions for 
collection of samples were provided to participants at their annual review 
appointment. Participants were instructed not to eat, smoke, consume 
caffeine or exercise for 30 minutes prior to sample collection (Schrepf et al., 
2015). Participants provided three timed saliva samples for the analysis of 
salivary cortisol: the first sample was collected before going to bed on the 
night prior to the study visit, the second immediately upon awakening the 
morning of their visit before getting out of bed, and the third was collected 
30 minutes after the second sample. Participants were instructed to record 
the time of saliva collection on their salivette collecting devices and to keep 
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the saliva samples refrigerated until coming in for their study visit to 
preserve sample integrity. Participants brought the three saliva samples to 
their study visit. Samples were labeled with a unique subject study ID and 
stored at the RHSC at -20 C; within a week of collection, a research nurse 
picked them up and brought them to the QMRI, where they were centrifuged 
and stored at -80 C.  
During the study visit, participants provided demographic information 
including age, ethnicity/race, level of education, marital status and employment 
status. Participants then completed the PSS-10 (Cohen et al., 1983). Lastly, 
participants provided a sample of hair for measurement of hair cortisol. A small 
sample of hair, 20mg (100-150 strands), was taken from the vertex posterior of 
the participant’s scalp using a new pair of thinning shears (Hoffman et al., 2014; 
Van Uum et al., 2008). Hair length was recorded and proximal ends of the hair 
samples were marked. Hair samples were stored in aluminum foil for protection 
before processing (Hoffman et al., 2014) and labeled with a unique subject study 
ID.  
During data collection, it was discovered that many subjects travel a great 
distance to the hospital for clinic visits. Therefore, to reduce the burden of 
participation, subjects were given the option to receive a research packet in the 
mail if they were unable to return to the RHSC for a separate study visit because 
of the travel distance. Since the current methods already required subjects to 
collect saliva samples at home, the main change was that subjects who decided 
to receive a research packet in the mail also self-collected a hair sample. They 
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were instructed on how to collect the hair sample when they consented to 
participate in the study. They were also asked to complete the PSS-10 at home. 
Biological samples and questionnaires were labeled with the subject’s study ID 
so as to ensure confidentiality. No identifying information was included in or on 
the research packet. The research packet included prepaid return packaging and 
an ice pack so that subjects could return samples and questionnaires to the 
Royal Hospital for Sick Children for processing.  
The following clinical characteristics were retrieved from participants’ 
medical records: cancer diagnosis, age at cancer diagnosis, 
chemotherapy/radiation received (yes/no) and age at menarche. 
Reproductive hormone levels (AMH, FSH, LH and E2), measured as part of 
routine care at the annual review visit, were also retrieved from participants’ 
medical records. 
Data Analysis and Interpretation 
 
 
Means and standard deviations or frequency distributions, as appropriate, 
for all demographic and clinical variables were reported to describe the sample 
and reveal distributional characteristics.  
Latent Growth Curve Modeling was used to examine diurnal cortisol 
patterns. Bayesian Structural Equation Modeling was used to explore the 
relationship between perceived stress and HPA activity and to explore 
relationships between perceived stress, biomarkers of HPA activity, gonadotropin 
levels, and AMH.  
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Latent Growth Curve Modeling 
 
  
Latent Growth Curve Modeling was used to define diurnal cortisol change 
over time (three time points). Growth curve modeling (GCM) examines change 
as a trajectory and assumes that trajectories vary across participants (Barker et 
al., 2013). This method was selected since chronic stress is characterized by a 
persistent and unstable trajectory of HPA activity (Hellhammer et al., 2009). 
Change processes are determined by combining the underlying pattern of growth 
(slope) with the initial or baseline measurement (intercept). The intercept and 
slope of this trajectory were then incorporated into the structural equation model 
as independent predictors of ovarian function. GCM was selected instead of 
more commonly utilized methods of analyzing diurnal cortisol (e.g. area under 
the curve, cortisol awakening response) because it permits a robust examination 
of change in small samples.  
GCM was evaluated as yit = λintηint + λslpηslp + et, where yit represents the 
observations for each subject i at each time t. λint represents the vector of fixed 
values that define the latent intercept, this is λint = [1,1,1], while λslp represents the 
vector of fixed values that define the linear slope, this is λslp = [0, 9.3, 9.8]. This 
represents the average time between the first observation to the second (9.3 
hours), and from the first observation to the third observation (9.8 hours). ηint 
represents the latent intercepts, while ηslp represents the latent slope, for which 
we estimate the respective mean and variance. The means represent the 
average starting point and average change over time, while the respective 
variance represents how much the subjects vary from the respective mean. 
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Lastly, et represents the residual variance at each time point t, this indicates that 
the GCM is estimated without the assumption of homogeneity of variance over 
time, the residual variance is allowed to differ over time.  
Bayesian analysis 
 
 
In Bayesian analysis, statistical inferences are drawn from parameter 
values that could give rise to the observed data (Scheines et al., 1999). The term 
prior is used to refer to the expected parameter distribution based on theory or 
previous research. The posterior distribution is the parameter distribution that 
results from multiplying the prior distribution by the likelihood (as observed in the 
sample data). The posterior distribution describes the behavior of the parameters 
conditional on the data. Because the Bayesian framework makes inferences from 
the posterior distribution, it allows researchers to make direct inferences about 
the parameters given the observed data. The posterior distribution describes 
both the best estimate given the data, and the level of uncertainty about the 
respective parameter by the width of it, typically represented by the credible 
interval (Yuan & MacKinnon, 2009). 
The Bayesian framework is an appropriate method for small sample sizes. 
Frequentist methods rely on the asymptotically correct estimation methods, 
basing the inference in function of the null hypothesis (Wagenmakers, Lee, 
Lodewyckx, & Iverson, 2008). Bayesian inference bases the inference on the 
observed data, which allows estimation of parameters with small samples in 
conditions where frequentist estimation fails (Lee & Song, 2004).  
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The Bayesian approach requires specification of prior distributions for 
each of the model parameters (Palomo et al., 2007). The selection of the prior 
distribution is important because the posterior distribution is informed by the prior 
distribution and the likelihood of the data (Palomo et al., 2007). The prior 
distribution incorporates information drawn from previous empirical studies or 
theory regarding the model parameters. Given the exploratory nature of this 
study, we first examined the model parameters using weakly informed priors. 
Weakly informed priors are not intended to guide the parameters, but instead 
provide information to delimitate the most likely data space for the parameters. 
Means/intercepts have a prior µ~N(0,100); the standard deviations have a prior 
δ~half-cauchy(0,2.5); the regressions have a prior β~N(0,50); and the 
correlations have a prior ρ~U(-1,1).  
Strong hypotheses are tested by model comparison. A model without 
constraints was compared to a model with constraints in the regressions (β), 
constraining if the β is positive or negative (according to theory). These 
constraints are set by specifying the respective β prior as a truncated normal 
(e.g: β~N(0,50)T(0,)) not allowing β to be above/below 0. Model comparison 
allowed us to evaluate if the model with directional constraints fit the data better 
than the unconstrained model. If the directional constraint model fit better, it is 
evidence that the β should be directional. The models were compared with 
Information Criteria Leave-One-Out (LOO), and Widely Applicable (WAIC)  
(Gelman et al., 2013; Kass & Raftery, 1995; Raftery, 1992; Vehtari, Gelman, & 
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Gabry, 2015, 2016). The theoretical model including the hypothesized 
directionality of the associations is presented in Figure 1. 
Bayesian Structural Equation Modeling 
 
 
Structural Equation Modeling (SEM) provides a broad framework for 
modeling relationships with multivariate outcomes (Palomo et al., 2007). The 
purpose of SEM is to test a theory by specifying a model that represents 
predictions about the theory’s constructs measured with appropriate observed 
variables (Kline, 2015). The outcome of SEM is a set of model parameters for 
hypothesized effects given the data. From these parameters, a set of logical 
implications result about the nature of the relationship or non-relationship 
between the variables (Kline, 2015). While SEM typically includes an 
approximation of unobserved or latent constructs as well as an estimation of the 
structure of the relationships among these observed constructs, in this study we 
used a special case of SEM called path analysis. In path analysis, every variable 
in the model is directly measured or observed (Bryan et al., 2007). While latent 
variables account for unreliability of measures and uncertainty in the model, they 
can also complicate a model, especially when the sample size is small. Path 
analysis was selected instead of multiple linear regression because it allowed us 
to test multiple relationships between variables, with multiple outcomes, 
conforming to the hypothesized model in this study. Establishing relationships 
including multiple paths and outcomes allowed us to test the presence of 
relationships accounting for the relationships with other variables of interest 
(Kline, 2015).  
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Bayesian SEM was selected because it facilitates greater precision in 
estimating the posterior distribution of the parameters for small samples. 
Additionally, Bayesian SEM offers the advantage of incorporating previous 
knowledge about the model’s parameters through the use of priors. Thus, 
Bayesian SEM provided an excellent framework for exploring the relationships 
between this study’s variables, allowing for an appropriate degree of uncertainty 
when estimating the model’s parameters (Scheines et al., 1999). We ran a series 
of path analysis models with salivary cortisol intercept and slope, PSS, Hair 
cortisol, BMI, Age, Age at diagnosis, and Age at menarche as predictors and with 
AMH, E2, FSH, and LH, as outcomes. 
Because the aim of the study was to explore relationships between 
variables, the analysis was not strictly confirmatory. If the data did not fit the 
model specified, alternative models were tested. The purpose of exploring 
various models was to provide additional information about the plausible 
relationships between the variables of interest and make recommendations for 
future model testing.  Data augmentation was used to account for missing data. 
Missing data was treated simultaneously as a parameter and data, filling any 
missing data points with the most likely value given the posterior distribution. At 
each iteration of the estimation, likely values were imputed for the missing data. 
These likely values were drawn from the posterior distribution estimated at that 
point in the iterations. In later steps of the estimation, the likely values were used 
as data in the path analysis, and this process continued until the model had 
converged (Merkle, 2011).  
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Data analysis was conducted in R (Core Team, 2017). Bayesian path 
analysis was run with the R package blavaan (Merkle & Rosseel, 2016) which 
estimates the model with the general Bayesian software JAGS (Plummer, 2003). 
Convergence of the Markov chains was determined using the potential scale 
reduction factor (PSRF), also known as univariate R-hat (Gelman & Rubin, 
1992). It was determined that the model converged when R-hat was lower than 
1.10 for every parameter (Brooks & Gelman, 1998). The models were run with 3 
chains, keeping the last 5000 iterations from each chain to build the posterior 
distributions. Model comparison with LOO and WAIC were done with loo R 
package (Vehtari et al., 2015); smaller values for LOO and WAIC represent a 
better fit. 
Results 
 
 
Twenty-four female childhood cancer survivors (mean age 21.79 ± 5.68) 
participated in the study. The majority had at least a high school education 
(62.5%) and was unmarried (79.2%). Childhood cancer diagnoses varied 
considerably and included: Osteosarcoma (n=1), Rhabdomyosarcoma (n=5), 
Wilms Tumor (n=1), Optic Chiasmal Glioma (n=1), Non-Hodgkin's Lymphoma 
(n=3), Ewing’s Sacrcoma (n=2), Immature teratoma L ovary (n=1), B-cell 
lymphoma (n=1), Hodgkin's Lymphoma (n=4), Right temporal lobe pilocytic 
astrocytoma (n=1), Pilocytic astrocytoma of the conus (n=1), Left renal tumor 
(n=1), Undifferentiated sarcoma of posterior sacral region (n=1), and Acute 
lymphoblastic leukaemia (n=1).  
 
	188	
Latent Growth Curve results 
 
 
The three measures of cortisol were standardized in function of the first 
time point. For each time point, we subtracted the mean from the measure at the 
first time point, and divided that number by the standard deviation of the measure 
at the first time point. This standardization sets the metric in function of the 
standard deviation from cortisol at the first time point (SD = 74.67) (Figure 2). 
Due to the standardization, the mean of the intercepts is 0.  
The GCM found that ηint ~ N(0.00, 0.65), indicating that the average 
starting point is at the average of the first time point (M = 105.25 ng/dL), and the 
variance is 0.65*74.67 = 48.53 ng/dL, in function of the standard deviation. For 
the other parameter of interest, ηslp ~ N(0.324, 0.126), indicating that on average, 
the participants’ cortisol levels increased about 0.324*74.67 = 24.19 ng/dL/hour, 
and the variance across the sample was 0.126*74.67 = 9.41 ng/dL. The residual 
variances indicate that the variance increases over time; at the third time point, 
the variability of cortisol is greater (Table 1). We found that the salivary cortisol 
intercept and slope were not correlated (r = 0.09).  
Path analysis results 
 
 
The first model included weakly informative priors, which did not constrain 
the directionality of the regressions. The second model constrained the direction 
of the regressions for the outcome AMH, the third constrained the direction of the 
regressions for E2, the fourth model constrained the direction of the regressions 
for FSH, the fifth model constrained the direction of the regressions for LH, the 
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sixth model constrained the direction of the regressions for all the outcomes, the 
seventh model constrained the direction of the regressions for all the outcomes in 
the opposite direction to the sixth model. These models allowed us to test if the 
data fit better with some constraints. The seventh model allowed us to do a 
sensitivity test; if the original theory driven constraints are meaningful the seventh 
model should decrease the fit.  
Table 2 shows the seven models and their fit comparison. Models 2 to 7 
were compared with model 1. For model 2 and model 5, the model fit is 
functionally the same. For models 3, 4, and 6 the model fit improved slightly. And 
for model 7, the fit decreased slightly. The model comparison demonstrates that 
the theory driven constraints do not decrease the fit of the model, and in some 
cases improve it. It also indicates that the opposite direction constraints do harm 
the fit of the model. Although model 6 improved the fit over model 1, this change 
in fit was not meaningful, as its change was within the margin of the respective 
standard errors. Functionally, model 1 and model 6 were equivalent. We chose to 
keep model 1 as the model from which to interpret the results.  
The results for model 1 are presented in Tables 3 to 9. We found that the 
predictors explained 33.2% of the variance of AMH, 41.8% of FSH, 39.2% of LH, 
and 0.0% of E2. Overall effects indicate that these predictors were less sensitive 
to E2. The standardized regression coefficients allowed us to compare the effect 
of different predictors for each outcome. For AMH, Age, Age at diagnosis, and 
Perceived Stress Scale (PSS) were the strongest predictors. As PSS increased 1 
SD, AMH decreased 0.287 SD. In the case of FSH, PSS was the strongest 
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predictor, followed by the intercept of salivary cortisol, and age at menarche. As 
PSS increased 1 SD, FSH decreased 0.53 SD. For LH, we found that the 3 
predictors related to cortisol (intercept, slope of salivary cortisol, and hair cortisol) 
and age at diagnosis were the strongest predictors. As the intercept of salivary 
cortisol increased by 1 SD, LH increased by 0.387 SD. In the case of E2, all the 
predictors were equivalent around 0.0, demonstrating that these predictors did 
not characterize the behavior of E2. 
The correlations between predictors and the residual correlation between 
outcomes are presented in tables 8 and 9. The residual correlation represents 
the relationship between the outcomes after some variance has been explained 
by the model. For both sets of correlations, the variables have either a correlation 
functionally equal to 0, or a weak correlation (r < 0.2).  
Discussion 
 
 
Aim 1: Description of perceived stress and HPA activity in female cancer 
survivors. 
 In this small sample of female childhood cancer survivors, the mean 
perceived stress scale (PSS) score was 16.43 ± 6.73; this is higher than the 
mean threshold for stress in the general population, which is 13.7 for 
women (Cohen et al., 1983). Surviving a life-threatening illness such as 
pediatric cancer represents a major early life stressor (Laufer et al., 2012) 
and several studies have demonstrated that childhood cancer survivors 
report higher levels of stress than healthy controls (Brown, Madan-Swain, & 
Lambert, 2003; Oancea et al., 2014). Keir et al. demonstrated that long-term 
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cancer survivors are just as likely as cancer patients to report high levels of 
stress, suggesting that the time since diagnosis and treatment does not 
mitigate the stress effects of cancer (Keir et al., 2007).  
 The average salivary cortisol intercept (corresponding to the PM 
timepoint) was 105.25 ng/dL with a variance of 48.53 ng/dL. On average, salivary 
cortisol levels increased 24.19 ng/dL per hour with a variance of 9.41 ng/dL. The 
latent growth curve demonstrated heterogeneity of variance over time (as shown 
in Figure 2), with wider variability observed at the later time points. Some slopes 
were positive and others were flat, creating an over-dispersion at the later time 
points. Both higher night salivary cortisol concentrations (>100 ng/dL) and 
flattened diurnal cortisol slopes have been observed in studies examining HPA 
activity in cancer survivors, a population at risk of experiencing high levels of 
psychological stress (Cuneo et al., 2017; Garland, Beck, Lipschitz, & Nakamura, 
2015; Schrepf et al., 2015; Sephton et al., 2013). It is hypothesized that these 
abnormal diurnal patterns induce systemic inflammation, which is associated with 
increased incidence of adverse long-term health outcomes for cancer survivors 
(cancer recurrence, chronic symptom experience, etc…) (Schrepf et al., 2015).  
 To our knowledge, no studies have yet examined hair cortisol levels 
in childhood cancer survivors. In our small sample of 24 CCS, we found a 
wide range of hair cortisol concentrations (1.08-211.70 pg/mg, mean 19.94 
± 43.23 pg/mg), a finding which is consistent with other studies that have 
examined hair cortisol concentrations in the general population (Russell et 
al., 2012; Stalder & Kirschbaum, 2012). However, the median hair cortisol 
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concentration in our sample was 7.01 pg/mg with 16/24 (67%) having 
concentrations lower than 10 pg/mg (see Figure 3). This is lower than the 
median concentrations reported in healthy samples (Stalder & Kirschbaum, 
2012). In a meta-analysis of chronic stress and HPA activity, Miller et al. 
(2007) report that patterns of HPA activity in response to chronic stress vary 
by time since onset. When the eliciting stimulus of a chronic stressor first 
begins, there is an initial activation of the HPA axis, which results in 
elevated concentrations of cortisol. As time passes, this activity lessens, 
and cortisol secretion rebounds to below normal (Miller, Chen, & Zhou, 
2007). This may explain the lower median hair cortisol concentrations 
observed in our sample of childhood cancer survivors. As both 
hypocortisolism and hypercortisolism are associated with adverse health 
outcomes, the finding of lower median hair cortisol concentrations in this 
sample is notable and requires further investigation (Miller et al., 2007).   
Correlation between perceived stress and HPA activity in cancer survivors 
In this exploratory study, perceived stress levels, salivary cortisol intercept 
and slope and hair cortisol concentrations were not correlated in childhood 
cancer survivors (Table 8). These findings are consistent with previous studies 
that have examined the relationship between self-reported measures of stress 
and measures of HPA activity (Miller et al., 2007; Stawski, Cichy, Piazza, & 
Almeida, 2013). Wells et al. (2014) used a pooled database from diverse 
community samples to examine the association between hair cortisol 
concentrations (HCC) and measures of perceived stress. Correlations of HCC 
	193	
with self-reported stress were small and both were non-significant after 
controlling for confounders (Wells et al., 2014).  
Correlation between biomarkers of HPA activity in cancer survivors 
We also found no correlation between hair and salivary cortisol in our 
sample of CCS. Sauve et al (2007) examined correlations between hair cortisol 
and concentrations of cortisol in urine, saliva, and serum in 39 non-obese 
subjects. Hair cortisol and saliva cortisol were not correlated (r = 0.306, p = 
0.119). One explanation for the lack of correlation between hair cortisol and 
salivary cortisol is the difference in time frames reflected by the measurements: 
salivary cortisol represents cortisol secretion at one time point during the day, 
whereas hair cortisol represents average cortisol secretion during 1-3 months 
(Sauvé et al., 2007). Since hair cortisol reflects long-term cortisol secretion, the 
association between hair and salivary cortisol would be expected to strengthen 
with an increasing number of accumulated shorter-term cortisol samples (Stalder 
& Kirschbaum, 2012) and this was recently confirmed in a study by Short et al.; 
HCC was most strongly associated with 30-day integrated cortisol production 
(average salivary cortisol AUC) and there were no significant associations 
between HCC and the 30-day summary measures using cortisol awakening 
response or diurnal slope (Short et al., 2016).  
Aim 2: To explore the relationship between perceived stress, HPA activity and 
gonadotropin and reproductive hormone levels and AMH in female cancer 
survivors 
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 For each outcome, the overall R2 will be discussed as well as the highest 
standardized regression coefficients for that outcome. 
Perceived stress, HPA activity and AMH 
 
 
In this study of 24 CCS, we found that the model predictors explained 33% 
of the variation in AMH levels, with the highest standardized regression 
coefficients observed for age, age at diagnosis, perceived stress and hair cortisol 
(Table 4). With an increase of one standard deviation in age, age at diagnosis 
and perceived stress, AMH declined 5.66 pmol/L, 5.19 pmol/L, and 5.02 pmol/L 
respectively. The inverse association between age and AMH is well established 
in the literature (Kelsey et al., 2011). Barton et al. (2013) also found that older 
age at diagnosis increased risk of post-treatment infertility in childhood cancer 
survivors, but only in unadjusted models (Barton et al., 2013). The association 
between perceived stress, HPA activity and the ovarian reserve has not been 
examined in childhood cancer survivors. However, Pal et al. (2010) examined 
associations between acute (serum cortisol) and chronic (history of abuse and/or 
drug use) psychosocial stress and Müllerian-Inhibiting-Substance (MIS), now 
referred to as AMH, in 89 pre-menopausal infertile women. Those with chronic 
stress demonstrated significantly lower MIS (AMH) levels (p = 0.034), and were 
three times more likely to be diagnosed with diminished ovarian reserve (p = 
0.025). However, no association was observed in their study between serum 
cortisol levels and diminished ovarian reserve. The authors concluded that 
chronic, but not current stress, was associated with diminished ovarian reserve. 
They proposed HPA dysregulation as a plausible explanation for this association; 
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because a biomarker of chronic stress was not included in the study, the authors 
were unable to provide evidence supporting this theory (Pal et al., 2010).  
In this study, we found that with an increase of one standard deviation in 
hair cortisol concentrations, AMH increased 3.76 pmol/L. And while the 
standardized regression coefficients of the diurnal cortisol intercept and slope 
were lower, they were also positively associated with AMH levels. Taken together 
(positive associations between hair cortisol concentrations, diurnal cortisol slope 
and intercept and AMH levels), these findings suggest a positive association 
between cortisol concentrations and the ovarian reserve, and support the 
hypothesis that threshold glucocorticoid levels are necessary to sustain ovarian 
function (Whirledge & Cidlowski, 2013). As stated earlier, we found lower median 
hair cortisol concentrations in our sample than reported in healthy populations 
(Stalder & Kirschbaum, 2012).  
Over half of the subjects in our sample exhibited flattened diurnal cortisol 
slopes. Lower daily cortisol output and flattened diurnal cortisol slopes have been 
observed in cancer survivors. Our findings are consistent with prior studies 
linking hypocortisolism with increased risk of experiencing the late effects of 
cancer treatment (Bower et al., 2005; Cuneo et al., 2017; Ho et al., 2013; Schrepf 
et al., 2015; Sephton et al., 2013). 
Perceived stress, HPA activity and Gonadotropin levels  
 
 
 In this study, we found that the model predictors explained 42% of the 
variation in FSH levels, with the highest standardized regression coefficients 
observed for salivary cortisol intercept, perceived stress and age at menarche 
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(Table 5). The model predictors explained 39% of the variation in LH levels, with 
the highest standardized regression coefficients observed for salivary cortisol 
intercept and slope, hair cortisol and age at diagnosis (Table 6). We also found 
that perceived stress was inversely associated with FSH and LH levels and was 
not associated with E2 levels.  
Because we were unable to time the collection of reproductive hormone 
levels according to menstrual cycle phase, we did not anticipate a strong 
association between perceived stress and FSH and LH levels. There are several 
possible explanations for the strong inverse association we observed irrespective 
of menstrual cycle phase. It may be that perceived stress has a significant effect 
on ovarian function, regardless of menstrual cycle phase.  
Schliep et al. (2015) found that daily stress (measured using the 
Perceived Stress Scale-4) was inversely associated with E2 and LH but 
positively associated with FSH levels in 259 healthy women aged 18-44 years, 
after adjusting for age, race, percent body fat, depression score, time-varying 
hormones and vigorous exercise (Schliep et al., 2015). These contradictory 
findings regarding stress and FSH may be due to the younger age range 
included in our study (16-35), in which extreme levels of FSH were less likely. 
Another explanation may be that stress perception varies across the menstrual 
cycle, such that the degree to which a woman perceives her life to be stressful is 
in part influenced by fluctuations in gonadotropin levels (Duchesne & Pruessner, 
2013).  
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 While perceived stress was inversely associated with FSH and LH, we 
found that HPA activity (hair, salivary cortisol intercept and slope) was positively 
associated with FSH and LH levels. Similar to perceived stress, HPA activity was 
not associated with E2 levels. Our findings support the role of glucocorticoids in 
regulating the hypothalamic-pituitary-gonadal axis. In our sample, we observed 
lower median hair cortisol levels than those reported in healthy samples; thus, 
the positive association we observed suggests that threshold glucocorticoid 
levels are needed to sustain reproductive function (Whirledge & Cidlowski, 2013). 
Another explanation is that cortisol levels may fluctuate across the menstrual 
cycle as has been suggested by others (Kirschbaum, Kudielka, Gaab, & 
Schommer, 1999; Nepomnaschy et al., 2011; Stephens et al., 2016; Wolfram, 
Bellingrath, & Kudielka, 2011). While preliminary, the findings from our small 
sample support an association between perceived stress, HPA activity and 
gonadotropin levels in female cancer survivors. More research is needed to 
clarify the mechanism behind this association and to determine whether it varies 
depending on the temporal nature of the stressor and menstrual cycle phase. 
Limitations 
 
 
 This exploratory study has several limitations. Due to the small 
sample, we were unable to adjust for hormonal contraceptive use in the 
overall model. Hormonal contraceptive use is associated with increased 
production of corticotropin-binding-globulin and subsequent decreases in 
unbound cortisol levels (Stephens et al., 2016). In addition, due to the wide 
variety of pediatric cancer diagnoses in this small sample, we could not 
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adjust for cancer diagnosis and treatment-related factors in the model. 
Several studies have found a significant effect of diagnosis and treatment-
related factors on post-treatment ovarian function, including the cancer 
pathology itself (Van Dorp et al., 2014), the therapeutic regimen 
(Charpentier et al., 2014) and the length of exposure (El-Shalakany et al., 
2013; Reinmuth et al., 2013). Another limitation is that due to the great 
distance that many of the participants needed to travel, we were unable to 
time study visits to coincide with a specific menstrual cycle phase. For this 
reason, we were unable to adjust gonadotropin and reproductive hormone 
levels to account for menstrual cycle phase. And last, the study design was 
cross-sectional and relied on a convenience sample.  
Conclusions 
 
 
In this exploratory study, we sought to examine the association 
between chronic stress and ovarian function in survivors of childhood 
cancer. The effects of chronic stress on the ovarian reserve are poorly 
understood. The findings from this study provide preliminary evidence to 
suggest that perceived stress is negatively associated with ovarian function, 
and that biomarkers of HPA activity are positively associated with ovarian 
function in female childhood cancer survivors. Few studies have examined 
predictors of the ovarian reserve in childhood cancer survivors other than 
diagnosis and treatment-related factors. Pre-treatment planning and the 
ability to provide individualized fertility prognoses depends on increased 
understanding of factors associated with the ovarian reserve in this 
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population (Anderson et al., 2013; Knopman et al., 2010). The findings from 
this study provide the foundation for further research examining the risk for 
post-treatment reproductive dysfunction in female CCS. Due to the small 
sample size, this study’s findings require validation in larger longitudinal 
studies. Given that our current understanding of the ovarian reserve is 
limited, the findings from this exploratory study can be used to clarify 
relationships between variables and propose a model for future hypothesis 
testing in experimental research. 
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Table 1: Clinical and Demographic Descriptive Statistics 
 N Minimum Maximum Mean SD 
Age 24 17 34 21.79 5.68 
Age diagnosed 24 1 16 10.38 5.22 
Age at Menarche 22 10.0 15.0 12.27 1.19 
BMI (kg/m2) 20 19.96 34.38 24.57 3.81 
PSS Total 23 6 32 16.43 6.727 
PM CORT (ng/dL) 20 18.92 262.66 105.26 74.68 
AM CORT (ng/dL) 21 32.63 644.01 318.74 203.46 
AM + 30 (ng/dL) 21 26.24 850.89 392.93 263.68 
HAIR CORT (pg/mg) 24 1.08 211.70 19.94 43.23 
FSH (U/L) 24 0.7 9.8 4.93 2.34 
LH (U/L) 24 0.5 10.7 4.53 3.12 
Estradiol (pmol/L) 24 50 685 197.88 175.04 
AMH (pmol/L) 23 2.4 79.5 23.28 17.94 
 
Note: Abbreviations: BMI, Body Mass Index; PSS, Perceived Stress Scale; PM CORT, 
Night cortisol; AM CORT, Morning cortisol; AM + 30, Morning cortisol plus 30 minutes; 
HAIR CORT, Hair cortisol; FSH, Follicle Stimulating Hormone; LH, Luteinizing Hormone; 
AMH, Anti-Müllerian Hormone  
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Figure 1: Bayesian Path Analysis Model  
 
Covariates	1. Age		2. BMI	3. Age	at	menarche	4. Age	at	diagnosis	
Diurnal	Cortisol	intercept	
Perceived	Stress	Scale	
Hair	Cortisol	
Follicle	Stimulating	Hormone	R2	=	0.418	
Anti-Müllerian	Hormone	R2	=	0.332	
Estradiol	R2	=	0.000	
Luteinizing	Hormone	R2	=	0.392	
Diurnal	Cortisol	slope	
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Figure 2: Graph of Diurnal Cortisol slopes including three time points 
 
Figure 3: Boxplot of hair cortisol concentrations 
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Table 2: Latent Growth Curve 
Parameter Estimate 95% CI Standardized 
estimate 
Intercept mean 0.00 -0.45, 0.46 0.00 
Intercept variance 0.65 0.09, 1.39 1.00 
Slope mean 0.32 0.16, 0.49 0.91 
Slope variance 0.12 0.06, 0.22 1.00 
Covariance 0.03 -0.12, 0.17 0.09 
Residual T1 0.482 0.00, 1.26 0.42 
Residual T2 0.86 0.00, 3.42 0.07 
Residual T3 4.06 0.00, 7.29 0.23 
Note: Estimate: mean of the posterior distribution; CI: Credible Interval 
 
Table 3: Path analysis model fit comparisons 
 LOO (pd) WAIC (pd) ΔLOO (SE) ΔWAI (SE) 
Model 1 1474.0 (58.5) 1463.0 (53.1)   
Model 2 1475.3 (58.1) 1463.7 (52.3) -0.6 (2.0) -0.3 (1.7) 
Model 3 1466.5 (55.2) 1457.3 (50.5) 3.8 (2.4) 2.9 (1.3) 
Model 4 1469.0 (55.7) 1460.2 (51.3) 2.5 (2.1) 1.4 (1.7) 
Model 5 1474.8 (55.3) 1464.5 (50.1) -0.4 (3.1) -0.7 (2.8) 
Model 6 1471.5 (51.4) 1464.9 (48.1) 1.3 (4.5) -1.0 (4.4) 
Model 7 1487.1 (49.4) 1479.6 (45.6) -6.6 (5.4) -8.3 (5.3) 
Note: LOO: leave one out information criteria; WAIC: Widely Applicable Information 
criteria; pd: effective number of parameters; SE: standard error; Δ: change 
 
Bayesian Path Analysis results by outcome 
Table 4: AMH 
Predictor β 95% CI Standardized 
estimate 
SC Intercept 4.138 -10.39, 18.81 0.133 
SC Slope 5.260 -7.14, 18.28 0.082 
PSS -5.020 -10.93, 1.58 -0.287 
Hair Cortisol 3.757 -2.43, 10.57 0.214 
BMI  1.955 -4.65, 8.29 0.112 
Age -5.664 -12.37, 1.18 -0.312 
Age at diagnosis -5.187 -11.86, 1.86 -0.289 
Age at menarche 2.996 -3.77, 9.32 0.172 
Note: Abbreviations: SC Intercept, salivary cortisol intercept; SC Slope, salivary cortisol 
slope; PSS, Perceived Stress Scale; BMI, Body Mass Index, CI, credible interval 
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Table 5: FSH 
Predictor β 95% CI Standardized 
estimate 
SC Intercept 1.040 -6.31, 8.45 0.233 
SC Slope 0.286 -5.60, 6.61 0.031 
PSS -1.332 -2.47, -0.05 -0.530 
Hair Cortisol 0.381 -0.93, 1.65 0.151 
BMI  0.294 -0.99, 1.54 0.117 
Age 0.153 -1.22, 1.51 0.058 
Age at diagnosis 0.113 -1.32, 1.52 0.044 
Age at menarche 0.571 -0.77, 1.70 0.228 
Note: Abbreviations: SC Intercept, salivary cortisol intercept; SC Slope, salivary cortisol 
slope; PSS, Perceived Stress Scale; BMI, Body Mass Index, CI, credible interval 
 
Table 6: LH 
Predictor β 95% CI Standardized 
estimate 
SC Intercept 2.259 -8.73, 13.95 0.387 
SC Slope 2.802 -7.85, 10.18 0.233 
PSS -0.537 -2.08, 1.04 -0.164 
Hair Cortisol 0.814 -0.88, 2.87 0.247 
BMI  -0.384 -2.40, 1.65 -0.117 
Age -0.430 -2.48, 1.46 -0.126 
Age at diagnosis 0.857 -1.34, 2.87 0.254 
Age at menarche -0.091 -1.67, 1.55 -0.028 
Note: Abbreviations: SC Intercept, salivary cortisol intercept; SC Slope, salivary cortisol 
slope; PSS, Perceived Stress Scale; BMI, Body Mass Index, CI, credible interval 
 
Table 7: E2 
Predictor β 95% CI Standardized 
estimate 
SC Intercept 0.140 -13.51, 14.35 0.000 
SC Slope 1.065 -13.37, 14.36 0.001 
PSS 0.749 -12.59, 14.75 0.003 
Hair Cortisol -0.535 -14.05, 13.34 -0.002 
BMI  0.589 -13.15, 13.94 0.002 
Age -0.100 -14.03, 13.36 -0.000 
Age at diagnosis -0.960 -14.56, 12.92 -0.004 
Age at menarche -1.115 -14.54, 12.86 -0.005 
Note: Abbreviations: SC Intercept, salivary cortisol intercept; SC Slope, salivary cortisol 
slope; PSS, Perceived Stress Scale; BMI, Body Mass Index, CI, credible interval 
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Table 8: Correlation between predictors 
 SC Int SC Slp PSS Hair C BMI Age Age dx Age Mn 
SC Inte 1        
SC Slp 0.045 1       
PSS 0.021 0.082 1      
Hair C 0.054 -0.035 0.006 1     
BMI 0.001 -0.067 0.081 -0.051 1    
Age 0.036 0.155 -0.027 -0.019 0.055 1   
Age dx -0.052 0.002 -0.083 0.111 0.023 0.120 1  
Age Mn -0.011 0.043 0.002 0.009 -0.100 0.064 0.010 1 
Note: Abbreviations: SC Inte, salivary cortisol intercept; SC Slp, salivary cortisol slope; 
PSS, Perceived Stress Scale; Hair C, Hair cortisol; BMI, Body Mass Index; Age dx: Age 
at diagnosis; Age Mn, Age at menarche; CI, credible interval 
 
Table 9: Residual correlation between outcomes 
 AMH E2 FSH LH 
AMH 1    
E2 -0.069 1   
FSH -0.186 -0.108 1  
LH 0.173 0.192 0.059 1 
Note: Abbreviations: AMH, Anti-Müllerian Hormone; E2, Estradiol; FSH, Follicle 
Stimulating Hormone; LH, Luteinizing Hormone 
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APPENDIX D: INSTRUMENTS Subject	ID:				 			 Study	Checklist		Please	write	the	name	of	person	completing	and	the	date	completed:		Item	 Name	of	person	completing	 Date	Consent	form	 	 	Minimum	data	set	 	 	Saliva	Cortisol	1	 	 	Saliva	Cortisol	2	 	 	Saliva	Cortisol	3	 	 	Saliva	IL-6	 	 	Hair	Sample	 	 	Demographic	Sheet	 	 	Perceived	Stress	Scale	 	 																
	216	
		 		DEMOGRAPHIC	QUESTIONAIRRE	(Please	check	or	fill	in	the	answer)		1. What	is	your	age?	_____________		2. What	is	the	highest	level	of	education	you	have	completed?	
o Primary	school	
o Secondary	school	
o University	
o Postgraduate	studies		3. What	is	your	ethnic	origin?	
o Asian	
o Indian	
o Pakistani	
o Black		
o White		
o Mixed	
o Other	
o Prefer	not	to	say		4. What	is	your	country	of	origin?		_____________________________		5. What	is	your	current	marital	status?	
o Married	
o Living	with	someone	
o Divorced	
o Separated	
o Single	
o Widowed	
o Prefer	not	to	say		6. What	is	your	sexual	orientation?		
o Heterosexual	
o Bisexual	
o Gay	woman/lesbian	
o Other	
o Prefer	not	to	say		
	217	
	7. What	best	describes	your	current	employment	status?	
o Employed	full	time	
o Employed	part	time	
o Homemaker	
o Unemployed	
o Student	
o Other		8. Which	of	the	following	best	describes	the	area	you	live	in?	
o Urban	
o Suburban	
o Rural		9. What	is	your	current	household	income	in	GBP?	
o Under	£10,000	
o £10,000-£19,999	
o £20,000-£29,999	
o £30,000-£39,999	
o £40,000-£49,999	
o £50,000-£59,999	
o £60,000-£75,999	
o £76,000-£99,999	
o £100,000-£150,000	
o Above	£150,000	
o Prefer	not	to	say		10. How	many	people	besides	you	live	in	your	household?	
o None	
o 1	
o 2	
o 3	
o 4	or	above		11. Do	you	have	any	children?	
o Yes	
o No	
o Prefer	not	to	say		12. If	you	have	children,	how	many	do	you	have?	
o N/A	
o 1	
o 2	
o 3	
o 4	or	more	
o Prefer	not	to	say	
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Subject ID:  
	
	
Perceived Stress Scale-10 
 
Instructions: This set of questions is about your feelings, thoughts, and activities 
over the last month. Please give one answer for each question. Possible 
responses are never, almost never, sometimes, fairly often, and very often.  
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Perceived Stress Scale Scoring 
 
PSS-10 scores are obtained by reversing the scores on the four positive items, e.g., 
0=4, 1=3, 2=2, etc. and then summing across all 10 items.  Items 4,5, 7, and 8 are the 
positively stated items.  																										
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Subject ID:  
	
 
Saliva Collection Instructions: 
1. General: Please avoid sample collection within 60 minutes after eating a 
major meal or within 12 hours after consuming alcohol. Ten minutes 
before the sample is collected, please rinse your mouth thoroughly with 
water. 
2. You will have four saliva collecting tubes. Three are for cortisol (marked 
with an orange sticker) and one is for IL-6 (marked with a blue sticker). 
3. Saliva tubes marked with an orange sticker will also be numbered. The 
numbers indicate the order in which the samples should be collected: 
a. Orange #1: This sample should be collected on the night prior to 
the study visit just before you go to bed. 
b. Orange #2: This sample should be collected on the morning of the 
study visit immediately after waking up, before getting out of bed.  
c. Orange #3: This sample should be collected 30 minutes after the 
second sample.  
d. Blue: This sample should be collected immediately after the third 
sample.  
4. To collect the sample, unwrap the oral cotton swab and place it 
underneath your tongue.  
5. After collecting the samples, write your study ID, date, and time of 
collection on each tube.  
6. Double-bag the samples in the sealable plastic bags that are provided and 
place them in the refrigerator until you come in for your study visit. 
7. Bring the samples to the study visit and give them to the research nurse.  										
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Subject ID:  
	
 
Saliva Sample Handling 
 
Saliva Sample 
 
Cortisol 1 
 
 
Cortisol 2 
 
 
Cortisol 3 
 
 
IL-6 
							Date	collected		 	 	 				 			 			 			 	 	 	 	
   D   D  M    M     Y    Y    Y    Y 
 	 	 	 				 			 			 			 	 	 	 	
   D   D  M    M     Y    Y    Y    Y 
 	 	 	 				 			 			 			 	 	 	 	
   D   D  M    M     Y    Y    Y    Y 
 
 	 	 				 			 			 			 	 	 	 	
   D   D  M    M     Y    Y    Y    Y 
 
							Time	collected		 	 				 			 			 			
  H   H   M  M 
 
 
 	 				 			 			 			
  H   H   M  M 
 
 	 				 			 			 			
  H   H   M  M 
 
 	 				 			 			 			
  H   H   M  M 
 
Time sample spent at 40c awaiting centrifuge processing 
prior to freezing 
	
																						 	 	Days	
			
 
Handing by Queen’s Medical Research Institute 
Add contact info 
	
 
Total volume of saliva sample after centrifuge 
Cortisol 1                                                                                                mL	
Cortisol 2                                                                                                mL	
Cortisol 3                                                                                                mL	
IL-6                                                                                                         mL	
	
	
	
 
Date and time into -80ºC 	 	 				 			 			 			 	 	 	 	
   D   D  M    M     Y    Y    Y    Y 
	 				 			 			 			
  H   H   M  M 
 
Number of Freeze-thaw cycles:    
 
 
Reason:………………………………… 
…………………………………………… 
…………………………………………… 
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Hair collection instructions 
1. Collect approximately 1cm width hair section from posterior vertex region. 
Place scissors as close to the scalp as possible. 
2. Secure hair sample with thread provided (indicating proximal end). 
3. Place hair sample in aluminum foil provided with the proximal end of the 
sample on the side of the foil marked “top”.  
4. Fold the aluminum foil to ensure sample is covered.  
5. Place sample wrapped in aluminum foil in the plastic bag provided.  
 
 
Figure 1. Hair sampling from posterior vertex region.  												
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Subject ID:  
 
 
Hair Sample Handling 
 
 
 
Hair Sample 
 
 
Length of sample                                                                                              
 
 
Has subject ever dyed hair (yes or 
no)  
 
 
If so, how recently?  
 
 
 
 
 
Date collected 
 
   
                
   D   D  M    M     Y    Y    Y    Y 
 
 
cm 
 
 
YES  /  NO 
 
 
 
 
_________________ 
 
 
 
 
 
Time collected 
 
  
            
  H   H   M  M 
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Subject ID:  
		
Minimum	Data	Set:	Please	ensure	the	following	clinical	data	is	collected	if	not	
already	available	in	the	participant’s	medical	records.	
	 1. Diagnosis	___________________________	2. Age	at	diagnosis	____________________	3. Treatment	Type:	___________________	a. Chemotherapy:	YES		/		NO	b. Radiotherapy:	YES		/		NO	4. Age	at	completion	of	treatment:	_________________	5. Comorbidities	a. ____________________	b. ____________________	c. ____________________	d. ____________________	6. Chronic	symptoms	(post	treatment)	a. ____________________	b. ____________________	c. ____________________	d. ____________________	7. Prescription	medications	a. ____________________	b. ____________________	c. ____________________	d. ____________________	8. Age	at	menarche:	_____________________	9. Average	menstrual	cycle	length	before	treatment:	__________________	10. Average	menstrual	cycle	length	after	treatment:	____________________	11. Date	of	last	menstrual	period:	______________________________										D   D /  M    M   /  Y    Y    Y    Y	    12. Parity:	________________	13. Weight:	_______________	14. Height:	________________	15. BP:	________________			
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APPENDIX E: PATIENT INFORMATION SHEET 
 
 
 
 
                
 
 
Dear _______________ (name of patient),  
 
You are receiving this letter because you may be eligible to participate in a 
research project examining the effect of Chronic Stress on Reproductive 
Function (CSRF) in female cancer survivors. Our knowledge of factors that 
contribute to reproductive problems in cancer survivors is incomplete. We know 
that stress inhibits reproductive function, and we would like to examine the extent 
to which it may contribute to reproductive problems in cancer survivors. In this 
way, if we find that stress contributes to reproductive problems, we can integrate 
stress reduction techniques into reproductive heath care in cancer survivors.  
Thank you in advance for taking the time to read through the study description. 
Feel free to contact us to discuss it further or request more information before 
making your decision. If you agree to be contacted regarding the study, please 
return the reply slip at the bottom of this letter, either electronically or by using 
the stamped envelope provided. 
Yours sincerely,  
 
 
Richard A Anderson 
Principal Investigator 
 
------------------------------------------------------------------------------------------------------------ 
I have read the enclosed patient information sheet explaining the study, “Effect of 
Chronic Stress on Reproductive Function in Female Cancer Survivors.”  
 
 
     I am interested in taking part: please contact me with further 
information 
 
Please do not contact me with further information about the study 
 
Signature: ________________________ Date: _________________ 
 
Name: 
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Effect of Chronic Stress on Reproductive Function in Female Cancer 
Survivors 
Participant Information Sheet  
 
What is the purpose of this study? 
The main purpose of this study is to explore the influence of chronic stress on 
reproductive function in females following treatment for childhood cancer. 
Reproductive function is measured by a blood test, and this is done as part of 
your normal care. Chronic stress will be measured by a brief questionnaire 
assessing perceived stress over the past month and hair and saliva samples to 
assess cortisol levels (a hormone released as part of the body’s stress response) 
and IL-6 levels (released as part of the body’s inflammatory response to stress). 
 
Do I have to take part? 
It is entirely your decision whether you would like to take part in this study or not. 
If you decide to take part, we will ask you to sign a consent form and we will ask 
you to keep a copy of this leaflet. 
If you decide not to take part, it will not affect your medical care. Even after you 
have decided to take part, you are free to withdraw and you need not give us a 
reason for withdrawal. 
 
What will happen to me if I decide to take part? 
If you decide to take part, we will schedule a brief 30-minute visit to collect study 
data.  
Before the study visit, you will receive a saliva collection kit with detailed 
instructions on how to collect the saliva samples. We will ask you to collect four 
saliva samples in total. We will ask you to collect one sample on the night before 
the study visit and the remaining three on the morning before you come in for 
your visit. We will ask you to bring the saliva samples to the study visit.  
 
During the visit, we will ask you some short questions about your medical history 
and collect a small hair sample from the back of your head. We will also ask you 
to fill out a brief questionnaire about your stress over the past month. The whole 
visit should take no more than half an hour.  
 
No drugs or extra blood tests are involved in this study.  
 
What do I need to do? 
If you agree to participate in this study, we will arrange a suitable date for your 
visit.   
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What are the side effects of any treatment when taking part? 
Collecting hair and saliva samples can be a little uncomfortable; any discomfort 
will be minimized as much as possible. 
 
What are the possible disadvantages and risks of taking part? 
We do not expect any disadvantages or risks from taking part in this study.  
 
What are the possible benefits of taking part? 
By taking part in this study, you may learn more about your current reproductive 
status and your stress levels.  
 
What if new information becomes available? 
We will continue to look at emerging studies from across the world in this field. If 
any new information that is relevant to this study becomes available, we will 
review the study in consultation with the Ethics Committee. 
 
What if something goes wrong? 
If you have a concern about any aspect of this study, you should ask to speak 
with the researchers who will do their best to answer your questions. If you 
remain unhappy and wish to complain formally, you can do this through the NHS 
Complaints Procedure. Details can be obtained from the hospital.  
 
In the event that something does go wrong and you are harmed during the 
research study there are no special compensation arrangements. If you are 
harmed and this is due to someone's negligence then you may have grounds for 
a legal action for compensation against The University of Edinburgh but you may 
have to pay your legal costs. The normal National Health Service complaints 
mechanisms are available to you. 
 
Will my taking part in the study be kept confidential? 
With your permission, we will let your GP know that you are taking part in this 
study. If we find any abnormalities, we will discuss this with you and if necessary, 
refer you to your GP or a specialist.  
 
We will keep your participation in this study and all related information 
confidential.  All information that is recorded or sent to our colleagues (e.g: 
laboratory staff) will be labeled with a unique reference number. Your name, 
address and any other identifying information will be removed.  
 
If at any point during the study you should lose the capacity to provide consent, 
you will be withdrawn from the study and no further data will be collected from 
you. Data already collected while you were able to provide consent will be 
retained.  
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What will happen to the results of the research study? 
Once we have analysed all the results, we will write one or more papers, which 
will be submitted to medical research journals for publications. Your personal 
details will not be included in any of these. After completion of the study, a lay 
summary of the study’s findings will be available upon request from the clinical 
team looking after you. 
 
What will happen to my saliva and hair samples after the study is 
completed? 
Samples will be stored for up to 5 years in the Queen’s Medical Research 
Institute at the University of Edinburgh for use in further research studies, which 
would require additional ethical approval. It is possible that we may work with a 
commercial organization in analyzing your samples, but you will not receive 
compensation should the samples have commercial value.  
 
Who is organizing and funding the research? 
This study is funded by the Medical Research Council, a publicly funded UK 
organization. 
 
Who has reviewed this study? 
The study has been reviewed by the South East Scotland Research Ethics 
Committee 
 
Contacts 
 
Research team: 
Professor Richard Anderson 
MRC Centre for Reproductive Health 
University of Edinburgh 
47 Little France Crescent  
Edinburgh EH16 4TJ 
Phone:    0131 2426386 
E-mail:   richard.anderson@ed.ac.uk 
 
Professor Hamish Wallace 
Paediatric Oncologist 
Royal Hospital for Sick Children 
9 Sciennes Road 
Edinburgh EH9 1LF 
 
If you wish to speak to someone not involved in the study, please contact: 
Dr Angela Edgar, 
Consultant Paediatric Oncologist 
Royal Hospital for Sick Children 
17 Millerfield Place 
Edinburgh EH9 1LF 
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Tel: 0131 2420425 
 
NHS complaints contact:  
NHS Lothian Complaints Team 
2nd Floor 
Waverley Gate 
2-4 Waterloo Place 
Edinburgh 
EH1 3EG 
Tel: 0131 465 5708 
Email: craft@nhslothian.scot.nhs.uk  
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APPENDIX F: CONSENT FORM 
 
 
 
 
 
 
 
 
 
 
 
 
Patient Identification Number: 
Effect of Chronic Stress on Reproductive Function in Female Cancer Survivors 
Please initial to confirm 
1. I confirm that I have read and understand the information sheet dated 16 July 2015 
(version 2) for the above study. 
 
 
2. I have had the opportunity to consider the information, ask questions and have had these 
answered satisfactorily. 
 
 
3. I understand that I will provide saliva and hair samples and answer some questions 
regarding my stress level over the past month as part of the research study. 
 
 
4. I understand that relevant sections of my medical notes and data collected may be looked 
at by individuals from the regulatory authorities and from the Sponsor(s) (NHS Lothian and 
the University of Edinburgh) or from the/other NHS Board(s) where it is relevant to my taking 
part in this research. I give permission for those individuals to have access to my records. 
 
 
5. I agree to my GP being informed of my participation in the study. 
 
 
6. I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my medical care or legal rights being affected. 
 
 
7. I consent to hair, and saliva being stored in a secure facility for use in future related 
ethically approved studies, which may include transfer to other academic or commercial 
collaborators. I understand that a unique number will identify all samples to ensure 
confidentiality.  
 
 
__________________________ 
Name of Participant 
______________ 
Date 
__________________________ 
Signature 
 
________________________ 
Name of Person taking consent  
(if different from researcher) 
______________ 
Date 
__________________________ 
Signature 
CSRF	
Consent	Form	
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Original (x1) to be retained in site file.  Copy (x1) to be included in patient notes.  Copy 
(x1) to be retained by the participant. 	
